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Abstract 
Introduction 
In the era of antiretroviral therapy (ART), people living with Human Immunodeficiency Virus 
(HIV) now have prolonged life spans. An emerging trend of non- acquired immune deficiency 
syndrome (AIDS) related complications now prevails in the aging HIV infected population. 
Increased levels of inflammation and chronic immune activation are associated with HIV 
infection. In the era of ART people living with HIV are at an increased risk of cardiovascular 
disease (CVD). Platelets play a pivotal role in both inflammation and immune activation and 
upon activation platelets degranulate and secrete various inflammatory, coagulatory and 
adhesion molecules. Activated platelets express surface P-selectin (CD62P) and are a key 
component of the coagulation pathway and serve as a link between inflammation and 
thrombosis. Activated platelets have been implicated in inflammatory and cardiovascular disease 
and have been identified as immune cells that play a crucial role in pathogen recognition and 
modulation of immune cells during infections. Several antiviral and antibacterial properties of 
platelet alpha granule contents have been established. Platelet aggregometry remains the most 
widely used technique to evaluate platelet function even though this technique is limited by many 
pre-analytical variables. Platelet flow cytometry on the other hand offers a rapid measurement of 
platelet function in their physiological environment with minimal artefactual activation. Few 
studies have however reported on standardized methods to evaluate platelet function in the 
context of HIV. Platelet function remains unclear and data on HIV infected treatment naïve 
individuals remains scarce. The aim of this project was to examine the relationship between 
platelet function and immune activation in patients with HIV  
Materials and methods 
This study consisted of five sub-studies, firstly platelet indices and levels of platelet activation 
were determined in a cohort of 330 participants (185 HIV infected ARV naïve and 145 uninfected 
healthy controls) using; flow cytometry and haemotology analyzers. The relationship between 
these indices and markers of platelet activation, disease progression and immune activation 
were assessed. Furthermore, levels of platelet activation and aggregation were evaluated in a 
cohort of 82 participants (41 HIV infected (ARV naïve) individuals and 41 uninfected healthy 
controls), using a novel whole blood flow cytometry based functional assay. These baseline 
levels were then correlated with markers of immune activation and disease progression in HIV.  
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In a subsequent study, platelet function in a cohort consisting of 58 HIV infected (ARV naïve) 
and 38 uninfected controls was evaluated using flow cytometry. Platelet response was 
measured post stimulation with adenosine diphosphate (ADP) at concentrations known to induce 
reversible (0.04mM) and irreversible (0.2mM) platelet aggregation. In order to assess platelet 
function in HIV, platelet response was evaluated in a cohort consisting of 58 HIV infected (ARV 
naïve) and 38 uninfected controls. Platelets were activated using varying concentrations of ADP, 
arachidonic acid (AA) and collagen and platelet function was measured using flow cytometry. 
Levels of circulating platelet leukocyte aggregates (PLAs) were also measured using flow 
cytometry in a cohort consisting of 35 HIV-infected (ARV naïve) individuals and 32 uninfected 
healthy controls. Associations between PLAs, immune activation and disease progression in HIV 
infected individuals were determined. The final study evaluated platelet aggregates, platelet 
derived microparticles (PMPs) and microparticles (MPs) in a cohort consisting of 46 HIV infected 
(ARV-naïve) and 40 uninfected healthy controls. Associations between MPs, PMPs, platelet 
aggregates and markers of immune activation and disease progression were evaluated.  
 
Results 
HIV infected individuals showed decreased mean platelet volume levels (HIV mean 7.91 ± 0.85 
vs. 8.52 ± 1.12, p<0.0001) that directly correlated with CD4 counts (r=-0.2898, p=0.0075) and 
viral load (r=0.2680, p=0.0177). Platelet distribution width (PDW) levels directly correlated 
(r=0.3455, p=0.0362) with active coagulation and inversely correlated (r=-0.3666, p=0.0463) with 
platelet aggregation. HIV infected individuals showed increased levels of platelet activation 
(%CD62P median 11.33[5.96-29.36] vs. control group 2.48[1.56-6.04], p=0.0001). In HIV, 
platelet function is retained and platelets showed increased response to submaximal 
concentrations of endogenous agonists. HIV infected individuals showed increased levels of 
circulating platelet monocyte aggregates (25.26[16.16-32.28] vs. control group 14.12[8.36-
18.83], p=0.0001) that directly correlated with markers of immune activation; %CD38/8 
(r=0.54624, p=0.0155), viral load (r=0.633, p<0.009). Furthermore we report on increased levels 
of circulating MPs (median %MPs 1.7[0.95-2.83] vs. Control group 1.12[0.63-1.57], p=0.0160); 
PMPs (median %PMPs 26.64[11.33-36.62] vs. Control group 20.02[18.08-26.08], p=0.0133); 
activated PMPs (median CD62P MFI 3.81[3.46-4.54] vs. Control group 3.41[3.16-3.6], 
p=0.0037) and platelet aggregates (Median %CD62P 14.10[5.49-39.94] vs. Control group 
0.17[0.10-10.99], p= 0.0097) in HIV infected asymptomatic individuals.  
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Conclusion 
This study supports the potential use of the MPV and PDW as readily available markers of 
platelet activation and immune activation in HIV. We also showed elevated levels of activated 
platelets in HIV infected individuals that were hyper responsive to endogenous agonists in a 
concentration dependent manner. Platelet flow cytometry is a rapid and valuable technique in 
the evaluation of platelet function in HIV. The measurement of platelet function using flow 
cytometry allows the evaluation of platelet signalling pathways that may be modified in HIV 
infected individuals. Lastly we describe an optimized whole blood flow cytometry based assay 
for the evaluation of circulating microparticles (MPs), platelet derived microparticles (PMPs) and 
levels of activated platelets and aggregates which mimics the in vivo physiological environment 
of MPs. To the best of our knowledge, this study is the first to report on a novel approach in 
evaluating platelet function in HIV using a series of optimised whole blood flow cytometry based 
platelet assays. In addition, minimal work has been performed previously on platelet function in 
the context of HIV-infection; and particularly in a cohort of asymptomatic, untreated patients as 
defined for this study.  
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Opsomming 
Inleiding  
In die era van antiretrovirale terapie (ART), het mense wat met die menslike 
immuniteitsgebreksvirus (MIV) leef, het nou 'n verlengde lewensduur. 'N opkomende neiging van 
nie-verworwe immuniteitsgebreksindroom (vigs) heers nou in die verouderende MIV-besmette 
bevolking. Verhoogde vlakke van inflammasie en chroniese immuun aktivering word 
geassosieer met MIV-infeksie en in die era van ART loop mense wat met MIV leef, 'n verhoogde 
risiko van kardiovaskulêre siekte (KVS). Plaatjies speel 'n belangrike rol in beide inflammasie en 
immuun aktivering en met aktivering degranulate en skei plaatjies verskeie inflammatoriese, 
coagulatory en adhesie molecule af. Geaktiveerde plaatjies druk oppervlak P-selectin (CD62P) 
is 'n belangrike komponent van die stollings weg en dien as 'n skakel tussen inflammasie en 
trombose. Geaktiveerde plaatjies is in beide inflammasie en kardiovaskulêre siekte betrokke en 
is geïdentifiseer as immuun selle wat 'n deurslaggewende rol speel in die patogeen erkenning 
en modulasie van immuun selle tydens infeksies. Verskeie antivirale en antibakteriese 
eienskappe van plaatjie alpha korrel inhoud is vasgestel. Plaatjie aggregometry bly die mees 
gebruikte tegniek om plaatjie funksie te evalueer, alhoewel hierdie tegniek is beperk deur baie 
pre-analitiese veranderlikes. Plaatjie vloeisitometrie aan die ander kant bied 'n vinnige meting 
van plaatjie funksie in hul fisiologiese omgewing met 'n minimale artefactual aktivering. Min 
studies het egter berig op gestandaardiseerde metodes om plaatjie funksie in die konteks van 
MIV te evalueer. Plaatjie funksie is steeds onduidelik en data oor MIV besmet behandeling naïef 
individue bly skaars. Die doel van hierdie projek was om die verhouding tussen die plaatjie 
funksie en immuun aktivering in pasiënte met MIV te ondersoek.  
 
Materiaal en metodes  
Hierdie studie het bestaan uit vyf sub-studies. In die eerste plekis plaatjie indekse en vlakke van 
plaatjie aktivering bepaal in 'n groep van 330 deelnemers (185 MIV-besmette ARV naïef en 145 
onbesmette gesonde kontrole) met behulp van vloeisitometrie en hematologie ontleders. Die 
verhouding tussen hierdie indekse en merkers van plaatjie aktivering, die siekte se progressive 
en immuun aktivering is beoordeel. Verder is die vlakke van plaatjie aktivering en samevoeging 
in 'n groep van 82 deelnemers (41 MIV-besmette (ARV naïef) individue en 41 onbesmette 
gesonde kontrole) geëvalueer, met behulp van 'n nuwe vol bloed vloeisitometrie gebaseerde 
funksionele toets. Hierdie basislyn vlakke is dan gekorreleer met merkers van immuun aktivering 
en die progreessie van die siekte in MIV.  
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In 'n daaropvolgende studie, is plaatjie funksie in 'n groep wat bestaan uit 58 MIV besmet te 
(ARV naïef) en 38 onbesmette beheer geëvalueer met behulp van vloeisitometrie. Plaatjie 
reaksie is na stimulasie gemeet met adenosine diphophate (ADP) by konsentrasies bekend 
omkeer (0.04mM) te oorreed en onomkeerbaar (0.2mm) plaatjie aggregasie. Ten einde plaatjie 
funksie in MIV te evalueer, is plaatjie reaksie in 'n groep wat bestaan uit 58 MIV-besmette (ARV 
naïef) en 38 onbesmette kontrole geëvalueer. Die plaatjies is geaktiveer deur gebruik te maak 
van wisselende konsentrasies van ADP, is aragidoonsuur (AA) en kollageen en plaatjie funksie 
gemeet met behulp van vloeisitometrie. Vlakke van sirkulerende plaatjie leukosiet gemiddeldes  
is ook gemeet met behulp van vloeisitometrie in 'n groep wat bestaan uit 35 MIV-positiewe (ARV 
naïef) individue en 32 onbesmette gesonde kontrole. Assosiasies tussen leukosiet gemiddeldes, 
immuun aktivering en die progressive van ie siekte in MIV-besmette individue is ook bepaal. Die 
finale studie het plaatjie-gemiddeldes, plaatjie afgelei mikrodeeltjies en mikrodeeltjies 
geëvalueer in 'n groep wat bestaan uit 46 MIV besmet (ARV-naïewe) en 40 onbesmette 
gesonde kontrole. Assosiasies tussen mikrodeeltjies, plaatjie afgelei, plaatjie gemiddeldes en 
merkers van immuun aktivering en die siekte se progressie is geëvalueer.  
Resultate  
MIV-besmette individue het gedaalde gemiddelde plaatjie volume vlakke getoon (HIV 
gemiddelde 7,91 ± 0,85 8,52 ± 1,12 teen, p <0,0001) wat direk gekorreleer het met CD4-tellings 
(r = -0,2898, p = 0,0075) en virale (r = 0,2680, p = 0,0177). Plaatjie verspreiding breedte vlakke 
het direk gekorreleer met (r = 0,3455, p = 0,0362) met 'n aktiewe koagulasie en omgekeerd 
gekorreleer (r = -0,3666, p = 0,0463) met plaatjie aggregasie. MIV-besmette individue het 
verhoogde vlakke van plaatjie aktivering getoon (% CD62P mediaan 11,33 [5,96-29,36] teen 
kontrole groep 2,48 [1,56-6,04], p = 0,0001). In MIV, was plaatjie funksie behou en plaatjies het 
'n verhoogde reaksie op submaksimale konsentrasies van endogene agoniste getoon. MIV-
besmette individue het verhoogde vlakke van sirkuleer plaatjie monosiet-gemiddeldes 
gedemonstreer (25.26 [16,16-32,28] teen kontrole groep 14,12 [8,36-18,83], p = 0,0001) wat 
direk gekorreleer het met merkers van immuun aktivering; % CD38 / 8 (r = 0,54624, p = 0,0155), 
virale lading (r = 0,633, p <0,009). Verder rapporteer ons op verhoogde vlakke van sirkulerende 
mikrodeeltjies (mediaan% LP 1.7 [0,95-2,83] teen kontrole groep 1,12 [0,63-1,57], p = 0,0160); 
PMPs (mediaan% PMPs 26,64 [11,33-36,62] teen kontrole groep 20,02 [18,08-26,08], p = 
0,0133); geaktiveer PMPs (mediaan CD62P MFI 3,81 [3,46-4,54] teen kontrole groep 3,41 [3,16-
3,6], p = 0,0037) en plaatjie gemiddeldes (Mediaan% CD62P 14,10 [5,49-39,94] teen 0.17 [0,10-
10,99], p= 0.0097)  in MIV besmet asimptomatiese individue.  
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Gevolgtrekking  
Hierdie studie ondersteun die potensiële gebruik van die MPV en PDW as waardevolle geredelik 
waardevolle merkers van plaatjie aktivering en immuun aktivering in MIV. Ons het ook getoon 
verhoogde vlakke van geaktiveer de plaatjies in MIV-besmette individue getoon wat hyper 
reageer op endogene agoniste was in 'n konsentrasie-afhanklike wyse. Plaatjie vloeisitometrie is 
'n vinnige en waardevolle tegniek in die evaluering van plaatjie funksie in MIV. Die meting van 
plaatjie funksie gebruik vloei cytometry maak die evaluering van plaatjie sein paaie wat in MIV-
geïnfekteerde individue verander moontlik. Laastens het ons beskryf 'n hele bloed 
vloeisitometrie gebaseer de toets vir die evaluering van sirkulerende mikrodeeltjies, plaatjie 
afgelei mikrodeeltjies en vlakke van geaktiveer plaatjies en gemiddeldes wat lyk soos die in vivo 
fisiologiese omgewing van MP's. Na die beste van ons kennis, is hierdie studie die eerste om te 
rapporteer oor 'n nuwe benadering in die evaluering van plaatjie funksie in MIV met behulp van 
'n reeks van new hele bloed vloeisitometrie gebaseer de plaatjie toetse. Daarbenewens is 
minimale werk voorheen uitgevoer op die plaatjie funksie in die konteks van MIV-infeksie; en 
veral in 'n groep van asimptomatiese, onbehandelde pasiënte soos vir hierdie studie. Hierdie 
projek het bewyse bygevoeg tot die teorie dat plaatjies, in MIV, kan 'n skakel wees tussen die 
aktiewe inflammatoriese reaksie en die toename in die aantal trombotische en kardiovaskulêre 
siekte waargeneem in pasiënte wat met hierdie siekte saamleef. 
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Preface 
This thesis is presented in the format of five articles. One of the articles has been published in a 
peer-reviewed journal (Nkambule et al., 2014). Another article has been considered for 
publication pending revision. This article has been presented as chapter 3 in this thesis and 
appears in the format recommended by the International Journal of laboratory Haematology. The 
remainder of the articles will also be submitted for publication in an international peer-reviewed 
journal soon.  
Chapter one is a brief overview of the research topic and a statement of the research problem 
including the aims and approach of thesis. Chapter two provides a comprehensive review on 
current and previously published work relating the chosen research topic. Research gaps are 
also identified in this section. Chapter three is presented as an original research article 
evaluating platelet indices in asymptomatic HIV infected treatment naïve individuals. Chapter 
four is presented as an article evaluating platelet function using a novel flow cytometry based 
platelet assay. Chapter five is presented as an original research article evaluating platelet 
leukocyte aggregates using a novel platelet based flow cytometry assay. Chapter six is 
presented as an article evaluating platelet derived microparticles, micropartricles and platelet 
aggregates in HIV infected asymptomatic treatment naïve individuals. Chapter seven provides a 
conclusion and future directions of the work presented in this thesis. 
 
Publications and presentations 
Nkambule, Bongani B., Glenda Davison, and Hayley Ipp. "The value of flow cytometry in the 
measurement of platelet activation and aggregation in human immunodeficiency virus infection." 
Platelets 0 (2014): 1-8. 
Nkambule BB., Davison GM and Hayley Ipp. The evaluation of platelet indices and markers of 
inflammation, coagulation and disease progression in treatment-naïve, asymptomatic HIV-
infected individuals. International Journal of laboratory hematology. (2014). In press. 
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Published abstracts 
EHA 17 Amsterdam, 2012 Education Book 
Platelet flow cytometry and markers of immune activation in asymptomatic , treatment 
naïve HIV infection. Bongani B Nkambule1, Richard H Glashoff2 and hayley Ipp1,2 
Divisions of Haematology and Virology, Department of Pathology, Stellenbosch University and 
NHLS, tygerberg, South Africa 
Background: In the era of antiretroviral therapy (ART), the risk of acquired immune deficiency 
syndrome (AIDS)-related deaths has decreased and people living with Human 
Immunodeficiency Virus (HIV) have prolonged life spans. HIV-infected patients are now at 
increased risk of developing cardiovascular disease (CVD) and other inflammatory-associated 
complications. Activated platelets play a key role during infection and the inflammatory process 
by mediating interactions between cells of innate immunity and the endothelium. Soluble 
markers of platelet activation are increased during HIV-infection. P-selectin (CD62P) is 
expressed on the platelet surface only upon platelet activation. Activated platelets play a role in 
HIV-induced atherosclerosis through the expression and release of mediators that induce 
endothelial activation and support leukocyte adhesion to the inflamed vessel wall.  
Aim: To determine the levels of platelet activation and function by Flow Cytometry in HIV-
infected individuals as compared with uninfected controls; and further, to correlate these levels 
with full blood count, coagulation and other inflammatory parameters.  
Methods: In this study, a total of 57 adult South Africans were recruited from a clinic in the 
Western Cape. These included 32 HIV positive, ART- naïve patients and 25 HIV negative 
controls. Platelet activation and platelet function were investigated using a novel whole blood 
Flow Cytometry assay: Platelet-specific markers CD41a and CD42b were used to ensure 
platelet-specific gating. CD62P expression was used to evaluate platelet activation. Platelet 
function was evaluated by investigating the response of platelets to endogenous agonists; 
adenosine diphosphate (ADP) and arachidonic acid (AA) at varying concentrations. A full blood 
count and differential as well as fibrinogen levels were determined using routine hematology 
laboratory analyzers. 
Results: Baseline levels of CD62P expression were significantly higher in treatment-naïve HIV 
positive patients compared with uninfected controls (mean %CD62P 71.74 + 2.18 vs control 
54.52+ 2.42; p=<0.0001). CD62P expression correlated directly with platelet counts (r=0.374, 
p=0.042) and platelet counts showed an inverse correlation with viral loads (r=-0.65, p=0.0061). 
Fibrinogen levels correlated with absolute WCCs (r=0.659, p=0.0021); absolute neutrophil count 
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(r=0.619, p=0.0105); absolute monocyte count (0.562, p=0.0235) and hsCRP (r=0.688 
p=0.0011). Importantly, fibrinogen showed a negative correlation with CD4 counts (r=-0.594, 
p=0.0014) and may be a valuable marker of prognosis in treatment- naïve, HIV positive patients. 
HsCRP levels correlated with absolute neutrophil counts (r=0.392, p=0.0005).The HIV Group 
showed an overall hyper-response to ADP at a concentration 0.025 µM as compared to 
uninfected controls (62.34 + 9.7 vs control 36.90 + 5.7, p=0.0433). 
Conclusions: We describe a novel Flow Cytometry technique that may be used to evaluate the 
levels of platelet activation and function in HIV-infected patients. In addition we report a cost-
effective panel in the form of fibrinogen, WCC and platelets that may be valuable in predicting 
the progression to AIDS or other inflammatory- associated complications in treatment-naïve HIV-
infected patients. This may impact on patient management prior to initiation of ART and provide 
a tool for monitoring responses to treatment. Longitudinal studies will be required to assess risk 
of thrombosis based on these assays and the potential for application in other chronic 
inflammatory conditions.  
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Laboratory medicine congress 2013, JULY 28-31. Cape Town international convention 
centre in Cape Town, South Africa 
The value of flow cytometry in the measurement of platelet activation and aggregation in 
human immunodeficiency virus (HIV) infection. Bongani B. Nkambule, Glenda Davidson 
,Hayley Ipp. Divisions of Haematology, Department of Pathology, Stellenbosch University, 
Tygerberg 1 . Department of Biomedical sciences, Faculty of Health and wellness sciences, 
Cape Peninsula University of Technology, Bellville, South Africa 2. 
Background: The activation status of platelets in HIV infection could be important as HIV is 
associated with a higher risk for thrombosis and cardiovascular disease. Platelet flow cytometry 
offers the assessment of platelets in their physiological state with minimal in vitro activation. 
Platelet P-selectin (CD62P) and platelet glycoprotein IV (CD36) have been described as 
markers of platelet activation and aggregation respectively. 
Objective: To measure platelet function in HIV using a novel whole blood platelet flow cytometry 
assay 
Method: 36 (ARV naïve) HIV+ve patients and 25 HIV-ve controls were recruited from a Clinic in 
the Western Cape. The response of platelets to adenosine diphosphate (ADP) was assessed at 
two concentrations (0.04mM, 0.2mM ADP). The expression of CD62P and CD36 was used to 
evaluate platelet function. 
Results: %CD62P was higher in HIV+ve patients compared with uninfected controls (mean 
%CD62P 47.62 + 4.214 vs control 33.58+ 3.15; p=0.00335). In addition baseline levels of CD36 
expression were significantly higher in HIV+ve patients compared with controls (mean %CD36 
41.73 + 2.9 vs control 34.13 + 4.04; p=0.0488). Furthermore, the HIV group showed a 
significantly higher overall response at 0.04mM ADP (HIV mean %CD62P 69.64 + 3.9 vs control 
61.17; p=0.0476) and at 0.2mM ADP (HIV group mean %CD36 80.11 + 3.98 vs control 70.39 + 
1.865; p=0.0407). 
Conclusions: We describe a platelet flow cytometry assay that asseses and discriminates 
between resting and activated platelets in HIV patients. We also report that, although platelets 
are significantly activated in HIV, they retain their functional capacity 
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CHAPTER 1 
1.1 Introduction 
South Africa has the highest number of People Living with HIV (PLWH), which is estimated at 
5.3 million. This represents a quarter of the burden of HIV in sub-Saharan Africa (Appay et al., 
2008). The improved access to antiretroviral therapies (ART) has resulted in an increase in the 
life span of HIV infected patients currently on uninterrupted ART (El-Sadr et al., 2006). However, 
analysis of data from the large SMART study has shown that markers of inflammation correlate 
with adverse outcomes in patients on anti-retroviral regimens (El-Sadr et al., 2006). Therefore, 
despite adequate control of viral loads in first-world countries, an era of non-AIDS related 
deaths, such as myocardial infarctions and cerebrovascular accidents (CVA‘s) now prevails 
(Matta et al., 2008). The incidence of coronary heart disease in developed countries is three-
times more in HIV-infected patients as compared to the general population (Vitetecoq et al., 
2003). The on-going activation of the immune system has been identified as a key driving force 
in the pathogenesis of these non-AIDS related deaths (Kuller et al., 2008). An emerging 
paradigm is the close association of inflammation with thrombosis, and platelets appear to be 
key role players (Jahoor et al., 1998). Inflammation plays an important role in platelet activation 
and enhances thrombin formation which further activates platelets. This therefore provides a 
positive feed-back system (Jahoor et al., 1998). Activated platelets are found at the sites of 
inflammation and release a variety of pro-inflammatory mediators which amplify the inflammatory 
response (Woollard et al., 2008). During the inflammatory response to invading pathogens, it is 
important for the body to regulate the balance between pro- and anti-inflammatory mediators 
(Woollard et al., 2008). Inflammation induces an imbalance between endothelial pro-coagulant 
and anti-coagulant properties which is facilitated by the interaction between leukocytes, 
endothelial cells and platelets (Lindemann et al., 2008)). Studies have suggested that 
unregulated on-going inflammation is a major predisposing factor to thrombotic complications in 
HIV-infection (Wagner et al., 2003; Corrales-Medina et al., 2010). 
 
Activated platelets play a role in HIV-induced atherosclerosis through the expression and 
release of mediators that induce endothelial cell activation and microparticle formation which 
support the adhesion of leukocytes to the inflamed vessel wall (Woollard et al., 2008). Platelets 
are the first cellular elements to accumulate at the site of vascular damage and are key elements 
involved in the processes of haemostasis, inflammation, atherosclerosis and tissue repair 
(Vandendries et al., 2004). Atherosclerotic plaques contain pro-coagulant proteins and platelet 
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activators that are exposed upon plaque rupture (Joven et al., 2006).  These findings triggered 
interest in platelets as potential key players in forming a link between inflammation, coagulation 
and thrombus formation following plaque rupture. In particular, studies which have focussed on 
the interactions of various cells have led to the establishment of an evolving role of platelets in 
the inflammatory and coagulation process (Webber et al., 2008). However the relevance of 
these interactions is not fully understood in the context of HIV. Activated platelets form 
complexes with neutrophils and monocytes, with subsequent neutrophil and monocyte activation 
(Thornton et al., 2010). In addition, they induce neutrophil activation and degranulation via the 
expression of certain molecules such as P-selectin (CD62P) and PSGL-1 interaction (Inwald et 
al., 2003).  
 
1.2 Statement of the problem 
Human immunodeficiency virus (HIV) infection is well established as an inflammatory condition.  
Recent studies have highlighted an increase in non-AIDS related complications such as 
cardiovascular disease (CVDs) and strokes, amongst people living with HIV (PLWH). Research 
has also shown that platelet activation and platelet induced complexes such as platelet-
monocyte aggregates (PMAs) and Platelet-Neutrophil aggregates (PNAs) induce coagulation 
with subsequent thrombus formation in animal models. However, these complexes have not 
been evaluated in the context of chronic HIV infection. Thus, investigation of the levels of 
circulating activated platelets, PMAs and PNAs may aid in evaluating the thrombotic risk profile 
of PLWH. This may add value to monitoring and stratifying HIV infected patients who are at an 
increased risk of thrombotic events.  
Platelet aggregometry has been considered as the gold standard for the assessment of platelet 
aggregation and function. However, standardization of this technique has proved to be 
complicated. Recent advances in platelet flow cytometry has provided a technique which has  
the potential to  standardize rapid platelet function assays and which may be utilized for the 
evaluation of platelet function in various inflammatory conditions and malignancies. 
Patients with chronic HIV-infection are at increased risk of thrombotic complications such as 
myocardial infarctions and strokes. Recent work has highlighted the important association 
between markers of inflammation and coagulation and increased risk of these adverse events. 
This work may have an impact on the patient management strategies in resource-limited 
settings. In addition, minimal work has been performed on platelet function in the context of HIV-
infection; and particularly in a cohort of asymptomatic, untreated patients as defined for this 
study. Therefore, the aim of this project was to evaluate the relationship between platelet 
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function and immune activation and disease progression in PLWH using novel flow cytometric 
techniques. 
 
1.3 Objectives of the study 
This was achieved by the following objectives: 
I. To optimize a flow cytometry based assay to measure platelet activation and aggregation, 
platelet derived microparticles, PMAs and PNAs. 
II. To measure baseline levels of platelet activation by flow cytometry in HIV infected and 
uninfected healthy controls. To correlate these baseline levels with Fibrinogen and D-dimer 
levels  
III. To measure platelet kinetics in HIV, by determining differences in platelet indices between 
HIV infected and uninfected controls. To correlate these baseline indices with markers of 
immune activation and disease progression.  
IV. To determine platelet function in chronic HIV infection by stimulation with the endogenous 
agonists; arachidonic acid (AA); Collagen and adenosine diphosphate (ADP)  
V. To measure the baseline levels of PMAs and PNAs.To measure the levels of monocyte 
activation and tissue factor (TF) expression and to compare these levels with PMAs. To 
further evaluate PMAs and PNAs post stimulation with lipopolysaccharide (LPS). 
VI. To evaluate and measure the levels of platelet derived microparticles and to correlate these 
levels with CD4 counts, activated CD8 cells and viral load tests  
 
1.4 Study approach 
The overall objective of the study was to determine associations between platelet function and 
markers of immune activation and disease progression in HIV. This was achieved by evaluating 
parameters of platelet activation and function such as, platelet indices; cell surface expression of 
markers of platelet activation (CD62P) and aggregation (CD36); platelet response to 
endogenous agonists; platelet leukocyte aggregates and microparticles and platelet derived 
microparticles. The study was divided into five cross-sectional cohorts, in which each study 
evaluated a specific aspect of platelet activation and function. These measurements were then 
correlated with well-established markers of immune activation and disease progression in HIV.  
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CHAPTER 2  Literature review 
2. Introduction  
An estimated 9.7 million people living with human immunodeficiency virus (PLWH) are currently 
on antiretroviral treatment (ART) in developing countries (UNAIDS, 2012). South Africa has the 
highest number of PLWH in Sub Saharan Africa (Losina et al., 2009) and the accessibility and 
availability of antiretroviral drugs has led to an increase in the life expectancy of PLWH (Rehle et 
al., 2010). The aging population of PLWH are now faced with an increasing trend of 
inflammatory and thrombotic complications (Savès et al., 2003; Matta et al., 2008). Unregulated 
inflammation appears to drive immune activation and may be a key predisposing factor of non-
AIDS related deaths (Mallon, 2013). Growing evidence supports the involvement of platelets in 
both immune regulation and the propagation of inflammation (Semple et al., 2011).  
This review focuses on the key aspects of platelet function in inflammation, coagulation and 
cellular interactions. Cellular components which are involved in the maintainance of haemostasis 
and that directly interact with platelets, such as endothelial cells, neutrophils and monocytes, will 
be discussed as they may regulate immune function and the inflammatory process. Although the 
pathogenesis of HIV is not the primary focus of this review, aspects of the immune response are 
briefly dealt with. PubMed and google scholar data bases were searched using the terms; 
―Platelet function‖ HIV pathogenesis‖, ―Immune activation‖, ―HIV ‖,―Platelet activation‖, ―platelet 
CD62P‖, ―Platelet function‖, ―aggregation‖, ―platelet CD36‖, ―platelet signalling‖, ―platelet 
agonists‖ ―thrombosis‖, ―Platelets in HIV‖, ―aggregometry‖. Articles citing the selected sources 
were also accessed to identify new knowledge and advances in the reported work. The 
reference list of the selected sources was used to identify key sources of the current topic.  
 
2.1. Inflammation and immune activation 
In order to understand the connection between platelets and the immune response a brief 
introduction to inflammation is required.The inflammatory response is categorised into two 
phases which are identified as the acute and chronic phase (Kumar et al., 2007). During 
inflammation, it is crucial that a fine balance between pro- and anti-inflammatory mediators is 
maintained (Jahoor et al., 1999). Inflammation plays an essential role in resolving infection or 
tissue damage and maintaining a state of haemostasis (Barton et al., 2008). Preferably, the 
inflammatory response should be rapid, microbe-specific and self-limiting to avoid consequential 
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damage to the host as observed in chronic infections (Nathan, 2002). The physiological function 
and pathological consequences of inflammation are  
dependent on the type of stimulus involved (Medzhitov et al., 2008). Notably, an immune 
response is only initiated as a result of an infection or antigen and is facilitated by receptors of 
the innate immune system which include toll-like receptors (TLRs), pattern recognition receptors 
(PRR) and nucleotide-binding oligomerization-domain protein like receptors (NRLs) (Medzhitov 
et al., 2008, Barton et al., 2008). Signal transduction, facilitated by TLRs and PPRs, are crucial 
in the recognition of pathogens and initiation of the inflammatory response. (Medzhitov, 2007). 
The acute inflammatory response coordinates the delivery and recruitment of plasma 
components and leukocytes to the sites of infection (Kumar et al., 2007) and is coordinated by a 
complex regulatory network of mediators of inflammation (Keating et al., 2012). These mediators 
are categorized based on their biochemical properties (table 2.1) (Medzhitov, 2008).  
If pathogen induced stimulation persists as a result of inadequate clearance, the inflammatory 
process acquires new characteristics which are associated with chronic inflammation (Kumar et 
al., 2007). The chronic inflammatory process is characterised by the infiltration of macrophages, 
T cells and subsequent granuloma formation (Drayton et al., 2006). The inflammatory pathway 
mainly consists of four components which involve; inducers which are triggers (Infection or 
tissue injury), sensors (cell receptors such TLRs), mediators (cytokines and chemokines) and 
effectors (tissues and cells affected by mediators of inflammation) (Medzhitov et al., 2008). 
However, the signalling mechanisms of these pathways and mediators are beyond the scope of 
this review and will not be discussed in detail. 
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Table 2.1. Inflammatory mediators (compiled by author based on work by Medzhitov, 2008) 
Mediator Mediator Effects 
Vasoactive 
amines 
Histamine, serotonin vascular permeability, vasodilation, 
vasoconstriction 
Vasoactive 
peptides 
Substance P, kinins Vasodilation, Vasoconstriction  
Complement 
fragments  
Anaphylatoxins Monocyte & granulocyte recruitment, mast cell 
degranulation 
Lipid 
mediators 
Eicosanoids & plate-
let activating factors  
Vasodilation, vasoconstriction, increased vascular 
permeability & platelet activation 
Cytokines TNFα, IL-1, IL-6 Endothelium, leukocyte activation, induction of 
acute response 
Chemokines  CXCL12, 
CCL9,CCL20,CCL21 
Leukocyte extravasation and chemotaxis 
Proteolytic Elastin, cathepsins, 
matrix 
metalloproteinases  
Degradation of ECM and basement-membrane 
proteins 
 
2.1.1. Characteristics of the inflammatory response 
Inflammation has been well described in microbial infections, where macrophages and mast 
cells which reside in tissue, recognise foreign structures and secrete inflammatory molecules 
(Kumar et al., 2007; Medzhitov et al., 2008). During injury, immune cells secrete proinflammatory 
cytokines; chemokines; prostaglandins and bradykinins that constitute an inflammatory milieu 
that induce immune activation (Chen et al., 2013). These include interleukin 1β; tumor necrosis 
factor α (TNFα) and monocyte chemotactic protein-1 (MCP-1) (Liao, 2013). Cytokine induced 
endothelial activation results in the extravasation of neutrophils while retaining red blood cells in 
the vasculature (Pober et al., 2007). During activation, endothelial cells express surface 
adhesion molecules such as VCAM-1, ICAM-1 and E selectin (Liao, 2013).  
Although several haemostatic functions of inflammation remain unclear, extensive work has 
been done to unravel the physiological role of the host immune response in pathogen-induced 
inflammation (Medzhitov et al., 2008). The inflammatory process is also characterised by 
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multiple interactions between leukocytes and platelets (Semple & Freedman, 2010) which are 
facilitated by P-selectin expressed on the surface of activated platelets and endothelial cells 
(Romo et al., 1999). Platelets initiate and propagate inflammation including immune mediated 
inflammation (table 2.1) (Andrews et al., 2006). The inflammatory process is mediated by 
various cytokines and chemokines which are secreted upon immune activation (Keating et al., 
2012). Platelets have been identified as key role players in the regulation of vascular 
inflammation (Semple & Freedman, 2010) and acute inflammation has been linked with 
activation and impairment of the coagulation system (Levi et al., 2008). Mechanisms of 
inflammation induced coagulation, involve the extrinsic coagulation pathway in which tissue 
factor directly initiates the activation of the clotting cascade (Levi et al., 2010). In addition, active 
coagulation is regulated by three main anticoagulation pathways all of which are impaired during 
the inflammation process (Levi & van der Poll, 2005).  
 
2.1.2. Immune activation and HIV 
HIV targets CCR5+ CD4+ T Cells and to a less extent macrophages and dendritic cells (Siliciano 
et al., 2003; Gresele et al., 2012). CCR5+ CD4+ T cells which are found in the gastrointestinal 
tract (GIT) are predominantly activated memory CCR5+ CD4+ T cells (Appy & Sauce, 2008). 
These memory T cells are susceptible to viral infection due to their inherent activation status 
(Brenchley et al., 2004). The consequences of immune activation and inflammation in HIV have 
been comprehensively reviewed in the literature (Appy & Sauce, 2008; Ipp & Zemlin, 2013). The 
knowledge gained from studies conducted on samian immunodeficiency virus (samian 
equivalent of HIV) hosts, suggest that chronic immune activation is a key contributor to 
pathogenic infection (Chahroudi et al., 2012). Furthermore, research has also shown that levels 
of T cell activation remain high in HIV infected individuals despite successful antiretroviral 
therapy (ART) (Sauce et al., 2011).  
Elevated markers of lymphocyte and monocyte activation have been described in PLWH 
(Grossman et al., 2002; Deeks et al., 2004; Funderburg et al., 2010; Karim et al., 2013) which 
has led to the theory that  immune activation is a key role player in HIV infection (Rotger et al., 
2011; Sauce et al., 2011). Previous observations highlight the vicious cycle of inflammation, 
immune activation and HIV replication (Decrion et al., 2005). In addition, a positive feedback 
mechanism which involves HIV replication and immune activation resulting in CD4+ T cell 
depletion has been described (Appy & Sauce, 2008).The gradual depletion of CD4+ T cells is a 
characteristic feature of untreated HIV infection (Deeks et al., 2004) and several direct and 
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indirect mechanisms may account for this phenomenon (Gasper-Smith et al., 2008; Richard et 
al., 2010). 
Immune activation is a major cause of CD4+ T cell depletion (Grossman et al., 2002). The loss 
of mucosal integrity and translocation of bacterial products into the circulation have been 
described as a contributor to the overall immune activation in HIV (Cassol et al., 2010) (figure 
2.1). HIV infection is characterised by increased T cell activation which may result in the 
apoptosis of T cells (Duoek et al., 2002). Furthermore, T cell activation and apoptosis could 
initiate the formation apoptotic microparticles (MPs) which have been implicated in immune 
suppression (Frleta et al., 2012). Furthermore, many reports have indicated the survival benefits 
of early ART initiation on immune reconstitution. This has been demonstrated by the 
measurement of circulating CD4+ T cells (Hunt et al., 2003; Goicoechea et al., 2006). 
 
Figure 2.1. Proposed contributors to HIV-associated chronic immune activation (adapted from Paiardini & 
Müller‐Trutwin, 2013) 
Persistent T-cell activation induces increased CD4+ T cell turn over which may result in the 
exhaustion of the immune system and alterations in the regenerative capacity of immune cells 
(McCune et al., 2001). ART restores the concentration of circulating T-cells via mechanisms that 
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include; decreasing cell turnover; redistribution of T cells and increased thymic output (Duoek et 
al., 2000). However, complete reconstitution of CD4+ T cells still remains a major challenge 
(Garcia et al., 2004; Moore et al., 2007). Alterations in the homing of CD4+ cell to the gut 
mucosal membrane, contributes to the mechanisms which inhibit the complete reconstitution of 
CD4+ cells in the GIT (Mavigner et al., 2012). Chronic immune activation persists in HIV infected 
individuals which leads to several inflammation associated complications in both ARV naïve and 
individuals on ART (Kaplan et al., 2011). Elevated levels of pro-inflammatory cytokines have 
been described in HIV (table 2.1) (Paiardini & Müller‐Trutwin, 2013) and this pro-inflammatory 
cytokine milieu further enhances the hypercoagulable state (Paiardini & Müller‐Trutwin, 2013).  
Elevated levels of pro-inflammatory cytokines such as; interleukin 1β (IL-1β); interleukin 6 (IL6) 
and tumor necrosis factor α (TNFα); have been described in HIV (Appy & Sauce, 2008). IL-1β, a 
major activator of endothelial cells is associated with CD4 T cell loss during the acute phase of 
HIV, whereas, IL-6 and TNFα are associated with disease progression in the chronic phase of 
the infection (Paiardini & Müller‐Trutwin, 2013). Macrophages, activated by tumor Necrosis 
Factor α (TNFα), induce the expression of the surface adhesion molecules P-selectin and E-
selectin on endothelial cells (Wagner et al., 2003). These mediate the tethering of leukocytes to 
the endothelial cells and facilitate rolling along this surface (Joven et al., 2006). Endothelial 
dysfunction and increased expression of adhesion molecules and inflammatory cytokines such 
as, vascular cell adhesion molecule-1 (VCAM-1), P-selectin, monocyte chemo-attractant protein-
1 (MCP-1) and von Willebrand factor (VWF), have been described during chronic HIV infection 
(Joven et al., 2006). Activated platelets secrete IL-1β amongst several chemokines, cytokines 
and coagulation factors involved in immune activation and coagulation (discussed in section 
2.6.1) (Zarbock et al., 2007). 
 
2.1.3. Markers of immune activation in HIV 
Several markers of immune activation and disease progression have been described in HIV 
(Hazenberg et al., 2003). Notably, markers of T cell activation and exhaustion have been shown 
to be markedly increased. The expression of CD38 on CD8+ T cells a marker of early T cell 
activation has been established as a strong predictor of disease progression in HIV (Liu et al., 
1998; Tuaillon et al., 2009). In addition, studies have shown associations between HIV, viral 
RNA levels and CD38 expression on CD8 + T cells (Tuaillon et al., 2009). Interestingly, these 
included markers of inflammation and active coagulation. In the large SMART study elevated D-
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dimer levels were associated with increased mortality and risks of cardiovascular disease (El-
Sadr et al., 2006).  
Recent studies have established the pivotal role that activated platelets play in immune 
activation, inflammation and coagulation (Carter et al., 2012; Morrell et al., 2014). This has led to 
the recognition of platelets as immune cells that link inflammation with thrombosis (von 
Hundelshausen and weber, 2007; Ware et al., 2013). Platelets express a repertoire of surface 
membrane receptors that enable them to directly interact with various cells and pathogens 
(Rivera et al., 2009; Flaujac et al., 2010) and the engulfment of HIV particles by activated 
platelets has been described. (Chaipan  et al., 2006). However, the physiological consequences 
of these interactions still remain unclear (Flaujac et al., 2010).  
 
2.1.4. Markers of platelet activation and coagulation 
Several biomarkers of inflammation have been described in HIV (Armah et al., 2012). Fibrinogen 
is an acute phase reactant (Jahoor et al., 1999) and a precursor of the blood coagulatory protein 
fibrin, while the degradation of fibrin to D-dimer is a measure of the formation and subsequent 
dissolution of blood clots (Thorton et al., 2010). Platelets interact with fibrinogen via their CD 41a 
(GPIIb/IIIa) receptor and this may result in platelet activation and secretion of P-selectin 
(CD62P). The expression of P-selectin (CD62P) on platelets is a well-recognized marker of 
platelet activation (Vandendries et al., 2004). This adhesion molecule is of interest because of its 
role in modulating interactions between blood cells and the endothelium, and the possible use of 
the soluble form as a plasma predictor of adverse cardiovascular events (Ridker et al., 2001). 
Although present on the external cell surface of both activated endothelium and activated 
platelets, it now seems clear that most, if not all, of the measured plasma P-selectin is of platelet 
origin (Ridker et al., 2001). Increased levels of soluble P-selectin, measured in citrated plasma, 
have been shown to predict which patients are at risk of an adverse cardiovascular event (Ridker 
et al., 2001; Blann et al., 2003). Of interest, elevated levels of CD62P have been reported in HIV 
infected individuals (Mayne et al., 2012; Nkambule et al., 2014) 
Platelet Glycoprotein (GP) IV (CD36) is a class B scavenger receptor that is involved in 
angiogenesis; atherosclerosis; inflammation and lipid metabolism (Podrez et al., 2007). 
Increased CD36 expression upon platelet aggregation has been described (Berger et al., 1993; 
Ghosh et al., 2008; Nkambule et al., 2014).Berger et al., using thrombin-stimulated platelets 
domenstrated an increase CD36 expression on fully degranulated platelets (Berger et al., 1993). 
The authors further showed that the intracellular pool of CD36 is associated with the open 
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canicular system and the inner surface of the α-granule membrane (Berger et al., 1996). A study 
conducted by Aiken et al., showed increased platelet aggregation induced by anti-CD36 
antibody clone OKM5 at a concentration of 20nmol/l in the presence of calcium and magnesium. 
Binding of the antibodies induced platelet aggregation and alpha granule and dense granule 
secretion (Aiken et al.,1990). CD36 acts a thrombospodin (TSP) receptor and is a component of 
the multiprotein complex (TSP/CD36/GPIIb-IIIa/Fg) found on activated platelets. This complex 
formed by the the colocalization of TSP with GPIIb-IIIa-fibrinogen (Fg) (Leung et al., 1984) and it 
may play role in the consolidation of platelet aggregates (Leung et al., 1982). Notably CD36 
mediated signalling has been recently described in signalling events that occur post aggregation 
(Silverstein, 2014). Elevated levels of fibrinogen have also been correlated with higher risk of 
vascular inflammatory conditions such as hypertension and atherosclerosis (Menezes et al., 
2009) and importantly, in various inflammatory conditions increased levels of D-dimers have 
been shown to correlate with coagulation activity and increased risks of thrombotic events 
(Menezes et al., 2009). Previous studies have demonstrated that oxidized lipids may induce 
activation of platelets via the CD36 receptor (Klinger et al., 2002). The authors proposed that this 
could be a possible explaination for the association of high levels of low-density lipoprotein 
cholesterol and thromboembolic risks, in a population with high baseline levels of LDL 
cholesterol. Notably, data on the expression of CD36 in HIV cohorts is scarce. Increased levels 
of platelet CD36 have however been described in both diabetes and HIV (Alkhatatbeh et al., 
2013; Nkambule et al., 2014).  
 
2.2. Megakaryopoiesis and thrombopoiesis 
Megakaryocytes (MKs) are derived from hematopoietic stem cells (Geddis et al., 2010). Upon 
differentiation into megakaryoblasts, these cells lose the capacity to proliferate and undergo 
maturation via endomitosis, a process involving nuclear division without cytoplasmic divisions 
(Bluteau et al., 2009). This results in the formation of polyploid MKs in the bone marrow 
(Hoffmann et al., 2014). The degree of MK ploidy is associated with both the rate of platelet 
production and peripheral platelet concentrations (Kuter, 1996; Raslova et al., 2003; Hoffmann 
et al., 2014).Megakaryoblasts proliferate and differentiate in response to thrombopoietin (TPO) 
stimulation (Geddis et al., 2010; Morita et al., 2010). TPO is a major regulator of 
megakaryopoiesis that binds c-Mpl, expressed on the surface of MKs (Schulze et al., 2005; 
Machlus et al., 2014). MKs are the largest hematopoietic cells present in the bone marrow milieu 
(Geddis et al., 2010).  
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In normal haemostasis, MKs regulate the rate of platelet formation and maintain a constant 
plateletcrit (Machlus et al., 2014). The exact mechanisms underlying platelet formation remain 
unclear, however two models of platelet formation have been proposed. Firstly, the 
fragmentation model in which platelets are formed as a result of MK fragmentation in the lungs 
and secondly, the proplatelet model which involves the formation of pseudopodial extensions of 
Mks that extend into marrow sinusoids (Italiano et al., 1999; Richardson et al., 2005; Junt et al., 
2007). Interestingly Schwertz et al., reported on the capability of platelets to undergo cell division 
and generate functional progeny (Schwertz et al., 2010) however the underlying biochemical 
mechanisms of these models are beyond the scope of this review and will not be discussed in 
detail. 
 
2.2.1. HIV and the megakaryocyte lineage 
HIV associated thrombocytopenia (HAT) has been reported as a common clinical manifestation 
of HIV. In a previous meta-analysis, a HAT prevalence of 5-30% in HIV infected individuals was 
reported (Liebman et al., 2007). However in the era of cART the prevalence of HAT has 
significantly declined, with a reported prevalence of 3.2% (Marks et al., 2009). 
Thrombocytopenia is recognized as an independent predictor of mortality in untreated HIV 
infection (Johannessen et al., 2008). Interestingly, in haemophiliacs thrombocytosis is 
associated with disease progression and mortality (Rieg et al., 2007). Thrombocytosis has been 
implicated in immune reconstitution inflammatory syndrome (IRIS) and in HIV-associated CVDs 
(Espinosa et al., 2010). HAT is dependent on the phase of HIV infection, an initial transient drop 
in platelet counts occurs in the acute phase of infection (Figure 2.2) with a the subsequent 
persistent decline during chronic infection (Wachtman et al., 2006).  
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Figure 2.2 Human immunodeficiency virus (HIV) related thrombocytopenia (Gardiner et al., 2013). 
The figure illustrates effects of HIV on platelet kinetics. In normal healthy individuals (A) Platelets circulate 
in an inactivated state and retain P-selectin in the α-granules.Platelet counts are maintained by the 
balance between clearance and megakaryocyte mediated thrombopoeisis. Thrombocytopenia as result of 
HIV or other causes may be associated with enhanced platelet-leukocyte aggreagtes (B) and 
megakaryopoiesis is inhibited by HIV GP120 interactions (Zhang et al., 2010). HIV induces platelet 
activation via direct and indirect mechanisms this results in platelet degranulation and excocytosis of P-
selectin to the surface of activated platelets. (C) After treatment it is unpredictable whether normal platelet 
count recovers. In HIV, or other infection, autoimmune or drug-induced thrombocytopenia, systemic 
effects on platelet clearance and /or megakaryocytes/platelet production may complicate both the clinical 
diagnosis and monitoring of treatment. 
 
The aetiology of HAT in the era of highly active antiretroviral therapy HAART, points to HIV RNA 
replication itself rather than low CD4 counts or AIDS related disease (Marks et al., 2009). The 
underlying mechanisms are complex and are multi faceted. HIV directly interacts with 
megakaryocytes (MacEneaney et al., 2011) and mature platelets (Flaujac et al., 2010). 
Thrombopoietin (TPO) is a major cytokine involved in regulating thrombopoiesis and platelet 
counts (Michele et al., 2007). MacEneaney et al., demonstrated the effects of HIV GP120 protein 
on the differentiation of TPO induced megakaryocytes. The authors suggested that GP120 
induces increased transforming growth factor β1 (TGFβ1) and APRIL down-regulation which 
results in the apoptosis of GPIIb/IIa (CD41) and CD61 subsets (MacEneaney et al., 2011). 
Zhang et al., further demonstrated that in the context of HIV, thrombocytopenia may be the 
result of the inhibition of megakaryopoiesis through c-Mpl facilitated inhibition (Zhang et al., 
2010). The authors assessed the role of the V3 loop of the GP120 envelope protein in the 
lineage specific inhibition of megakaryopoiesis. They constructed HIV-1 V3 loop clones from 
isolates obtained from thrombocytopenic HIV-1 infected patients and using the SCID-hu Thy 
model, the authors reported significant loss in the expression of the Tpo receptor (c-Mpl) from 
the SCID-hu implants. They concluded that the Tpo/ c-Mpl signalling pathway plays a pivotal role 
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in megakaryopoiesis and that decreased expression of c-Mpl may inhibit the differentiation of 
CD34+ progenitor cells into megakaryocytes (Zhang et al., 2010).  
 
2.3. Platelet morphology and granules 
Platelets circulate as anuclear discs with a small diameter of 2-3µm (Linden & Jackson et al., 
2010). Three distinct zones have been described in platelets which include; (1) a peripheral zone 
that consists of coagulation factors and endogenous platelet agonists (Rendu et al., 2001); (2) 
sol-gel zone that contains the open canalicular and dense tubular system; (3) organelle zone 
that contains platelet granules and several chemokines and mitogenic factors (Cimmino & 
Golino, 2013). The platelet granules contain several chemokines, coagulation proteins and 
immunological molecules (Blair & Flaumenhaft, 2009). 
2.3.1. Platelet granules  
Platelets contain three distinct types of granules: alpha (α) granules, dense granules and 
lysosomes (figure 2.3) (Blair & Flaumenhaft, 2009; Fitch-Tewfik et al., 2013). Alpha granules are 
the largest (200-400nm) and most abundant type of granules found in platelets (Harper et al., 
2010; Blair & Flaumenhaft, 2009). The dense granules are the smallest (150nm) and contain 
high levels of phosphate and calcium (Ca2+) amongst their granular contents (Rendu et al., 
2001).  
Lysosomes are intermediate in size (200-250nm) and contain hydrolytic enzymes that are active 
towards constituents of the extracellular matrix (ECM). Lysosmes may be released during 
platelet activation, however a more potent stimulus is required compared to that which facilitates 
α granule secretion (Ren et al., 2007). The functional role of lysosomes remain unclear, however 
they have been associated with the regulation of thrombus formation and remodelling of the 
ECM (Ciferri et al., 2000). Interestingly, Thon et al., described the presence of a novel T granule 
that contains toll like receptor 9 (TLR9) transcripts and may play a crucial role in platelet 
mediated immune regulation (Thon et al., 2012).  
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2.4. Platelet function 
The essential role that platelets play in wound healing and inhibition of haemorrhage has been 
well established. Platelet receptors and endothelial cell molecules play a crucial role in inducing 
platelet activation and aggregation which is necessary to maintain haemostasis. Upon vascular 
injury, molecules present on the extracellular matrix (ECM) are exposed. Amongst these, vWF 
and collagen are the most potent platelet agonists which induce platelet activation and 
irreversible platelet aggregation (Ruggeri et al., 2006; Kuijpers et al., 2009). Several ECM 
components react with platelets such as fibronectin, laminin and thrombospodin (Jurk & Kehrel, 
2005) however this review will only focus on major platelet receptors and signaling pathways 
involved in overall platelet function.  
Platelet activation results in the secretion of platelet derived chemokines and molecules that are 
involved in inflammation, proliferation vasoconstriction and coagulation (Projahn & Rory, 2012). 
In normal haemostasis platelets monitor and maintain vascular integrity (Li et al., 2010) . 
Although platelets lack a cellular nucleus they contain mRNA and translational machinery which 
are necessary for protein synthesis (Semple et al., 2011). Changes in normal platelet function 
have been described in coagulopathies (Berger et al., 2010; Klovaite et al., 2011). Shear stress 
plays a crucial role in the modulation of platelet function (Hathcock et al., 2006; Reininger et al., 
2009). The force generating blood flow produces shear stress, which is associated with flow 
rate, blood viscosity and vessel diameter (Cimmino & Golino, 2013). Platelet activation may 
occur in pathologically high shear pressure (Brass, 2010). In general, platelet activation is 
facilitated by platelet agonists and surface receptor interactions (Brass, 2010).  
The shear rate increases with elevated shear force and decreases with increasing blood 
viscosity (Cimmino & Golino, 2013). Platelets, a major contributor to arterial thrombosis in 
diseases such as atherosclerosis, are associated with increased shear stress (Jennings, 2009). 
Platelet adhesion under high shear rates is facilitated by vWF molecules which uncoil from their 
globular shape and stretch. This action exposes the vWF A1 domain (Schneider et al., 2007) 
which allows the platelet GPIbα receptor to bind to the exposed A1 domain. This process may 
result in platelet activation (Nesbitt et al., 2002). vWF is the only subendothelial component that 
is capable of binding circulating platelets to the endothelium at high shear conditions (Ruggeri et 
al., 2006). Interestingly, under conditions of high shear rates platelet aggregation may occur 
independently of platelet activation (Ruggeri et al., 2006). Circulating non activated platelets 
directly interact with soluble vWF via the GPIbα receptor, resulting in the formation of platelet 
aggregates and promoting platelet recruitment without inducing platelet activation (Reininger et 
al., 2009). Platelet function can be classified into four distinct steps which involve several 
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biochemical and cellular processes. These include adhesion; activation; secretion and 
aggregation (Cimmino & Golino, 2013). 
2.4.1. Adhesion 
Circulating platelets are non-adherent and are activated upon exposure to soluble platelet 
agonists and adhesive proteins immobilised at sites of vascular injury (Li et al., 2010). Platelet 
adhesion and aggregation are characterised by the transition of platelets from freely circulating 
in blood to binding and interacting with ligands expressed on the endothelial surface (Ruggerri et 
al., 2007). Platelet adhesion and aggregation are two distinct biochemically complex processes 
which are essential for normal platelet function (Cimmino & Golino, 2013). Platelet adhesion 
involves the tethering of platelets on the vessel wall or the extracellular matrix upon vascular 
injury (Vargo-Szabo et al., 2008). This process is dependent on the collective function of platelet 
cell surface receptors which facilitate the adhesion of platelets to the endothelial surface 
resulting in the activation and aggregation of platelets (Ruggerri et al., 2007). Platelet adhesion 
is facilitated by a receptor complex glycoprotein (GP) Ib/V/IX (Cimmino & Golino, 2013).  
The initial tethering of platelets is primarily dependent on GPVI and subendothelial collagen 
interactions (Wu et al., 2002; Vargo-Szabo et al., 2008). These interactions result in the 
adherence of platelets onto the endothelial surface (Brass, 2010). In addition, P-selectin 
(CD62P) plays a crucial role in the adhesion of platelets to activated endothelial cells via PSGL-
1 and GPIb receptor interactions (van Gils et al., 2009). P selectin is largely responsible for 
platelet leukocyte interactions which lead to the rolling and subsequent activation of leukocytes 
bound to the activate endothelium (Maugeri et al., 2009). This process is facilitated by 
chemokines such as monocyte chemoattractant protein I (MCP-I) and RANTES (von 
Hundelshausen et al., 2001). Mechanisms facilitating platelet leukocyte interactions are 
discussed in later sections of this review. 
In response to vascular injury platelets are activated by thrombin and collagen (Brass, 2010). 
Several collagen receptors are expressed on the surface of platelets that are involved in platelet 
tethering and adhesion such as; GPVI and GPIa/IIa (α2β1 integrin) (Vargo-Szabo et al., 2008; 
Angiolillo et al., 2010). GPIa mediates the adhesion of platelets to collagen whereas GPIV plays 
a crucial role in the signalling transduction which results in collagen induced platelet activation 
(Watson & Gibbins et al., 1998). 
Adhesion receptors play a crucial role in initiating platelet activation at sites of vascular injury (Li 
et al., 2010). GPIb or platelets glycoprotein (GP) Ibα is a receptor densely expressed on the 
surface of platelets and binds to the exposed vWF A1 domain. Platelet signalling pathways 
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converge into similar signal transduction pathways involving Src family kinases, phosphoisitide 
3-kinases and immunoreceptor tyrosine-based activation motif (ITAM) (Li et al., 2010). Using an 
animal model, Massberg et al., described the crucial role played by platelet adhesion receptors 
GPIbα and GPαIIb β3 (Massberg et al., 2002). These authors further suggested that activated 
platelets promote atherosclerosis and that inhibition of platelet adhesion receptors including GP 
IIb and P-selectin (CD62P) may result in the reduction of atherosclerotic lesions (Massberg et 
al., 2005).  
Platelet endothelial cell adhesion molecule-1 (PECAM-1) is also an adhesion receptor, 
expressed on endothelial cells, platelets and leukocytes (Delisser et al., 1994; Watt et al., 1995). 
PEDCAM-1 plays a key role in the adhesion and extravasation of leukocytes during inflammation 
and is a mediator of cell activation (Osawa et al., 1997). The role of PEDCAM-1 (CD31) in cell-
cell adhesion has been described and this involves hemophilic or heterophilic interactions 
(Albelda et al., 1992; Sun et al., 1996; Newton et al., 1997). Using CD31-deficient mice Duncan 
et al., demonstrated that CD31 is not crucial in in the formation of platelet aggregates and 
vasculogenesis (Duncan et al., 1999). While Mahooti et al., demonstrated that in CD31-deficient 
mice platelet-endothelial interactions were disrupted and this resulted in an increased bleeding. 
Recent work by De Cuyper et al., also suggested the use of CD31 as a platelet marker in the 
evaluation of platelet function as using monoclonals targeting this receptor do not interfere with 
the platelet aggregation (De Cuyper et al., 2013) 
 
2.4.2. Activation 
Platelet activation is initiated by several agonists in a process facilitated by membrane receptors 
and complex signal transduction pathways (Varga-Szabo et al., 2009). During platelet activation, 
platelet morphology changes from discoid to spherical with filopodia extrusions (Dunois-Larde et 
al., 2009; Jennings et al., 2009). Filopodia are enriched with GPIIb/IIIa and molecules involved 
interactions with platelets in the immediate environment (Brisson et al., 1997). This process 
involves several intracellular signal transduction pathways involving; increased intracellular 
ca2+; phosphoinositide metabolism; phosphorylation and nuclear proteins. Platelet shape 
change leads to actin polymerization and the formation of pseudopodia (Jurk & Kehrel, 2005). 
During platelet activation, degranulation and secretion of granular contents occurs (Nieswandt et 
al., 2003). P-selectin stored in the platelet α granules translocates to the membrane surface and 
mediates interactions between endothelial cells, peripheral circulating platelets and leukocytes 
(Linden et al., 2007; Maugeri et al., 2009). The interactions between vWF and collagen result in 
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increased affinity of collagen (Cruz et al., 2005). Collagen is regarded as a potent platelet 
agonist (Wagner et al., 1996). 
 
Figure 2.5 Aspects of platelet function (compiled by author, based on work Ruggerri et al., 2007; 
Vargo-Szabo et al., 2008). The schematic diagram illustrates the steps involved in platelet function. (1) 
Platelet adhesion is facilitated by adhesion receptors GPIb/V/IX and vWF interactions. (2) Activation 
involves the platelet degranulation and surface P-selectin expression. (3) Secretion of platelet granular 
contents facilitate the recruitment of circulating platelets and activation of leukocytes. (4) Aggregation 
occurs as a result of interactions between activated platelets involving the fibrinogen receptor GPIIb-IIa 
complex. Platelet aggregation may also occur as a result of soluble vWF and GPIbα interactions. 
 
2.4.3. Secretion 
Platelet activation induces platelet degranulation and secretion of chemokines; cytokines; growth 
factors and coagulation factors stored in the platelet granules (Linden et al., 2007). The majority 
of platelet chemokines are released from the α-granules upon activation (Brandt et al., 2000). 
Activated platelets secrete several endogenous agonists such as ADP, TXA2 and serotonin 
(Dale et al., 2002). The secretion of platelet granules is a highly orchestrated process and may 
be dependant on specific transduction signals rather than the general release of platelet 
granular constituents (Italiano et al., 2008). PAR-4 signalling results in the release of anti-
angiogenic granular contents such as endostatin while supressing the secretion of angiogenic 
molecules such as vascular endothelial growth factor (VEGF) (Ma et al., 2005). In contrast, 
PAR-1 facilitates the release of VEGF while inhibiting the secretion of endostatin (shown in 
Figure 2.6) (Ma et al., 2005). PAR1 and PAR2 are major platelet receptors and their role in 
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signalling pathways are mentioned in later sections of this review. The process of platelet 
secretion is orchestrated and stimuli-dependant (White & Rompietti, 2007) and  is critical for 
normal haemostasis (Cimmino & Golino, 2013).  
 
Figure 2.6 Signalling-dependant granule secretions (Adapted from Italiano et al., 2008; White & 
Rompietti, 2009). The figure illustrates deferential secretion of platelet granules that is dependent on the 
type of signalling receptors involved. PAR1 signalling results in VEGF secretion whereas PAR 4 facilitated 
signalling results in endostatin secretion. 
 
2.5. The immunological role of platelets in infectious disease 
The function of platelets as solely role players within haemostasis has changed and they are 
now considered as also having a role within the immune system (Semple et al., 2011). Platelets 
are involved in immune surveillance and the relay of pathogen associated information to innate 
immune cells (Beaulieu et al., 2010). They express several immunoregulatory molecules on their 
surface which include; CD40 and CD40L. These two surface proteins are involved in both T and 
B cell co-stimulation (Semple et al., 2011). In addition, platelets express a variety of surface toll-
like receptors which contribute to the enhanced platelet activity and thrombosis (Panigrahi et al., 
2013). The interaction between platelets with various bacteria and viruses is facilitated by a 
repertoire of platelet surface receptors. These interactions subsequently result in platelet 
activation (Cox et al., 2011) or in the enhancement of receptor function (Tilley et al., 2013). The 
mechanisms underlying platelet-pathogen interactions involve both direct and indirect 
mechanisms. In direct mechanisms the platelet receptor ligands act as bridging proteins which 
bind to pathogens via their relevant platelet receptors (Flaujac et al., 2010). The presence of the 
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Fc receptor FcγRIIa, enables platelets to interact with pathogens by binding to IgG in immune 
complexes (Tilley et al., 2013). Thus platelets can interact with a broad range of bacteria and 
viruses (shown in figure 2.8) and although platelets are acaryote cells, they contain mRNA and 
are capable of synthesizing protein (Semple et al., 2011; Speth et al., 2013). 
2.5.1. Platelet toll-like receptor (TLR) expression 
TLRs, a family of receptors capable of recognizing pathogen associated molecular patterns are 
expressed on neutrophils, monocytes, dendritic cells and platelets (Medzitov & Janeway, 2003) 
and are able to  modulate immune activation in response to pathogens (Elzey et al., 2003). 
Platelets express toll-like receptors (TLRs), (O‘ Neil et al., 2006) and studies suggest that TLR 
expression on platelets serves as a link between platelets and the inflammatory response to 
pathogens (Aslam et al., 2006; Shiraki et al., 2004). Several studies have demonstrated TLRs 
expression on platelets however these findings have been contradicted by some researchers 
(Shiraki et al., 2004; Cognasse et al., 2005; Ward et al., 2005). Montrucchio et al., further 
demonstrated that platelets lack TLR4 and do not bind to LPS (Montrucchio et al., 2003). 
Interestingly, a novel platelet T granule has been reported which contains TLR9 (Thon et al., 
2012).   
 
 
 
 
Figure 2.7 Linking platelets to the immune system by phenotype (adapted from Semple & Freedman, 
2010). The figure illustrates several immunoregulatory molecules expressed/secreted by platelets. (A) 
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Molecules may be acquired by platelets via direct interactions with leukocytes or as a result of plasma 
adsorption. (B) Illustrates molecules expressed constitutively on platelets, while (C) represents molecules 
that are secreted by platelets upon activation.  
2.5.2. The role of TLRs in platelet functions 
The functionality of TLRs in platelets has been studied with a focus on TLR4 and TLR2 (Ståhl et 
al., 2006; Clark et al., 2007; Semple et al., 2007). In an animal model, LPS stimulated mice 
platelets, which were TLR4 deficient, were unable to adhere to fibrinogen. The authors 
demonstrated that through TLR4, LPS can regulate platelet function (Andonegui et al., 2005; 
Beaulieu et al., 2010). TLR4 enables platelets to act as sensory cells which surround and 
recognize pathogens while regulating pro-inflammatory cytokine release (Beaulieu et al., 2010). 
Interestingly, in vitro studies have shown that enterohemorrhagic E. Coli -LPS (EHEC-LPS) can 
bind to platelets via TLR4 and CD62P resulting in increased αIIβ3 integrin and fibrinogen binding. 
The same authors also demonstrate that in vitro LPS stimulation is able to induce ATP and 
CD62P secretion from platelet granules (Zhang et al., 2009).  
The binding of LPS to TLR4 results in platelet activation and increased platelet neutrophil cross-
talk (Aslam et al., 2006). This results in neutrophil activation and bacterial trapping with 
subsequent killing (Aslam et al., 2006). Contradictory findings have been reported however, and 
some investigators have suggested that LPS alone does not induce platelet activation but rather 
enhances agonist-induced platelet aggregation (Zhang et al., 2009). Cognasse et al., 
demonstrated increased CD63 and not CD62P expression post in vitro LPS stimulation 
(Cognasse et al., 2005). Therefore the effects of LPS on platelet function still remain 
inconclusive. 
 TLR2 directly activates platelets inducing platelet adhesion and aggregation via the PI3K/Akt 
signaling pathway (Blair et al., 2009). The activation of the PI3K/Akt pathway results in increased 
CD62P expression, ROS production and αIIβ3 activation (Blair et al., 2009).  
TLR9 has been recently described as a functional receptor in platelets which plays a crucial role 
in modulating platelet function and thrombosis (Panigrahi et al., 2013).  
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Table 2.2. Toll-Like receptors expressed on platelets 
Effects on platelet function TLR Signaling   
pathway 
Aggregation; Adhesion; α granule release, ROS 
production, heterotypic aggregation 
TLR1 ,TLR2, 
TLR6 
PI3K/Akt 
Cytoskeletal rearrangement, α and dense granule 
release; heterotypic aggregation 
TLR4 PKG 
Modulation of platelet function and thrombosis TLR9 MyD88 
 
 
2.5.3. Platelet receptors interactions with pathogens and HIV 
The platelet specific receptor GPIIb/IIIa binds to bacteria and viruses via indirect mechanisms 
that involve its ligands fibrinogen and fibronectin (Cox et al., 2011). These ligands act as 
bridging proteins, linking the ligand bound pathogen with the platelet specific receptor (Cox et 
al., 2011). The platelet receptor GPIIb/IIIa is also capable of directly binding to pathogens 
(Flaujac et al., 2010) while GPIbα can directly bind to bacteria or vWF bound pathogens. 
Notably, these interactions may not induce platelet activation (Ruggeri et al., 2007). Previous 
studies have, in addition, identified platelet integrins that enable the binding of platelets to viral 
particles (Flaujac et al., 2009). Although numerous platelet receptors which directly interact with 
viruses have been described (figure 2.5) (Flaujac et al., 2009), these are beyond the scope of 
this review. 
HIV directly binds to platelets via gp 120 which interacts with CXCR4 and the fibronectin 
receptor expressed on platelets (Pugliese et al., 1996). Previous studies have described the 
binding and engulfment of HIV by platelets (Boukour et al., 2006; Chaipan et al., 2006; Flaujac et 
al., 2010) however the consequences of these interactions on the fate of the virus are not fully 
understood, as both intact and degraded engulfed HIV particles have been described (Boukour 
et al., 2006). The C-type-like receptor 2 (CLEC-2) expressed on the surface of platelets plays a 
role in the engulgment of HIV particles. Interestingly, Chaipan et al., showed that dendritic cell-
specific intercellular adhesion molecule 3-grabing nonintegrin (DC-SIGN) (Chaipan et al., 2006) 
(figure 2.8), is a C-type lectin receptor expressed on the surface of platelets, monocytes and 
dendritic cells (Boukour et al., 2006). DC-SIGN plays a significant role in the binding of HIV to 
platelets (Chaipan et al., 2006). The mechanisms of DC-SIGN mediated engulfment of HIV has 
been described in dendritic cells, and involve the endocytosis of HIV particles into endocytic 
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vesicles. This is followed by the degradation of viral particles in an acidic compartment of the 
vesicle (Geijenbeek et al., 2000). However the fate of this endocytosed viral parcticles in the 
platelets is not fully understood. These interactions may however result in platelet activation and 
alterations in platelet morphology (Ruggeri et al., 2007) as increased levels of circulating 
activated platelets have been reported in HIV infected individuals (Holme et al., 1998; Nkambule 
et al., 2014). Activated platelets contribute to the innate immune system by secreting antiviral 
chemokines, such as platelet factor 4 (CXCL4), which has been reported as a broad spectrum 
HIV-1 inhibitor (Auerbach et al., 2012).  
 
Figure 2.8 Platelet receptors involved in platelet-virus interactions 
 
 
2.6. Role of platelets in inflammation 
Previous studies support the involvement of platelets in the initiation and propagation of 
inflammation (Shi et al., 2011; Rondina et al., 2013). The alpha granule plays a crucial role in 
linking platelet activation and inflammation as it serves as a major source of adhesion receptors 
facilitating platelet leuckocyte interactions (Blair et al., 2009). These interactions play a key role 
in the propagation of inflammation and further promote the inflammatory phenotype of cells 
(Kasper et al., 2007). The adhesion or interaction of immune cells with platelets results in the 
activation and release of chemokines (Blair et al, 2009; Cerletti et al., 2012). The alpha granule 
is a source of several chemokines such as CXCL7 (β-TG), CXCL4 (PF-4) and its non-allelic 
variant (PF4alt) that regulate the function of immune cells (Linden & Jackson, 2010; von 
Hundelshausen et al., 2007). PF-4 induces neutrophil activation and promotes the adhesion of 
neutrophils to sites of inflammation (Kasper et al., 2004) and is also involved in the differentiation 
of monocytes into foam cells (Kasper et al., 2007). von Hundelshausen et al., described the 
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combined effects of PF-4 and CCL5 (RANTES) which together induce the adhesion of 
monocytes to endothelial cells (von Hundelshausen et al., 2007). CXCL7 is involved in the 
chemotaxis and adhesion of neutrophils to activated endothelial cells and their subsequent 
diapedisis (Schenk et al., 2002).  
 
 
2.6.1. The physiological role of platelet α granule contents 
Platelets play a crucial role in the formation of atherosclerotic plaques as the contents of the 
alpha granule drive the adherence of platelets and leukocytes to activated endothelial cells. In 
fact, in mouse models of atherosclerosis, deficiency in platelet P-selectin (which translocates 
from the alpha granule to the membrane upon platelet activation) results in alterations of fatty 
streak formation and reduces plaque size (Huo et al., 2003). The deposition of RANTES onto 
inflamed endothelium is facilitated by P-selectin (Schober et al., 2002) and both P-selectin and 
P-selectin glycoprotein ligand-1 (PSGL-1) are crucial for the interactions between neutrophils 
and endothelial cells (these interactions are discussed in section 2.7) (Luo et al., 2012).  
The alpha granule contents also consist of molecules that are involved in vascular repair and 
angiogenesis (CXCL12); neoplasia (PF-4, CXCL7); regulation of megakaryopoiesis (CXCL4, 
CXCL12); thrombopoiesis (PF-4) and importantly antimicrobial (PF-4; CXCL5; RANTES; 
CXCL7) and antiviral (PF-4; RANTES) properties (Karshovska et al., 2013). Platelet derived 
chemokines that possess antimicrobial properties are known as thrombocidins (Yeaman et al., 
2007). For the purpose of this review, only the antiviral properties of chemokines in the context 
of HIV will be discussed. 
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Figure 2.9. Overview of platelet derived chemokines. The figure illustrates several chemokines secreted 
by platelets upon activation and degranulation and their physiological function. Karshovska et al., 2013) 
2.6.1.1 The alpha granule  
The formation of alpha granules occurs in megakaryocytes, as a result of vesicle budding from 
the trans-Golgi network (TGN) (Blair et al., 2009). These vesicles then fuse into multivescular 
bodies (MVBs) which contain endocytosed and synthesised molecules that ultimately form the 
alpha granule (Blair et al., 2009). MVBs facilitate the sorting of both the dense and α granule 
(Youssefian et al., 2000). Maturation of α granules in circulating platelets, is facilitated by the 
endocytosis of plasma membranes (Behnke et al., 1992). Endocytosed proteins are prossesed 
from the endosome to immature MVBs (MVB1) and proceed to mature MVBs (MVB2) (Figure 
2.4) and finally forming the α granule (Blair & Flaumenhaft, 2009). Mechanisms modulating 
platelet endocytosis remain elusive (Panigada et al., 2002). The α granule contains coagulants 
and anticoagulants; proinflammatory and anti-inflammatory molecules (Fitch-Tewfik et al., 2013).  
 
Stellenbosch University  https://scholar.sun.ac.za
 
 
28 
 
 
Figure 2.3 Platelet structure. The schematic diagram illustrates (Fitch-Tewfik et al., 2013) 
 
The functional relevance of the co-localisation of molecules that are functionally antagonistic in α 
granules, remains unclear. However, the presence of α granule subpopulations has been 
described which suggests the presence of biologically distinct α granule subtypes (Italiano et al., 
2008).  
In addition, previous studies suggest that platelet α granules contents may be sorted and stored 
in distinct and separate granular compartments that are differentially released in response to 
different agonists (Sehgal & Storrie, 2007; Italiano et al., 2008; Blair & Flaumenhaft, 2009). The 
granular contents play a crucial role in haemostasis and platelet function (Blair & Flaumenhaft, 
2009) and defects in α granule formation may result in mild to moderate bleeding, as reported in 
patients with congenital gray platelet syndrome (Burkhart et al., 2012). The α granule contains 
coagulation factors (V, XI, XIII) and molecules that facilitate platelet based coagulation such as 
fibrinogen and von Willebrand factor (discussed in section 2.8) (Maynard et al., 2007). 
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Figure 2.4 Working model of α granule formation in MKs (Blair & Flaumenhaft, 2009). The 
schematic diagram illustrates the formation of alpha granules in MKs. MVB maturation facilitates 
the processing of alpha granule contents and alpha granule formation. 
2.6.2. Platelet derived chemokines involved in HIV 
The direct interaction between platelets and HIV is facilitated by platelet surface receptors 
(discussed in section 2.5.3). The most predominant chemokines involved in HIV are PF-4 and 
RANTES (Flaujac et al., 2010) and elevated levels of activated platelets and RANTES have 
been reported in HIV infected individuals (Holme et al., 1998). The proposed mechanisms which 
permit the antiviral properties of these chemokines involve their inherent antiretroviral activity; 
the attraction of immune cells or the occupation of the receptor CCR5 by its ligand RANTES 
(CCL5) which inhibits the attachment of HIV envelope protein (Env) and prevents cell entry 
(Karshovska et al., 2013). Auerbach et al., described the antiviral properties of PF-4 which 
prevented the infection of CD4+ T cells and macrophages by HIV (Auerbach et al., 2012).  
This may also explain a recent finding by Tsegaye et al., who showed that the release of PF-4 
by activated platelets inhibited the entry of HIV-1 into T cells (Tsegaye et al., 2013). However, in 
infected macrophages PF-4 has been shown to facilitate HIV RNA replication and promotes viral 
spread. Intrestingly, in a recent study Berre et al., demonstrated that soluble antibodies directed 
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against CD36 inhibit the release of HIV from infected macrophages and further inhibit the 
transmission of viral particles to T- cells (Berre et al., 2013). 
2.7. Pathways of platelet activation 
Three distinct platelet receptors mediate transduction pathways essential for platelet function 
and which also play a role in thrombosis (Blann et al., 2003). These include two G protein 
coupled receptors (CPCRs) P2Y1 (Gq coupled) and P2Y12 (Gi coupled) and one ATP receptor 
P2X1 (Karim et al., 2009). These receptors mediate the effects of nucleotides on platelets. The 
P2Y1 receptor facilitates partial aggregation in response to ADP, while the P2Y12 receptor is 
responsible for complete aggregation (Varga-Szabo et al., 2009). ADP plays an essential role in 
haemostasis and in thrombus development, extension and stabilization (Quinn et al., 2005; 
Varga-Szabo et al., 2009). The P2Y1 receptor initiates platelet activation via the Gq mediated 
signaling pathway, which involves the activation of phospholipase Cү (PLCү). This results in 
further activation of downstream targets that eventually lead to thromboxane production and 
enhanced granule secretion (Varga-Szabo et al., 2009). The major platelet receptors involved in 
platelet activation and aggregation are tabulated below (table 2.3). 
 
2.7.1. Platelet agonists and receptors 
The signalling pathways of platelets are similar to those of neurons (Ridker et al., 2001, Giorgi et 
al., 2005). Recent studies have highlighted multiple complex platelet activation pathways that 
regulate platelet activation (Ridker et al., 2001). Soluble platelet agonists play a crucial role in 
platelet activation and thrombus formation. Upon platelet activation and degranulation 
(discussed in section 2.2.2) platelets secrete soluble agonists such as thromboxane (TXA2); 
adenosine diphosphate (ADP) and serotonin (Offermanns et al., 2006). These soluble agonists 
amplify platelet activation and promote platelet recruitment (table 2.3) (Li et al., 2010). 
Furthermore, agonists produced by both the inflammatory and coagulatory process such as 
thrombin and platelet activation factor also play an essential role in platelet activation and 
aggregation (Offermanns et al., 2006). Several novel platelet agonists have been described 
(table 2.4) (Morrell et al., 2011), however for the purpose of this review the biochemistry of these 
agonists will not be discussed further. 
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Table 2.3. Major platelet membrane receptors and their physiological agonists 
Recptor Agonists Receptor 
Type 
Signalling 
pathway 
Role 
Glycoprotein VI 
(GPVI) 
Collagen Ig Tyrosine Kinase Activation, 
Adhesion 
 Laminin    
α2β1 Collagen Integrin Tyrosine kinase  
Glycoprotein Ib-V-IX 
(GPIb-XI-V) 
vWF Leucine-
rich 
Tyrosine kinase Adhesion 
αIIbβ3 Fibrinogen, 
vWF 
Integrin Tyrosine kinase Aggregation 
P2Y1 ADP GPCR Gαq Aggregation 
P2Y12 ADP CPCR
 Gαi aggregation 
P2X1 ATP Ca
2+ 
channel 
  
Thromboxane 
Receptor (TP) 
TXA2 GPCR Gαq, Gα12/13 aggregation 
PAR1 Thrombin GPCR
 Gαq, Gα12/13 Aggregation 
PAR4 Thrombin GPCR Gαq, Gα12/13 Aggregation 
     
 
Thrombin and thromboxane (TXA2) induce platelet activation via a G-protein-coupled receptor 
(Gq) and protease-activated receptor (PAR1 and PAR2). The Gq stimulates phospholipase β 
which then acts as a catalyst and releases inositol triphosphate (IP3) and diacyglycerol (DAG) 
(Crittenden et al., 2004). This results in the activation of protein kinase and the calcium signaling 
pathway which leads to platelet activation and aggregation. Although the platelet agonist 
receptors may differ, their signaling pathways share a common intracellular signaling pathway 
that involves PLC (Li et al., 2010).  
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Table 2.4. Recently recognized platelet agonists 
Agonist Class Pathway Defined receptor 
Stimulatory molecule Glutamate, Ox-LDL AMPAR & KAR, CD36 
Receptor CLEC-2 PDPN & HIV-1 
Inflammatory mediator SDF-1, TARC, BSDL CXCR4 
Pathogen Plasmodium, HIV-1 CD36, CXCR4 & CLEC-2 
 
2.7.2. G-protein-Coupled receptors 
G proteins consist of three subunits which are the α ;β; and ү ( Li et al., 2010). Upon activation 
the α subunit undergoes conversion from its GDP form to its activated GTP bound form 
(Offermanns et al., 2006). The activated Gα then dissociates from the receptor complex and 
transmits downstream GPCR signals (Stephens et al., 1997). G proteins can be categorized into 
subfamilies (Gq, G12/G13, Gi/Gz and Gs) which are coupled with selective receptors 
(offermanns et al., 2006). The Gq, G12/G13, Gi/Gz subunits are coupled to agonist receptors 
whereas the Gs subunit is coupled to inhibitory receptors which bind to platelet inhibitors such as 
prostacyclin (Li et al., 2010). Protease activated receptors play a crucial role in thrombin induced 
platelet activation and aggregation (Coughin et al., 2005). In fact, platelet activation via PAR 
receptors induces selective secretion of platelet granule contents (described in section 2.2.3) 
(White & Rompietti, 2009). The prostaglandin H2 receptor (TP) that is coupled to Gq and G13 
binds to TXA2 and induces platelet degranulation and activation.  
 
2.7.3. Gq signaling mediated signaling 
The P2Y1 receptor is a Gq coupled receptor, expressed on a wide variety of tissues including the 
heart, neural tissue and blood cells (Crittenden et al., 2004). It is required for ADP-induced 
platelet aggregation (Lisa et al., 2009) and induces the mobilization of Ca2+ stored in platelets. 
This process results in changes to the platelet shape and transient aggregation in response to 
ADP (Ohlmann et al., 2010). In addition Mangin et al in 2004 demonstrated that when 
thromboxane A2 (TXA2) formation is prevented, the P2Y1 receptor participates in collagen-
induced platelet aggregation and shape change (Mangin et al., 2004). Overall, the P2Y1 
receptor is crucial for ADP-induced platelet activation, as pharmacological inhibition of this 
receptor results in the absence of platelet aggregation and shape change in response to ADP 
(Magnin et al., 2004). Phospholipase C (PLCβ) is essential for Gq mediated signaling which 
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induces platelet secretion, activation of integrins and platelet aggregation (Offermanns et al., 
1997). However, Gq mediated signaling does not induce complete platelet aggregation in 
response to ADP, TXA2 or sub maximal concentrations of thrombin (Li et al., 2010). Gq signaling 
induces platelet shape change via signaling pathways involving Ca2+ and p160 Rho kinase 
dependant pathways (Jin et al., 1998; Vogt et al., 2003).  
 
2.7.4. Gi mediated Signaling 
The P2Y12 receptor is a Gi coupled receptor involved in platelet aggregation in response to ADP, 
TXA2 and thrombin (Conley et al., 2003; Li et al., 2010). Gi mediated platelet activation involves 
the activation of the phosphoinositide 3-kinase (PI3K) and small GTPase Rap Ib which facilitates 
integrin activation (Conley et al., 2003; Li et al., 2010). Interestingly, Gi signalling positively 
regulates Gq signaling whereas Gq seems to inhibit Gi signalling (hardy et al., 2004).  
 
2.7.5. G13 mediated signaling 
Gα13 mediated signalling plays a role in platelet shape change, aggregation and most 
importantly in platelet adhesion (Li et al., 2010). Gα13 interacts with integrinβ3 and mediates 
activity of integrins involved in inside out signaling (Gong et al., 2010). G13 has been described 
as a regulator of RhoGTPases which have been implicated in thrombosis and malignancies 
(Aittaleb et al., 2010; Cadamuro et al., 2013).  
 
2.7.6. Common intracellular pathway involved in platelet activation 
Platelet signaling mechanisms converge to a common intracellular pathway (Varga-Szabo et al., 
2009). Although GCPRs signaling transduction pathways may vary the final signaling event 
mediating platelet activation are similar (figure 2.6) (Li et al., 2010). PLC is the most common 
pathway activated by various agonists such as TXA2; thrombin and ADP. PLC facilitates the 
release of inositol triphosphate (IP3) diacyglycerol (DAG) which is involved in platelet shape 
change, degranulation and protein kinase C activation (Li et al., 2010).  
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Figure 2.10 G protein coupled receptor signaling (adapted from Li et al., 2010). The schematic diagram 
illustrates the complex signaling pathways involved in platelet activation. Platelet receptors play a crucial 
role in the recognition of platelet agonists and inducing platelet activation in response to agonists. Several 
pathways converge to a common activation pathway that involves PLCβ and results in activation of PKC 
and subsequent platelet degranulation.  
 
2.8. Platelets and coagulation.  
The platelet alpha granule contains molecules involved in coagulation such as (Factors V,XI, 
XIII, fibrinogen and von Willebrand factor). Platelets interact with fibrinogen via the αIIb β3 integrin 
however the fate of integrin-bound fibrinogen remains unclear. The expression of 
phosphatidylserine (PS) on activated platelets promotes and enhances coagulation (Heemskerk 
et al., 2013). PS expressing platelets provide a negatively charged phospholipid platform for the 
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assembly of coagulation factors which include FVIIa; FIXa; FX; FVa;FXa and prothrombin 
(Monroe et al., 2002). Notably FX and thrombin bind specifically to platelets expressing surface 
PS which is involved in the cleavage of FX and prothrombin into active FX (FXa) and thrombin 
(Heemskerk et al., 2013). Thrombin is a potent vitamin K dependant platelet agonist that induces 
platelet activation by PAR 1 ,PAR 4 (illustrated in figure 2.9) and GPIb mediated interactions 
(table 2.3) (Ravanat et al., 2000).  
 
2.8.1. Platelet TF expression  
The expression of TF by megakaryocytes and platelets remains highly debated, with 
contradictory findings being reported (Camera et al., 2010, Kretz et al., 2010; Østerud et al., 
2013). Pre-analytical variables that may explain these findings have been described and include 
sample preparation methods and the choice of monoclonal antibody clone used for the detection 
of platelet TF which may induce artefactual platelet activation. To date, three mechanisms for 
the presence of platelet TF have been described. These involve; (1) microparticle facilitated 
transfer of TF; (2) the release of TF stored within the α granule and (3) the de novo protein 
synthesis of TF mRNA (Rauch et al., 2000; Muller et al., 2003; Panes et al., 2007). In the context 
of HIV, where increased levels of plasma TF have been reported (Funderburg et al., 2010), 
activated platelets may be implicated as an additional source of TF. This may further support the 
role of platelet activation in coagulation. 
 
2.9 Platelet leukocyte aggregates 
Platelets are capable of directly or indirectly interacting with several hematopoietic cells. This 
may result in the formation of heterotypic aggregates which are a hallmark of inflammatory and 
acute coronary syndromes as upon adhering to platelets the function of leukocytes is modulated 
(Metcalf et al., 2013). Furthermore, the pro-inflammatory activity of platelets is mediated by the 
direct or indirect interactions of platelets and leukocytes (Freedman & Loscalzo, 2002). 
Increased levels of platelet leuckocyte aggregates have been described in thrombosis (Singh et 
al., 2012) and have been proposed as a marker of cardiovascular disease (Falanga et al., 2005). 
Platelets preferably form complexes with monocytes which is primarly due to the increased 
PSGL-1 density on monocytes (Kappelmayer et al., 2001). Receptors involved in innate 
immunity such as TLR4, along with CD40L and P selectin, have been described in PLAs 
(Maugeri et al., 2011).  
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2.9.1 Platelet neutrophil aggregates 
Activated platelets release chemoattractants such as CXCL7, which recruit neutrophils to sites of 
inflammation and vascular injury. Neutrophils then interact with platelets via P-selectin and 
PSGL-1. These interactions result in neutrophil activation, degranulation and tissue factor 
expression (Maugeri et al., 2008; Manfredi et al., 2009). Neutrophils are the most abundant 
leucocytes in circulation (Manfredi et al., 2010) and adhere to the activated endothelium via P-
selectin mediated interactions (Maugeri et al., 2009). The process of neutrophil rolling, adhesion 
and final extravasation involves a well-regulated multistep process. Briefly, P-selectin and 
PSGL-1 interactions facilitate the adhesion of neutrophils to the vessel wall while integrins such 
as αIIbβ3 (GPIIb-IIa complex) are essential for firm tethering and diapedesis (Maugeri et al., 
2009). P-selectin stored in the wiebel-palade bodies of endothelial cells translocates to the 
endothelial cell surface upon activation (Maugeri et al., 2009) and interactions between 
neutrophils and endothelial cells results in the activation of intracellular pathways that promote 
neutrophil diapedisis (Li et al., 2008). As a result of the density of surface platelet P-selectin, 
neutrophils preferably and rapidly interact with platelets compared to activated endothelial cells 
(Linden et al., 2007). Interestingly, activated platelets in the circulation are rapidly phagocytosed 
by neutrophils (Maugeri et al., 2009). This phenomenon has been previously described as a 
possible P-selectin facilitated clearance system which seems to be dysfunctional in CVDs 
(Maugeri et al., 2009).  
 
2.9.2 Platelet monocyte aggregates 
Platelet monocyte interactions may also result in the maturation of classical monocytes to an 
inflammatory phenotype (Singh et al., 2012). Circulating platelet monocyte aggregates have 
been described as a more sensitive marker of platelet activation (Michelson et al., 2001) 
Previous work by Laura et al., described a rapid flow cytometry based assay for the detection of 
platelet monocyte aggregates (Laura et al., 2009). The adherence of neutrophils and monocytes 
to activated platelets during PLA formation is facilitated by P-selectin and its counter receptor 
PSGL1 (Bournazos et al., 2008; Singh et al., 2012). Monocytes are also capable of adhering to 
activated platelets via P-selectin and CD40-CD40L ligand interactions (Li et al., 2008). 
Interactions facilitated by P-selectin results in monocyte activation and increased tissue factor 
expression (Christersson et al., 2008). It is postulated that P-selectin mediated PMAs may be a 
link between platelet activation and coagulation. Interestingly, Stephen et al., demonstrated that 
although the inhibition of P-selectin reduces platelet-monocyte interactions, platelet induced 
monocyte activation is not inhibited (Stephen et al., 2013). P-selectin mediated interactions 
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between platelets and monocytes results in the expression of cyclooxygenase (COX)-2 on 
monocytes (Dixon et al., 2006).  
Increased levels of circulating platelet monocyte aggregates (PMAs) have been associated with 
CVDs and inflammatory conditions (Furman et al., 2001; McCabe et al., 2004; Elalamy et al., 
2008) and in HIV (Singh et al., 2012). PMAs are regarded as a more sensitive marker of platelet 
activation than PNAs and the expression of P-selectin (Michelson et al., 2001; Lippi et al., 2007). 
Increased levels of PMAs have been reported in PLWH despite successful ART (Singh et al., 
2012). Notably, data from cohorts consisting of ARV naïve HIV infected individuals is scarce and 
hence, associations between HIV replication and PMA formation remain elusive. Singh et al., 
demonstrated increased PMAs levels that directly correlated with levels of activated platelets in 
HIV (Singh et al., 2012).  
 
2.10 Platelet derived Microparticles 
Microparticles (MPs) are released upon cellular activation and apoptosis and can also form as a 
result of membrane remodelling and fragmentation caused by necrosis. MPs are heterogenous 
in size and range between 0.1-1µm. These submicron fragments contain surface receptors of 
their cell of origin. Although several mechanisms involved in the formation of MPs have been 
proposed which include platelet activation and apoptosis (Leytin et al., 2012), the physiological 
origin of microparticles remains unknown (Flaumenhaft et al., 2006). Platelet derived 
microparticles (PMPs) are defined as submicron particles that express a platelet specific marker 
and may also express surface phosphatidyleserine (PS). PMPs that do not express surface PS 
have been described and are associated with inflammatory conditions (Nielsen et al., 2011).  
The contribution of activated platelets in PMP formation remains unclear as inhibitors of platelet 
activation do not completely halt the formation of PMPs in stored platelets (Bode et al., 1991). 
The life span and kinetics involved in the clearance of PMPs also remains unknown 
(Flaumenhaft et al., 2006). The role of PMPs in innate and adaptive immunity, have however 
been described (Semple et al., 2010) and deficiencies in PMP formation have been 
demonstrated in bleeding disorders (Castaman et al., 1997). Increased levels of PMP have been 
reported in HIV (Holme et al., 1998; Pretorius et al., 2008; Corrales-Medina et al., 2010) with 
numbers of of activated PMPs being associated with levels of HIV RNA (Mayne et al., 2012). 
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2.11. Research gaps 
Platelet signalling and activation involves a complex network of signalling pathways. Novel 
platelet agonists have been described which are capable of inducing the activation and secretion 
of platelet derived chemokines which may regulate the function of immune cells. This may be 
important in the context of HIV, as platelet function could either enhance viral RNA replication or 
inhibit the infection by circulating T cells. Patients with chronic HIV-infection are at increased risk 
of thrombotic complications such as myocardial infarctions and strokes (Friis-Moller et al., 2003; 
Mondy et al., 2007; Benjamin et al., 2012). The mechanisms underlying these thrombotic 
conditions remain unclear but could be associated with altered platelet signalling and function. 
Recent work has highlighted the important association between markers of inflammation and 
coagulation and the increased risk of these adverse events.  
Therefore, by defining a panel of tests for the evaluation of platelet function and thrombotic risk, 
a direct impact on patient management strategies especially in resource-limited settings could 
be made. In addition, minimal work has been performed on platelet function in the context of 
HIV-infection; particularly in a cohort of asymptomatic, untreated patients. The relevance of 
platelet leukocyte interactions in this setting also remains unclear. In the context of HIV, the 
evaluation of the association between platelet leukocyte aggregates and traditional markers of 
immune activation and disease progression may give insight into the physiological role these 
interactions play in this disease. In addition, a thrombotic risk panel of tests may be of value in 
the assessment of specific anti-platelet therapies which could be used as preventative strategies 
in the management of patients at risk of inflammatory-associated complications. 
 
2.12. Conclusion 
The role of platelets as immune cells has led to the description of various mechanisms and 
receptors that explain the immunoregulatory function of platelets. Notably the establishment of 
activated platelets as mediators of inflammation and coagulation forms the basis of associating 
platelet function with inflammatory and coagulatory conditions. Extensive work has been done to 
identify and describe the function of various platelet receptors, chemokines and cytokines. 
Recent work has also described the antiviral properties of these chemokines and the potential 
role they play in the suppression of HIV pathogenesis. Platelet functional assays may therefore 
offer insight into understanding platelet function in the context of this disease. Flow cytometry 
allows for the rapid evaluation of platelet receptors and their biological function.  
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Abstract 
Introduction: Cardiovascular disease and thrombotic events have emerged as major causes 
of mortality in people living with HIV. Activated platelets play a key role in both inflammation 
and thrombosis. Haematology analysers measure a variety of platelet indices which could be 
surrogate markers of platelet activation. Flow cytometry offers the discrimination of platelet 
subpopulations and evaluation of the activation status of platelets. This study aimed to 
measure platelet indices in untreated HIV infection and to evaluate their relationship with 
markers of immune activation and disease progression. 
Materials and methods: One hundred and eighty five (185) antiretroviral therapy (ART)- 
naïve HIV infected and 145 HIV negative individuals were recruited. Platelet indices 
measured using the ADVIA 2120 platform consisted of, platelet count (PLT), mean platelet 
volume (MPV fl), platelet distribution width (PDW%) and plateletcrit (PCT%). These were 
correlated with CD4 count, %CD38 on CD8+(CD38/8) T-cells, viral load, fibrinogen , D-
dimers and platelet CD62P and CD36, determined using flow Cytometry.  
Results: The HIV group had decreased MPV levels (median 7.7[7.1 to 8.3] vs. control group 
8.4[7.8 to 9.2], p<0.0001) which correlated with PCT% (r=0.3038, p=0.0013); viral load 
(r=0.2680, p=0.0177) and PDW% (r=0.2479, p=0.0257). Additionally, the MPV correlated 
with CD4 count r=-0.2898, p=0.0075. The HIV group had decreased PDW%, 49.35[46.40 to 
52.65] vs. control group, 53.90 [50 to 56.80], p=0.0170. In addition the PDW% showed 
correlations with D-dimers (r=0.443, p=0.03) and %CD36(r=-0.3666, p=0.0463). 
Conclusion: Platelet indices may offer a rapid and affordable method for monitoring platelet 
activation and disease progression in HIV patients. 
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1.1 Introduction 
Sub-Saharan Africa has an estimated 23.4 million people living with HIV (PLWH) (UNAIDS, 
2012). Although uninterrupted antiretroviral therapy (ART) supresses HIV RNA replication 
and successfully lowers plasma viral load (Quinn et al., 2000); studies have shown that long 
term use of ART increases the risk of cardiovascular events in PLWH (Friss-Moller et al., 
2003; Triant et al., 2007). In addition, PLWH are now faced with an increasing trend of non-
AIDS related complications (Deeks et al., 2009). The strategies for management of 
antiretroviral therapy (SMART) study reported increased cardiovascular events associated 
with higher levels of the coagulation marker D-dimer and inflammatory markers interleukin-6 
and hs-CRP; highlighting the important concept of ongoing inflammation as a risk for CVD 
(El-Sadr et al., 2006). Therefore, HIV infection should be viewed as a chronic inflammatory 
condition, associated with increased risks of thrombotic events (Cole et al., 2004; Torriani et 
al., 2008; Grunfeld et al., 2011). Activated platelets play a key role in both inflammation and 
thrombosis (Van der Bom et al., 2009; Rondina et al., 2013) and this contributes to vascular 
diseases (Grunfeld et al., 2011).  
In normal haemostasis circulating platelets are heterogeneous in size and reactivity, with 
larger platelets being more active metabolically compared to smaller platelets (Leslie et al., 
2010; Rondina et al., 2013). Large platelets are pro-thrombotic and contain high levels of 
thromboxane A2 and B2 per unit volume (Cay et al., 2012). Activated platelets play a key 
role in the pathogenesis of thrombotic complications (Leslie et al., 2010); cardiovascular 
disease (Cay et al., 2012) and hypertension (Coban et al., 2005). During platelet activation 
the influx of calcium into the platelet cytoplasm, triggers morphologic changes which can be 
measured using haematology analysers and flow cytometry (Santimone et al., 2011). 
Platelet indices are readily available and can be utilised to assess morphological changes 
during the inflammatory process (Fateh-Moghadam et al., 2005). Amongst a variety of 
platelet indices, the mean platelet volume (MPV) and platelet distribution width (PDW) have 
been studied previously (Santimone et al., 2011). The MPV is an established marker of 
platelet activation in various inflammatory and thrombotic conditions (Berger et al., 2010). In 
active inflammatory conditions the MPV is decreased due to mechanisms that involve the 
migration and breakdown of the larger platelets at sites of inflammation. In contrast, in 
conditions where the inflammatory process is inactive, a decline in the breakdown of large, 
young platelets results in an elevated MPV (Gasparyan et al., 2011). In addition, studies 
have shown that the MPV is a reliable measure of platelet function in stored platelet 
concentrates (Vagdatli et al., 2010). The platelet distribution width has been reported as a 
potential surrogate marker for chronic inflammation (De Gonzalo-Calvo et al., 2013) and 
platelet aggregation (Vagdatli et al., 2010).  
Stellenbosch University  https://scholar.sun.ac.za
 
 
67 
 
Haematology analysers rapidly measure a variety of platelet indices including the platelet 
count, PDW, plateletcrit (PCT) and MPV (Kim et al., 2008). Reference intervals for these 
indices have been reported in previous studies; with PCT% 0.19-0.40; MPV 8.80-12.50 
(Adibi et al., 2007; Farias et al., 2010; Naina et al., 2010; Botma et al., 2012). The PDW% 
reported in previous studies varies markedly, with reference intervals ranging from 10-56.6% 
(Wiwanitkit et al., 2004; Farias et al., 2010; Chandrashekar et al., 2013). Notably, studies 
investigating the relevance of platelet indices in the context of HIV are scarce (Mena et al., 
2011). Hence, the potential prognostic value of these indices in the context of HIV remains 
inconclusive (Miguez et al., 2005). The aim of the present study was to evaluate platelet 
indices in HIV and to investigate the relationship of these indices with traditional markers of 
disease progression, inflammation and markers of platelet activation.  
2. Materials and methods 
2.1. Blood collection 
All full blood count (FBC) analysis was done on the ADVIA 2120 (Siemens Healthcare 
diagnostics Inc, tarrytown NY, USA) platform at the Division of Haematology, Tygerberg 
Hospital, which is a South African National Accreditation System (SANAS) accredited 
laboratory. 5ml of blood was collected into standardized tubes containing potassium 
ethylenediametetraacetate (EDTA) as an anticoagulant. The platelet parameters measured 
by the ADVIA 2120 platform consisted of the Platelet count, MPV, PDW and PCT. 
2.2 Participant sampling  
Participants were recruited from the Emavundleni Voluntary Counselling and Testing (VCT) 
Clinic in Crossroads, Cape Town. The total number and demographic characteristics of the 
study participants are reported in Table 1.  
None of the participants were on ART, aspirin, anti-inflammatory drugs or TB treatment. The 
study protocol was registered and underwent ethics review at both Stellenbosch University 
(approval number N07/09/197) and UCT (approval number 417/2006) according to the 
declaration of Helsinki. Participant informed consent was taken according to the University of 
Stellenbosch HREC regulations. 
2.3 Study design 
In this cross-sectional study we compared the platelet indices; platelet counts (PLT), mean 
platelet volume (MPV), Platelet distribution width (PDW), plateletcrit (PCT) of the control 
group with that of the HIV group. This was followed by flow cytometric analysis of platelet 
aggregation and activation markers CD36 and CD62P respectively. The relationship between 
these markers and the indices was then assessed. 
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2.4 Antibodies and reagents 
The anti-human CD31-FITC (clone 5.6E), CD36-APC (clone FA6.152), CD62P-APC (clone 
AK-4) antibodies were all purchased from Beckman Coulter, Miami, USA. Phosphate 
buffered saline (PBS) without Ca2+ or MgCl2 was obtained from SIGMA-ALDRICH Co, MO, 
USA.  
2.5 Viral load and CD4 counts 
Viral loads were determined using the NucliSensEasyQ® HIV-1 v1.2 Viral Load Test 
(BioMerieux Inc., Boxtel, Netherlands) at the Division of Medical Virology, Faculty of Health 
Sciences, and Stellenbosch University which is SANAS-accredited.The BD MultiTEST CD3-
FITC/CD8-PE/CD45-PerCP/CD4-APC reagent (BD Biosciences, San Jose, USA) and BD 
TruCOUNT tubes (BD Biosciences, San Jose, USA) were used for CD4 counts. CD4 count 
measurements were performed according to the manufacturer‘s instruction in the Division of 
Medical Virology, Faculty of Health Sciences, Stellenbosch University. 
2.6 D-dimer and fibrinogen measurements 
Quantitative D-dimer measurements were performed using the Hemosil ™ Dimertest ®kit 
(Instrumentation lab, Bedford, USA). Fibrinogen measurements were performed on the ACL 
TOP (Beckman Coulter, Miami, USA). All measurements were done on citrated whole blood 
according to the manufacturer‘s instruction at the National Health Laboratory Services 
(NHLS), Haematology coagulation laboratory, Tygerberg Hospital.  
2.7 Flow cytometry 
Sample collection: A total of 2-3ml of venous blood was collected by venipuncture into 4.5ml 
tubes containing 3.2% sodium citrate (BD Vacutainer, San Jose, CA). Sodium citrate was the 
anticoagulant of choice as blood collected in EDTA may show artificially elevated levels of 
the platelet activation marker CD62P-APC (Maurer-spurej et al., 2001). Samples were kept 
at room temperature during transit from clinic to the laboratory. The time between sample 
collection and analysis was limited to 1-3hrs. Instrument set-up and detector settings: Flow 
cytometry data acquisition was performed using a Beckman Coulter FC500 flow cytometer 
(Beckman Coulter, Miami, USA). Flow check pro fluorescent beads of known size (Beckman 
Coulter, Miami, USA) were used to verify and standardise the optics and fluidics of the 
cytometer. Forward scatter (FSC) and side scatter (SSC) parameters were set at a log-scale, 
to allow the detection of platelets and red blood cells. An unstained fresh blood sample was 
used to set the voltages for the FSC/SSC; this allowed the separation of red blood cells and 
platelets based on cell size and granularity. Stained activated platelets were used to 
determine percentage of spectral overlap and to perform compensation. Antibody titration 
assays were performed to establish optimal antibody concentrations. 
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Staining protocol and gating strategy: The platelet marker CD31-FITC was used to 
characterize platelets as previously described and CD36-APC and CD62P-APC were used to 
monitor platelet aggregation and activation (De Cuyper et al., 2013; Nkambule et al., 2014). 
Briefly 50µl of citrated whole blood was stained and incubated in the dark for 20 minutes at 
room temperature. 500µl of PBS staining buffer (containing 1,25µl of fetal bovine serum 
(FBS) and 500ml of PBS which does not contain Ca2+ or MgCl2) was added and samples 
were analysed immediately. The use of CD31 allowed the detection and separation of free 
platelets from red blood cells (RBCs) and platelet-bound RBCs (Platelet-RBCs) (Figure 1A).  
 
Figure 1. Gating strategy. The figure illustrates the gating strategy used to discriminate platelet 
subpopulations based on size and internal complexity. The color dot plot A illustrates the 
discrimination between RBCs and Platelets using CD31 FITC and side scatter (SS) properties. Events 
that were positive for CD31 were gated as platelets and negative events were gated as red blood cells 
(RBCs), illustrated in figure A. Histogram plots C and D illustrate the use of RBC as internal controls to 
distinguish between positive and negative (CD36 and CD62P) cell surface expression.  
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2.8 CD38/8 measurement: 
The expression of CD38 on CD8 T cells, is a well-established marker of immune activation 
and independent predictor of disease progression in HIV (Savarino et al., 2000). The 
percentage of CD8+ T-cells expressing CD38 was analysed using flow cytometry. Briefly, 
whole blood samples were stained with a titrated monoclonal antibody cocktail containing; 
CD8 Per-CP; CD38 APC; CD3 FITC (BD Biosciences, San Jose, CA). Data acquisition was 
perfomed using a BD FACSCalibur instrument and analysis was done using the BD Cell 
Quest Pro (Version 2) software (BD Biosciences, San Jose CA, USA).  
2.9 Statistical analysis 
Statistical analysis was performed using GraphPad prism 5.00 for windows (GraphPad 
Software, San Diego CA, USA).The Mann-Whitney U test was used to compare non-
parametric data and these values were reported as median and interquartile range. For 
parametric data an unpaired student t test was performed and data was reported as mean 
and standard deviation. Correlations were performed using a spearman rank correlation. A p 
value of <0.05 represented statistical significance. 
3. Results 
A total of 330 participants were enrolled in this study, 185 adult untreated (ARV naïve) HIV 
infected patients and 145 HIV negative controls. The demographics and characteristics of the 
control and HIV groups are illustrated in Table 1. The groups had similar age and sex 
distributions and were recruited from the same clinic in the Western Cape and therefore had 
similar socio-economic and ethnic backgrounds. The HIV group had a slightly  higher PLT 
count mean 299.1 ± 78.31 compared to the control group mean 288.6 ± 59.64, however this 
was not statistically significant (p=0.1542). All the other platelet indices and markers of 
immune and platelet activation were statistically significant, as shown in Table 1.  
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Table 1. Cohort characteristics; platelet parameters and disease markers 
 Control Group 
(n=145 ) 
HIV Group 
(n=185 ) 
Reference 
Interval 
P-value 
Age, years (interquartile range) 28[24-35] 30[26-37]  0.0518
 
Male: female 1:1.51 1:4.5   
Platelet (PLT) count x10
9
/L 288.6 ± 59.64 299.1 ± 78.31 178 - 429 0.2082 
Mean platelet volume (MPV), fL 8.52 ± 1.12 7.91 ± 0.85 8.80 - 12.50 <0.0001 
Plateletcrit (PCT),% 0.23 ± 0.03 0.26 ± 0.04 0.22 - 0.40 <0.0001
 
Platelet distribution  
width (PDW) ,% 
51.70[45.65-55.95] 49.40[46.40-52.65] - 0.0266
 
%CD62P 0.68[0.08-3.3] 11.95[1.68-24.51] - <0.0001
 
%CD36 11.22[5.59-18.25] 38.65[25.85-54.55] - <0.0001
 
CD4 count cells/mm
3
 852.9 ± 244.6 373.8 ± 168.2 500-2010 <0.0001
 
D-dimers 0.2 [0.2-0.2] 0.23[0.2-0.33] 0.00-0.25 -<0.0001
 
Fibrinogen 2.91 ± 0.05 2.8± 0.07 1.56-4.0 0.2651 
%CD38/8  
Viral load (log) 
31.13 ± 18.65 
- 
50.30 ± 22.62 
4.080[3.4-4.8] 
 <0.0001 
-
 
    
 
Significant values shown in boldface  
 
3.1 Decreased MPV in HIV positive individuals compared to uninfected controls 
The MPV which is a measure of mean platelet volume was significantly decreased in the HIV 
group (n=80) compared to the control group (n=82), (HIV mean 7.91 ± 0.85 vs. 8.52 ± 1.12, 
p<0.0001). In the HIV group, the MPV showed a positive correlation with log viral load 
r=0.2680, p=0.0177 (figure 2a); PDW% r=0.2479, p=0.0257. Furthermore, the MPV showed 
an inverse correlation with CD4 counts r=-0.2898, p=0.0075 (figure 2b). No correlations were 
detected with; CD38/8 (r=0.307, p=0.53); markers of platelet activation %CD62P (r= 0.328, 
p=0.082) and aggregation %CD36 (r=0.248, p= 0.282); and D-dimer levels (r=0.117, 
p=0.445). 
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Figure 2. HIV group correlations between markers of disease progression and platelet indices. A. 
MPV showed a positive correlation with viral load and B a negative correlation with CD4+ T cell count.  
 
3.2 Increased PCT% in HIV positive individuals compared to uninfected controls  
PCT% is an indicator of the total platelet composition in blood. Although the PCT% was 
higher in the HIV group compared to the control group, (0.26[0.23 to 0.29] vs. 0.23 [0.21 to 
0.25], p<0.0001) the values were still within the normal reference interval and therefore the 
clinical significance of this finding remains to be determined. 
3.3 Decreased PDW% levels in HIV positive individuals compared to uninfected 
controls  
The PDW%, a measure of variation in platelet size was decreased in the HIV group 
compared to the control group, (HIV group median 49.35[46.40 to 52.65] vs. 53.90 [50 to 
56.80], p=0.0170). In order to establish the value of PDW as a marker of coagulation and 
platelet aggregation, this index was correlated with D-dimers and platelet %CD36 
expression. PDW% showed a positive correlation with D-dimers and inverse relationship with 
%CD36 (values shown in Table 2). 
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Table 2. PDW% correlations 
Parameter Spearman r P-value 
Platelet count -0.3474 0.0002 
Plateletcrit (PCT) % -0.3138 0.0008 
%CD62P 0.1326 0.4929 
%CD36 -0.3666 0.0463 
D-Dimers 0.3455 0.0362 
Fibrinogen 0.2318 0.1347 
CD4 count -0.1023 0.2786 
CD38/8 0.307 0.530 
Viral load 0.0346 0.7283 
Significant values shown in boldface 
 
4. Discussion 
Several investigators have assessed the value of platelet indices in platelet activation (Park 
et al., 2002; Chapman et al., 2003). However the potential value of these indices in the 
context of HIV-infection remains inconclusive (Miguez-Burbano et al., 2005). The present 
study aimed at evaluating the relationship between platelet indices and traditional markers of 
disease progression, inflammation and platelet activation in the context of untreated HIV 
infection. Platelet indices are affordable and readily available as part of routine full blood 
counts performed using hematology analyzers. These indices offer a more rapid analysis of 
platelet activation using an automated system that limits observer bias (Beyan et al., 2006). 
The MPV reflects platelet size and the rate of platelet production (Bancraft et al., 2000). MPV 
values increase during platelet activation and have been established as a marker of platelet 
activation (Park et al., 2002).  
Interestingly, the HIV group MPV levels were significantly decreased compared to the control 
group (Table I), which was in contrast to the finding of significantly increased levels of 
activation (CD62P) and aggregation (CD36). It is possible that in the untreated HIV group; 
levels of inflammation were such that an increased consumption of the larger platelets 
occurred; effectively removing them from the circulation. In low grade inflammatory 
conditions, inflammatory cytokines induce thrombopoiesis resulting in increased circulating 
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large young platelets. However, in high grade inflammatory diseases the rapid breakdown of 
these larger platelets results in a lower MPV (Gasparyan et al., 2011). Furthermore, 
persistent platelet activation in HIV may be induced by direct engulfment of HIV virions by 
platelets (Chaipan et al., 2006). In addition, platelet activation may be a consequence of 
enhanced thrombin production from increased tissue factor expression on activated 
monocytes and endothelial cells in HIV infection (Baker et al., 2013). Moreover, the up 
regulation of platelet receptor ligands on leukocytes in response to the increased 
inflammatory cytokine milieu, may further enhance the migration and adhesion of platelets to 
inflammatory sites (von Hundelshausen et al., 2007). The increased consumption of large 
platelets have been previously (Baker et al., 2013) as a result of the migration of large hyper- 
reactive platelets from the circulation into extravascular sites of inflammation (Öztürk et al., 
2013). This is likely to be the mechanism underlying the decrease in MPV levels measured in 
our HIV group. Decreased MPV levels have also been reported in several chronic 
inflammatory diseases (von Hundelshausen et al., 2007; Lichtenstein et al., 2010; Baker et 
al., 2013; Öztürk et al., 2013). In addition, our current findings are consistent with recent 
findings reported by Qadri et al., in a cohort of HIV infected women (Qadri et al., 2013). The 
authors reported a decreased MPV in HIV infected patients (8.66 vs. 9.05) compared to 
uninfected counterparts. Although these patients were all women, demographic differences 
in the MPV reference intervals between the cohorts exist, the MPV levels in our study were 
similarly decreased. Gender related differences in MPV reference intervals have been 
reported, with higher MPV levels in females (9.0-12.50fl) compared to [8.80-11.30] (Botma et 
al., 2012). 
In the present study, MPV levels correlated inversely with CD4 counts and directly with viral 
loads. This association contradicts findings reported in recent studies (von Hundelshausen et 
al., 2007; Mena et al., 2011). Mena et al. reported no association between MPV and CD4 
counts in a cohort of ART-naïve HIV infected patients with mean baseline CD4 counts of 
591cells/mm3. The differences between baseline CD4 counts (mean 373.8 cells/mm3) in our 
study and that of Mena et al. may account for these discrepancies. In contrast to our findings, 
Qadri et al. reported no associations between MPV, CD4 counts and viral load (Qadri et al., 
2013). Notably, only 37 (16%) of these participants were treatment-naïve (Qadri et al., 2013) 
which may explain the contrary findings observed in our study. The majority of the 
participants in the study by Qadri et al., were on treatment and this may have impacted the 
association of MPV with CD4 counts and viral load as HIV RNA replication was controlled in 
the majority of these participants. The direct correlation of the MPV with viral load in our 
study was supported by the findings of Mena et al. interestingly, as a host defence 
mechanism; platelets are capable of directly interacting and engulfing HIV virions which may 
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result in platelet degranulation and a decrease in both MPV levels (Schoorl et al., 2011) and 
HIV RNA in blood (Boukour et al., 2006).  
PDW has been reported as a potential measure of platelet activation and aggregation 
(Vagdatli et al., 2010). Vagdatli et al., reported PDW as a specific marker of coagulation and 
a decrease in PDW may indicate the presence of aggregated platelets (Vagdatli et al., 2010). 
In the current study, the HIV group had significantly decreased levels of PDW compared to 
uninfected controls and this showed a correlation with the marker of aggregation (CD36). In 
addition, we observed a positive correlation between PDW and D-dimers, a marker of 
fibrinolysis and associated with increased risk of mortality in HIV infected individuals (Kuller 
et al., 2008). This supports the relevance of PDW% as a potential marker of coagulation 
which may be a valuable marker in the context of HIV infection.  
In the present study the PDW% index which is associated with active coagulation inversely 
correlated with %CD36 a marker of platelet aggregation. This suggests the value of PDW% 
as a rapid indicator of platelet activation. Thus, we have shown that the MPV and PDW 
indices may offer a more affordable, standardised and rapid platelet activation monitoring 
technique.  
CD38 is a transmembrane glycoprotein that is upregulated during early T-cell activation (De 
Cuyper et al., 2013). In the context of HIV, increased levels of CD38 on CD8 T cells have 
been described as a marker of generalised immune activation and a strong predictor disease 
progression (De Cuyper et al., 2013; Karim et al., 2013). In our study, the HIV group showed 
increased levels of immune activation as shown by increased percentages of CD8 T cells 
expressing CD38. However, the levels of immune activation were not associated with the 
chosen platelet indices. This may further suggest that in HIV, alterations in platelet kinetics 
may involve complex mechanisms that are not solely dependent on immune activation. 
To the best of our knowledge, the present study forms the largest study investigating platelet 
indices and in particular, the MPV, in HIV treatment-naïve patients and uninfected controls. 
However, this study is subject to the limitations of a cross- sectional study, which include the 
lack of evidence of causality between the studied parameters and platelet indices. Future 
longitudinal follow-up studies should be done to determine the prognostic value of these 
indices. 
In conclusion, our findings suggest that the MPV and PDW may be valuable markers of 
platelet and immune activation in HIV infected patients. Moreover, platelet indices may offer 
a rapid and affordable method of monitoring platelet activation in HIV patients.  
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Abstract 
Introduction 
Human immunodeficiency virus (HIV) induces inflammation and platelet activation. People 
living with HIV (PLWH) are at increased risk of thrombotic events and activated platelets link 
inflammation with thrombosis. Platelet function in HIV remains unclear. P-selectin (CD62P), a 
marker of platelet activation, and platelet glycoprotein GPIV (CD36) a marker of platelet 
aggregation, can be measured using flow cytometry. We aimed to evaluate platelet function 
in HIV using a whole blood platelet flow cytometry based assay. 
Materials and methods 
Fifty-eight (58) antiretroviral therapy (ART) naïve HIV infected and 38 HIV negative 
individuals were recruited in a clinic in Cape Town. Platelet surface CD36 and P-selectin 
CD62P were measured using flow cytometry. These measurements were then correlated 
with CD4 count, viral load and % of CD8+ T-cells cells expressing CD38. Platelet function 
was evaluated using adenosine diphosphate (ADP), arachidonic acid (AA) and collagen at 
varying concentrations. The CD62P mean fluorescence intensity (MFI) was used as a 
measure of agonist induced platelet response.  
Results 
The HIV group showed increased levels of circulating activated platelets, (median %CD62P 
5.51[3.03– 10.11] vs. Control group 2.14[0.19 – 3.59], p<0.0001 and %CD36 21.93[11.03-
44.92] vs. Control 16.15[2.24-25.37], p=0.0087). In the HIV group, levels of platelet activation 
correlated with Viral load (r=0.336, P=0.008) and showed no significant correlation with CD4 
count (r=0.028, p=0.891). The HIV group also had increased levels of cells expressing CD36, 
a marker of platelet aggregation which directly correlated with viral load (r=0.398, p=0.024) 
and showed no correlation with CD4 count (r=0.205, p=0.730). There were no significant 
differences in baseline CD36 and CD62P MFI. The HIV group showed a hyper response to 
AA and collagen at various concentrations. Notably, the HIV group only showed a hyper 
response to ADP at a maximal concentration of 20µM (median CD62P MFI, 1.91[1.64-4.95] 
vs. Control 1.75[1.45-2.44] p=0.0279.  
Conclusion 
We show elevated levels of activated platelets in HIV infected individuals that have enhanced 
reactivity to endogenous agonists in a concentration dependent manner. Platelet flow 
cytometry is a rapid and valuable technique in the evaluation of platelet function in HIV. The 
measurement of platelet function using flow cytometry allows the evaluation of platelet 
signalling pathways that may be modified in HIV infected individuals. 
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1. Introduction 
An increasing trend of non-AIDS related deaths has been reported in the ageing population 
of people living with HIV (PLWH) (Satchell et al., 2011; May et al., 2013) and cardiovascular 
diseases (CVDs) are reported as the most common cause of mortality (Lohse et al., 2007). 
Uninterrupted antiretroviral therapy (ART) successfully suppresses viral replication and 
improves the clinical outcome of human immunodeficiency virus (HIV) infected individuals 
(Fauci et al., 2012). However, a decreased life expectancy has been reported in people living 
with HIV (PLWH), compared to uninfected counterparts (Nakagwa et al., 2011). In HIV 
infected individuals, chronic immune activation is associated with an increased thrombotic 
risk that persists regardless of ART and involves factors that are both dependant and 
independent of viral replication (Appay et al., 2008; Sauce et al., 2011). Aspects of both the 
innate and adaptive immune response contribute to chronic immune activation and 
inflammation in PLWH (Sauce et al., 2013).  
Elevated levels of immune activation and coagulation are linked to disease progression in 
HIV (Deeks, 2011). Previous studies have highlighted the complications that arise as a result 
of chronic immune activation and long term use of ART (Hogg et al., 2008). CXCR4 receptor 
expression on the megakaryocyte lineage fosters interactions between platelets and HIV 
(Gear et al., 2003). These Interactions which involve various platelet receptors  have resulted 
in the engulfment of HIV particles and subsequent platelet activation (Torre & Pugliese et al., 
2008; Flaujac et al., 2010) which may play a crucial role in thrombosis (Satchell et al., 2011).  
Functional assays measure platelet responses to various agonists such as collagen, 
adenosine diphosphate (ADP), thromboxane A 2 (TXA2) and thrombin (Mangalpally et al., 
2010; Satchell et al., 2011). The response to these agonists gives insight into the 
functionality of signal transduction pathways involved in platelet activation (Varga-Szabo et 
al., 2009). The platelet response is measured and interpreted as a degree of activation and 
aggregation which defines the functional capacity of platelets (Satchell et al., 2011). ADP and 
TXA2 induce platelet aggregation via G-protein-coupled receptors (Crittenden et al., 2004; 
Varga-Szabo et al., 2009). The metabolism of phospholipids by phospholipase A2 (PLA2) is 
crucial in platelet activation (Li et al., 2008). Arachidonic Acid (AA) a precursor of TXA2, is 
released by platelets upon the PLA2 facilitated cleavage of membrane phospholipids (Li et al., 
2008).  
Platelets express surface receptors for exogenous agonists and are either activated or 
aggregate in response to them (Ghosh et al., 2008). Platelet aggregometry remains a widely 
used technique to assess platelet function (Satchell et al., 2010) however it is a cumbersome 
technique which is dependent on sample preparation and requires large volumes of blood 
(Brass et al., 2010). Although efforts have been made to standardise the technique, poor 
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reproducibility of results and the time-consuming nature of this method remains a major 
concern (Breddin et al., 2005). Platelet flow cytometry offers a rapid alternative to evaluate 
platelet function (De Cuyper et al., 2013). P-selectin (CD62P) is an established marker of 
platelet activation (Maugeri et al., 2009) and during activation, is released from the α-
granules and expressed on the surface of the platelet (Linden et al., 2007). Platelet 
glycoprotein IV (CD36) is a scavenger receptor ubiquitously expressed on the surface of 
platelets (van Velzen et al., 2012) and has been identified as a receptor for collagen and 
thrombospondin-1 which plays a crucial role in platelet adhesion and aggregation (van 
Velzen et al., 2012). The underlying mechanism of platelet activation in the context of HIV 
remains complex and unclear (Corrales-Medina et al., 2010; Satchell et al., 2010). Therefore, 
using a whole blood platelet flow cytometry based assay, we sought to evaluate levels of 
platelet activation and aggregation in HIV and to further evaluate platelet responses to 
various endogenous agonists. In order to determine the role of platelets in HIV, we further 
assessed the relationship between activated platelets and conventional markers of immune 
activation and disease progression.  
2. Methodology 
Ninety-six (96) participants were recruited. Fifty eight of these were HIV positive ARV-Naïve 
and thirty eight were HIV negative individuals. Patients were recruited from the Emavundleni 
Voluntary Counselling and Testing (VCT) Clinic in Crossroads, Cape Town which is 
associated with the Institute of Infectious Diseases and Molecular Medicine (IIDMM) and the 
Desmond Tutu HIV Centre, University of Cape Town (UCT). None of the participants were 
taking aspirin or anti-inflammatory drugs on the day of testing. Participant demographics and 
baseline characteristics are reported in table 1. The study protocol was reviewed by the 
health research ethics committee (HREC) at Stellenbosch University and the research ethics 
committees (REC) at University of Cape Town. Ethical review was performed according to 
the declaration of Helsinki. The study was approved by both committees and registered 
under the ethical approval number N07/09/197 and 417/2006, respectively. Written patient 
informed consent was taken according to the University of Stellenbosch HREC regulations 
2.1 Design of the study  
Baseline platelet %CD36 and %CD62P measurements were performed on both groups in 
order to determine baseline levels of activation.  In addition, CD4 count, viral load and % 
CD8+/CD38+ T cells were measured. The platelet response to agonists was then evaluated 
using flow cytometry.  CD62P mean fluorescent intensity (MFI) levels were compared pre 
and post stimulation with ADP, AA and collagen at varying concentrations. These 
measurements were used as a measure of platelet function. 
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2.2 Sample collection 
A total of 2-3ml venous blood was collected by venipuncture into 4.5ml tubes containing 
3.2% sodium citrate (BD Vacutainer, San Jose, CA). Samples were kept at room 
temperature during transit from clinic to the laboratory in order to limit any effects of 
temperature fluctuations on platelet activation. The time frame between sample collection 
and analysis was limited to 1-3hrs. 
2.3 Markers of immune activation and disease progression  
2.3.1 CD4 T-cell counts measurements were performed using the BD MultiTEST CD3-
FITC/CD8-PE/CD45-PerCP/CD4-APC reagent (BD Biosciences, San Jose, CA) and BD 
TruCOUNT tubes (BD Biosciences, San Jose, CA). CD4 T cell counts were performed at the 
Division of Medical Virology, Faculty of Health Sciences, Stellenbosch University, which is 
accredited by the South African National Accreditation System (SANAS). 
2.3.2 Viral load measurements: were performed according to the manufacturer instructions, 
using the NucliSensEasyQ® HIV-1 v1.2 Viral Load Test (BioMerieux Inc., Boxtel, 
Netherlands), at the Division of Medical Virology, Faculty of Health Sciences, and 
Stellenbosch University which is a SANAS-accredited laboratory.  
2.3.3  CD38 on CD8+ T cell measurements: To measure the percentage of CD8+ cells 
expressing CD38, 50µl of heparinized whole blood was stained with a titrated monoclonal 
antibody cocktail containing; CD8 Per-CP; CD38 APC; CD3 FITC (BD Biosciences, San 
Jose, CA). Data analysis was done using the BD Cell Quest Pro Version 2 software (BD 
Biosciences, San Jose, CA). 
2.3.4 D-dimer measurements: were performed using the HemosIL TM Dimertest® Kit 
(Instrumentation Lab) and the ACL TOP platform at the NHLS Haematology coagulation 
laboratory at Tygerberg Hospital which is South African National Accreditation System 
(SANAS) accredited.. Measurements were performed using 4.5ml of citrated blood and 
sample collection was done using tubes containing 3.2% sodium citrate.  
2.4 Platelet flow cytometry 
2.4.1 Instrument settings: The Beckman Coulter FC500 flow cytometer (Beckman Coulter, 
Miami Florida) was used for data acquisition. Flow check pro (Beckman Coulter, Miami, 
USA) fluorescent labelled beads of known size and fluorescence intensity were used to verify 
optical path and laminar flow of the cytometer. Flow set beads (Beckman Coulter, Miami, 
USA) and the Beckman Coulter quickcomp kit (Beckman Coulter, Miami, USA) were used for 
voltage settings and compensation. This ensured the reporting of standardized and 
consistent results that were not influenced by long-term instrumental drifts. 
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2.4.2 Sample preparation and Staining: CD31-FITC (Beckman Coulter, Miami, USA) was 
used to characterize platelets (Fig 1A) as this monoclonal antibody does not bind to 
receptors that directly affect platelet aggregation (De Cuyper et al., 2013). CD62P-APC (BD 
Biosciences, San Jose, CA) and CD36-APC (Beckman Coulter, Miami, USA) were used to 
monitor platelet activation and aggregation respectively. Briefly, 50µl of citrated whole blood 
was stained using 5µl of the antibody cocktail and incubated in the dark for 20 minutes at 
room temperature. 500µl of PBS (which did not contain Ca2+ or MgCl2) was added and 
samples were analysed immediately. 
2.5 Platelet stimulation with endogenous agonists:  
2.5.1 Preparation of platelet agonist concentrations: Agonists were reconstituted 
according to the manufacturer instructions (all obtained from BIO/Data Corporation, Holland, 
The Netherlands). Briefly, serial dilutions were performed on the reconstituted agonists to 
obtain concentrations similar to those previously used in aggregometry based assays 
(Satchell et al., 2010, Gaglia et al., 2011; O‘Brien et al., 2013). The final concentrations were; 
ADP (5µM, 10µM, 20µM); AA (5mg/ml; 2.5mg/ml; 1.25mg/ml) and Collagen (47.5µg/ml; 
95µg/ml; 190µg/ml).  
2.5.2 Platelet stimulation: To stimulate platelets, 50µl of citrated whole blood was incubated 
with 20µl of ADP, AA and collagen at the varying concentrations. Samples were incubated in 
the dark, at room temperature for 10 minutes and were then stained and analysed 
immediately. 
 
2.5.3 Gating Strategy 
Freely circulating platelets were gated based on side scatter, set at logarithmic scale and the 
expression of CD31 (PEDCAM-1) which is not present on the surface membrane of red 
blood cells (RBCs). This allowed the exclusion of platelet bound RBCs (Figure 1A). 
Fluorescence minus one (FMO) controls were used to determine CD62P and CD36 positive 
events cells (figure 1 C-E). 
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Figure 1. Gating strategy. The figure illustrates the gating strategy, applied on an individual control 
sample. Platelets were discriminated based on side scatter and CD31 expression (shown in figure A). 
The purity of the gated platelet population was ensured by gating on circulating free platelets and 
excluding platelet bound-RBCs from the analysis (shown in figure A). FMOs were used to distinguish 
between positive and negative events (figures C and E). Figures D and F illustrate the measurement 
of %CD62P and %CD36 expression on gated platelets. 
2.6 Statistical analysis 
The D‘Agostino-Pearson Normality test was used to determine the distribution of the data. 
For parametric data the student unpaired t-test was used to compare the means of groups 
and expressed as mean ± SD. While the Mann-Whitney test was used for non-parametric 
data and expressed as median and Interquartile range [IQR]. In addition, paired data tests 
were performed to assess the effects of platelet agonists on CD62P MFI. A paired t test was 
performed for parametric data and Wilcoxon matched data test was performed for non-
parametric data. All statistical analysis was two-tailed and a p value ≤ 0.05 was considered 
as statistically significant. Graph pad prism 5 for windows, version 5.0 was used for statistical 
analysis. 
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3. Results  
The mean age and platelet counts between the two groups were similar (Table 1). The HIV 
group had decreased levels of circulating CD 4+ T cells, mean 357.8 ± 192.6 vs. Control 
768.9 ± 214 , p<0.0001. Furthermore the HIV group showed increased levels of CD8+ T-cells 
expressing CD38 median 21.35[16-42.53] vs. Control group 9.23[6.8-12.96], p<0.0001. To 
determine the association between increased levels of immune activation with platelet 
activation and disease progression in the HIV group, levels of %CD38 on CD8+ T cells were 
correlated with, %CD62P (r=-0.109, p=0.589); %CD36 (r=0.111 ,p=0.496); CD4 count 
(r=0.046, p=0.731) and Viral load (r=0.379, P=0.008). Although the HIV group showed 
increased D-dimer levels 0.23[0.2-0.32] vs. Control group 0.2[0.2-0.2], p= 0.0015, these 
values were within the normal reference interval (shown in table 1). 
3.1 Increased levels of platelet %CD36 directly correlates with HIV RNA levels 
In order to determine baseline levels of platelet activation and aggregation, platelet surface 
%CD62P and %CD36 expression was assessed. The HIV group showed increased levels of 
circulating activated platelets, median %CD62P 5.51[3.03– 10.11] vs. Control group 
2.14[0.19 – 3.59], p<0.0001. To further evaluate the association between increased levels of 
circulating activated platelets and markers of immune activation and disease progression in 
the HIV group, levels of %CD62P were correlated with, CD4 count (r=0.028, p=0.891) and 
viral load (r=0.336, P=0.008). In addition the HIV group showed increased levels of %CD36 
21.93[11.03-44.92] vs. Control 16.15[2.24-25.37], p=0.0087. In the HIV group %CD36, a 
marker of platelet aggregation, showed a direct correlation with viral load (r=0.398, p=0.024) 
and no correlation with CD4 count (r=0.205, p=0.730). 
To evaluate quantitative differences in the levels of platelet activation and aggregation, the 
mean fluorescence intensity of CD62P and CD36 were measured. There were no significant 
differences in CD62P MFI levels between the groups, HIV group CD62P MFI 1.35[1.06-4.67] 
vs. Control group 1.77[1.47-3.125], p= 0.1191. In addition the baseline CD36MFI levels of 
both groups were similar, HIV group CD36 MFI, 1.815[1.45-4.76] vs. 2.42[2.24-2.88], 
p=0.1374.  
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Table I. Participant demographics and baseline characteristics 
Parameter Control HIV P- value Reference 
Interval 
No. of participants 38 58   
Age 30.30 ± 8.27 32.40 ± 7.34   
Gender (% males) 50 22.5 -  
Ethnicity     
Black (%) 100 100 - - 
CD4 count (cells/µl) 768.9 ± 214  357.8 ± 192.6 <0.0001 500-2010 
Platelet count (x10
9
/l) 274[236-313.3] 306[226-346.5] 0.2772 178-400 
%CD62P 2.14[0.19-3.59] 5.51[3.03-
10.11] 
<0.0001 - 
CD62P MFI 1.77[1.47-3.125] 1.35[1.06-4.67] 0.1191  
%CD36 16.15[2.24-
25.37] 
21.93[11.03-
44.92] 
0.0087 - 
CD36 MFI 2.42[2.24-2.88] 1.815[1.45-
4.76] 
0.1374  
D-dimer (mg/l) 0.2[0.2-0.2] 0.23[0.2-0.32] 0.0015 0.00-0.25 
% CD8/38 9.23[6.8-12.96] 21.35[16-
42.53] 
<0.0001  
Log10 mean Viral 
Load(copies/ml) 
- 4.08 ± 0.75 -  
Significant values (p<0.05), are shown in boldface 
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Figure 2. Platelet response to agonists. The color dot plots illustrate illustrate; agonist induced 
%CD62P surface expression on an individual control sample using the gating strategy described 
above (figure 1). 
3.2 Increased platelet agonist induced activation in HIV infected individuals at a 
submaximal concentration of collagen  
In the control group, maximal platelet activation was obtained at 20µM of ADP (mean 25.15); 
1.25mg/ml of AA (mean 33.08); 0.48µg/ml of collagen (median 6.23) (shown in figure 3A). In the HIV 
group maximal platelet activation was achieved at; 20µM of ADP (mean 29.53); 5 mg/ml of AA 
(median 28.26) and at 95µg/ml of collagen (median 9.87).  
In order to evaluate the platelet response to agonists, %CD62P measurements in the control group 
were performed post stimulation with agonists and compared to the HIV group. The HIV group showed 
no significant differences in the expression of %CD62P post stimulation with varying concentrations of  
ADP and AA (figure 3). The HIV group showed increased levels of %CD62P expression post 
stimulation with collagen at; 47.5µg/ml (the HIV group median 18.20[8.39-29.35] vs. 9.43[7.10-14.61], 
p=0.0383), and at 190 g/ml demonstrated significantly decreased levels of %CD62P expression,( HIV 
median 17.60 [8.24-28.59] vs. 9.12[5.52-16.88], p=0.0421). 
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Figure 3. %CD62P expression post agonist stimulation. The figure illustrates platelet response 
measured as the changes in the levels of %CD62P expression in response to agonists at varying 
concentrations in both the HIV and control group. Figure A-C illustrates platelet response to ADP. 
Figure D-F illustrates platelet response to AA and figures G-I illustrate platelet response to collagen. 
3.3 Increased platelet response to endogenous agonists in HIV infected individuals 
compared to uninfected controls 
In order to assess differences in the platelet response to agonists, CD62P MFI levels post 
stimulation with agonists was measured in the control group and compared to the HIV group. 
In the control group, maximal platelet activation was obtained at 5µM of ADP (median 2.15); 
5mg/ml of AA (median 5.86); 95mg/ml of collagen (median 6.23) (shown in figure 3A). In the 
HIV group maximal platelet activation was achieved at; 20µM of ADP (median 2.42); 2.5 
mg/ml of AA (median 11.46) and at 95µg/ml of collagen (median 9.87).  
The HIV group showed increased response to ADP at a concentration of 20µM (median 
CD62P MFI, 1.91[1.64-4.95] vs. Control 1.75[1.45-2.44] p=0.0279. However at lower 
concentrations of ADP there were no significant differences in platelet response, at 5µM of 
ADP (HIV group median CD62P MFI 2.42[1.72-4.84] vs. Control group 2.03[1.57-3.41], 
p=0.0.4093); and at 10µM of ADP (HIV group median CD62P MFI 2.24[1.59-5.16] vs. Control 
group 1.81[1.52-3.78], p=0.2819). 
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Figure 4. Platelet response to agonists. The figure illustrates platelet response measured as the 
changes in the levels of CD62P MFI in response to agonists at varying concentrations in both the HIV 
and control group. Figure A-C illustrates platelet response to ADP. Figure D-F illustrates platelet 
response to AA and figures G-I illustrate platelet response to collagen.  
The HIV group showed an overall hyper-response to arachidonic acid (figure 4), with a higher 
CD62P MFI, at 1.25mg/ml of AA (CD62P MFI 12.54 ± 7.91 vs. 5.21 ± 1.66, p<0.0001); at 
2.5mg/ml of AA HIV group 12.09[5.55-14.53] vs. Control group 4.60[4.02-5.48], p<0.0001 
and at 5mg/ml of AA 9.64[5.56-16.06] vs. Control group 4.66[3.89-6.903], p=0.0006. A similar 
trend was observed post stimulation with collagen (shown in figure 4), with increased overall 
CD62P MFI levels shown in the HIV group at different concentrations of collagen. At 47.5 
µg/ml the HIV group showed a hyper-response with median CD62P MFI 9.51[5.79-11.46] vs. 
Control group 6.02[5-7.71], p=0.0096. At 95µg/ml, HIV group CD62P MFI 9.79 ± 4.53 vs. 
Control group 6.69 ± 2.29 and at 190µg/ml, CD62P MFI 9.61 ± 4.82 vs. 6.81 ± 3.78, 
p=0.0290.  
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4. Discussion 
This study aimed at evaluating markers of platelet activation and aggregation in 
asymptomatic HIV infection using a whole blood platelet flow cytometry assay. Furthermore 
we aimed at assessing the relationship between these platelet markers and conventional 
markers of immune activation and disease progression. We further evaluated differences in 
the response of platelets to endogenous agonists in HIV, compared to uninfected controls. 
Flow cytometry allows the quantification and rapid analysis of platelet antigenic 
characteristics in whole blood (Linden et al., 2004). In addition the use of whole blood 
minimises any artefactual in vitro activation that may be as a result of platelet enrichment 
methods that involve centrifugation of blood samples. In this study we made use of a whole 
blood platelet flow cytometry assay that allowed the assessment of platelet function with 
minimal artefactual platelet activation.  
In this study, the HIV group showed decreased levels of CD4+ T-cells compared to uninfected 
controls. In addition, the HIV group showed elevated levels of CD38+ CD8+ T cells, a marker 
of general immune activation. Increased levels of Immune activation in HIV are associated 
with increased all-cause mortality (Kuller et al., 2008).The levels of immune activation directly 
correlated with viral load and showed no correlation with CD4 counts and markers of platelet 
activation and aggregation. We also report on elevated D-dimer levels in HIV, although these 
fell within the normal reference interval of 0.00-0.25 (shown in table 1). The HIV group 
demonstrated increased levels of circulating activated platelets compared to uninfected 
controls. This is consistent with previous studies where the authors reported on elevated 
levels of platelet activation in HIV infected patients on ART (Holme et al., 1998; Mayne et al., 
2012). In our study both %CD62P and %CD36 correlated with viral load and showed no 
correlation with CD4 count. This may suggest the association between viral RNA levels and 
platelet activation. This is consistent with findings reported by Holme et al., where the 
authors reported an association between increased levels of activated platelets and HIV RNA 
levels in HIV patients on ART (Holme et al., 1998). Notably, there were no significant 
differences in the baseline CD36 and CD62P MFI. This may suggest the presence of 
quantitative rather than qualitative differences in platelet activation in HIV infected 
individuals, which is similar to findings reported by Corrales-Medina et al., who reported no 
qualitative differences in the levels of platelet activation in HIV compared to uninfected 
controls (Carroles-Medina et al., 2010).  
The lack of quantitative differences between baseline platelet activation in the HIV group and 
control group demonstrated by CD62P MFI levels, allowed the use of CD62P MFI as a 
parameter to evaluate platelet response to agonists. We report on hyper activation of 
platelets in HIV infected individuals compared to uninfected controls which is consistent with 
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results reported by O‘Brien et al., where the authors described hyper-reactive platelets in HIV 
infected individuals on ART (O‘Brien et al., 2013). In contrast, Satchell et al., demonstrated 
hypo-responsive platelets in HIV infected patients compared to uninfected individuals, which 
was dependant on the type of agonist used (Satchell et al., 2010). The authors reported a 
decreased response to ADP and collagen in HIV infected individuals and notably, the 
majority of the participants were on ART and had undetectable HIV RNA levels which was 
defined as <50 copies/ml (Satchell et al., 2010). Differences between the cohort 
characteristics may explain these contradictory findings. In addition, differences in the type of 
assay used to evaluate platelet response exist. In this study we report on platelet 
degranulation and surface receptor changes as a qualitative measure of platelet response, 
as demonstrated by the levels of platelet %CD62P expression and CD62P MFI. In contrast, 
Satchell et al., used a light transmission based aggregometry assay that reports on light 
absorbance and platelet aggregation as a measure of platelet response to agonists (Satchell 
et al., 2010).  
Based on qualitative differences between the two groups, our study showed hyper-reactive 
platelets in HIV when compared to uninfected controls. Notably, differences between the two 
groups, in platelet responses to ADP were only observed when evaluating CD62P MFI at a 
concentration 20µM and no differences in the %CD62P expression were observed at this 
concentration of ADP (p=0.9811)(figure 2). ADP at lower concentrations of 3-5µM induces 
platelet responses which are PLA2 dependent whereas at higher concentrations of 20µM, 
they are PLC dependent (Quinn et al., 2005). This may suggest that in the context of HIV 
ADP induced platelet hyper-reactivity is dependent on PLC mediated signalling pathways. 
Interestingly in the HIV group maximum platelet activation was achieved at submaximal 
concentrations of 2.5mg/ml AA. This was unlike the control group where maximal platelet 
activation was achieved at a  concentration of 5mg/ml. Activated PLA2 facilitates the release 
of cell membrane AA and makes it available as a substrate that is converted into 
prostaglandin G2 (PGG2) in the presence of cyclooxygenase (COX). PGG2 is then peroxidised 
into prostaglandin G2 (PGH2) (Cho et al., 2003). Taken together this may suggest an 
enhanced response to submaximal AA concentrations in HIV infected individuals. 
Thromboxane A2 synthetase converts PGH2 into TXA2 which is then released by activated 
platelets which may result in autocrine and paracrine platelet activation (Quinn et al., 2005). 
TXA2 amplifies the initial activation stimulus and promotes the recruitment of additional 
platelets which further promotes thrombus growth and stability (Son et al., 2004). Taken 
together, our findings may suggest that in HIV increased platelet activation, in response to 
submaximal AA concentrations, may promote a pro-coagulatory phenotype and agents 
inhibiting TXA2 activity may be useful in the management of thrombotic disorders in this 
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disease. In support of this CVDs have been reported in patients with increased levels of AA 
induced platelet activation despite being on aspirin therapy (Gaglia et al., 2011). 
Collagen directly activates platelets through the α2 β1 integrin and GPIV receptor (Podrez et 
al., 2007). Maximal platelet activation was achieved at a similar concentration of 95µg/ml 
collagen, in both the HIV and control group (shown in figure 3). Platelets in the HIV infected 
group showed an overall hyper response to collagen as measured by both %CD62P 
expression and CD62P MFI (figures 2 and 3). CD36 signalling is PLC dependent whereas α2 
β1 integrin mediated signalling is dependent on PLA2., Furthermore, collagen induced 
platelet activation exacerbates inflammation (Boilard et al., 2010).. Interestingly the HIV 
group had increased baseline levels of %CD36 and platelet activation via this receptor may 
result in increased levels of inflammation. Signals generated via the CD36 (GPIV) receptor 
are more potent than that of the α2 β1 integrin (Podrez et al., 2007). Moreover, platelets 
expressing CD36 have been reported as hyper reactive to platelet agonists (Podrez et al., 
2007).  
The in vitro cross-sectional nature of the study limits the description of a causative 
relationship between platelet function and thrombotic events in the current cohort. Future 
longitudinal follow up studies will be essential in evaluating the possible thrombotic risk 
profiling and predictive value of this assay. In conclusion, we describe elevated levels of both 
activated and aggregated circulating platelets in HIV. We further show that the levels of 
platelet aggregation and activation directly correlate with viral load and not CD4 count. 
However the potential value of evaluating platelet function using the described flow cytometry 
assay in the monitoring of platelet activation and function in HIV will require further studies. 
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Abstract 
Background 
Platelet monocyte aggregates (PMAs) are a more sensitive marker of platelet activation 
compared to platelet neutrophil aggregates (PNAs) and platelet surface P-Selectin (CD62P) 
expression. Platelet aggregates play a crucial role in the immune defence mechanism 
against bacteria and viruses and increased levels of lipopolysaccharide (LPS) have been 
reported in human immunodeficiency virus (HIV) infected individuals. Platelets are capable of 
interacting with bacterial LPS and subsequently forming platelet leukocyte aggregates 
(PLAs). This study aimed at determining the levels of circulating PLAs in treatment naïve HIV 
infected individuals and to determine the relationship of PLAs in HIV infected individuals, with 
markers of immune activation, disease progression and platelet aggregation. A further aim 
was to assess the effects of LPS stimulation on the formation of PLAs 
Methodology 
Thirty-two (32) HIV negative and 35 HIV positive individuals were recruited from a clinic in 
the Western Cape. All participants had normal leukocyte and platelet counts. Platelet 
monocyte and platelet neutrophil aggregates were measured using flow cytometry at 
baseline and were correlated with markers of platelet activation (CD62P) and aggregation 
(CD36); monocyte and neutrophil activation (CD69); monocyte tissue factor expression 
(CD142); immune activation (CD38 on T+ cells); CD4 count and viral load and a marker of 
active coagulation (D-dimers). Platelet monocyte aggregates were also measured post 
stimulation with lipopolysaccharide.  
Results  
PMA levels were higher in HIV 25.26[16.16-32.28] vs. 14.12[8.36-18.83], p=0.0001 when 
compared to negative individuals. PMAs correlated with %CD38/8 expression (r=0.54624, 
p=0.0155); CD4 count (r=-0.6964, p=0.0039) viral load (r=0.633, P<0.009) and levels of 
monocyte %CD69 expression (r= 0.757, p=0.030). In addition the %PMAs correlated with 
platelet %CD36 expression (r=0.606, p= 0.017).The HIV group showed increased levels of 
%CD62P 5.44[2.72-11.87] vs. Control 1.15 [0.19-3.59], p<0.0001; %CD36 22.53[10.59-
55.15] vs. 11.01[3.69-26.98], p=0.0312 and tissue factor expression (CD142) (CD142 MFI 
4.84[4.01-8.17] vs. 1.74[1.07-9.3], p=0.0240). Stimulation with LPS induced a significant 
increase in PMAs in both groups; however there were no significant differences in PMAs 
between the two groups. 
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 Conclusion 
We describe increased levels of circulating PMAs which directly correlates with markers of 
immune activation, disease progression and platelet aggregation in HIV treatment naïve 
individuals.  
 
1. Introduction 
Inflammation and chronic immune activation are associated with increased mortality and 
disease progression in human immunodeficiency virus (HIV) infected individuals (Ross et al., 
2009). Activated monocytes and platelets have been described as facilitators of both 
inflammation and cardiovascular disease (CVD) (Cerletti et al., 2010; Funderburg et al., 
2014) however the association between inflammation and CVDs in HIV remains inconclusive 
(O'Brien et al., 2013). Platelet aggregates play a crucial role in the immune defence 
mechanism against bacterial and viral pathogens (Beck et al., 2013; David, 2013). The broad 
repertoire of platelet surface receptors enables the formation of interactions between 
platelets and invading organisms (Speth et al., 2013). Scavanger and toll-like receptors 
(TLRs) expressed on the surface of platelets allow them to function as sensory cells for 
pathogens and pathogen induced inflammatory ligands (Metcalf et al., 2013; Clark et al., 
2007; Arazna et al., 2013). Consequently, platelets are able to initiate interactions with cells 
involved in both the innate and adaptive immune response (de Gaetano et al., 2007; 
Bournazos et al., 2008; Metcalf et al., 2013). These interactions induce platelet activation 
and degranulation which subsequently increases the trapping of adjacent circulating 
leukocytes resulting in the formation of neutrophil extracellar traps (NETS) which are able to 
trap pathogens within the circulation (Clark et al., 2007). Platelets have been described as 
initiators and mediators of inflammation at the vessel wall (Shi & Morrell, 2011) and 
alterations in normal platelet kinetics have been reported in human immunodeficiency  virus 
(HIV) infected individuals (O'Brien et al., 2013; Satchell et al., 2010). Furthermore, decreases 
in platelet counts have been associated with elevated platelet monocyte aggregates (Metcalf 
et al., 2013) plasma HIV RNA levels and disease progression (Reig et al., 2007).  
Although activated platelets preferentially form complexes with monocytes, they have the 
capacity to directly interact with neutrophils via P-selectin and P-Selectin glycoprotein ligand-
1 (PSGL-1) receptor engagements (Singh et al., 2012). Elevated platelet leukocyte 
aggregates (PLAs) play a crucial role in the pathogenesis of thrombotic conditions. However, 
platelet monocyte aggregates (PMAs) have been reported as a more sensitive marker of 
platelet activation (Harding et al., 2007) than platelet neutrophil aggregates (PNAs) and 
platelet surface P-selectin(CD62P) expression (Michelson et al., 2001). Furthermore, 
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elevated levels of circulating PMAs have been demonstrated in HIV individuals on 
antiretroviral therapy (ART) (Singh et al., 2012).  
Interactions between platelets and monocytes can often result in the activation of monocytes 
and the modulation of monocyte function (Metcalf et al., 2013). The result of increased 
monocyte activation was recently linked with cardiovascular disease in a study which 
described an association between monocytes expressing increased levels of toll like receptor 
4 (TLR4) and cardiovascular disease (Tapp et al., 2013).  
On the other hand, platelet-neutrophil interactions may induce neutrophil activation with the 
subsequent release of pro-inflammatory molecules (Nathan, 2006). Platelets are capable of 
interacting with bacterial LPS and forming complexes with neutrophils (PNA‘s) (Clark et al., 
2007). These PNAs, which are the result of LPS bound platelets, release reactive oxygen 
species (ROS) and are associated with neutrophil mediated endothelial cell damage (Clark et 
al., 2007).  
Although antiretroviral therapy (ART) suppresses HIV viral replication, chronic immune 
activation and bacterial translocation in HIV infected individuals persists (Cassol et al., 2010). 
Bacterial translocation in HIV has been associated with chronic immune activation and 
increased levels of LPS have been reported in HIV infected individuals (Brenchley et al., 
2006). However, data regarding LPS induced PLAs in the context of HIV remains scarce.  
Flow cytometry offers a sensitive and rapid technique for the evaluation of PLAs (Harding et 
al., 2007; de Gaetano, 2007). However due to the sensitivity of the technique, several 
methodological considerations have to be considered in order to ensure that ex vivo artefacts 
are kept minimal (Harding et al., 2007). In this study PMAs and PNAs where measured using 
a rapid flow cytometry technique. Efforts to minimise artefactual platelet-leukocyte aggregate 
formation included avoiding centrifugation and washing of samples. This study aimed at 
measuring baseline PNAs and PMAs in treatment naïve HIV infected individuals and to 
correlate these with markers of platelet activation (CD62P) and aggregation (CD36), 
monocyte and neutrophil activation (CD69); immune activation(CD38 on T+ cells), CD4 
count, viral load and  marker of active coagulation (D-dimers). We further determined the 
response of platelet monocyte aggregates/complexes to stimulation with LPS. 
 
2. Methodology 
2.1 Participants and sample collection 
Participants were recruited from the Emavundleni Voluntary Counselling and testing (VCT) 
clinic in crossroads, Cape Town. The participant demographics are described in table 1. 
Participants were excluded if they were on aspirin, anti-inflammatory or anti-TB drugs. Ethical 
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review was performed according to the declaration of Helsinki and the study was approved 
by the Stellenbosch University human research ethics committee (HREC) (no. N07/09/197). 
The study was also registered with the University of Cape Town research ethics committee 
(REC) (no. 417/2006). Informed consent was obtained from each participant. 
2.2 Study Design 
Baseline platelet-monocyte and platelet-neutrophil complexes were measured using flow 
cytometry. CD4 T cell count; viral load; full blood counts, D-dimers and fibrinogen were also 
measured. Associations between each baseline study parameter were assessed. This was 
followed by LPS induced monocyte activation. The levels of both PMAs and PNAs were then 
measured and a comparison between the post LPS stimulation sample and the baseline 
sample was made. 
2.3 Sample collection 
A volume of 2-3ml of venous blood was collected by venipuncture into 4.5ml tubes containing 
3.2% sodium citrate (BD Vacutainer, San Jose). Samples were kept at room temperature 
during transit from clinic to the laboratory. The time frame between sample collection and 
sample analysis was limited to 1-3hrs. 
2.4 Antibodies and reagents 
The anti-human CD14-PC5, CD69-PC7, CD42b monoclonal antibodies were purchased from 
Beckman Coulter, USA. The anti-human CD16-PE, 7AAD and CD142(HTF-1) were 
purchased from BD Biosciences, San Jose, CA. Antibody titration assays were performed to 
detect the optimal antibody concentrations. 
2.5 Markers of immune activation  
2.5.1 CD4 T Cell count: The BD MultiTEST CD3-FITC/CD8-PE/CD45-PerCP/CD4-APC 
reagent (BD Biosciences) and BD TruCOUNT tubes (BD Biosciences, San Jose, CA) were 
utilised for the measurement of CD4 T cell count. CD4 T cell flow cytometry was performed 
at the Division of Medical Virology, Faculty of Health Sciences, Stellenbosch University,which 
is accredited by the South African National Accreditation System (SANAS). 
2.5.2 Viral load measurements: Blood samples were collected into 5ml EDTA tubes, which 
were centrifuged at 20°C at 300g for 12 minutes. 1 ml of plasma was transferred into a 
Greiner Bio-one cryotube (Greiner Bio-One GmbH, Frickenhausen, Germany) and sent for 
viral load testing. The viral load assay performed was a NucliSensEasyQ® HIV-1 v1.2 Viral 
Load Test (BioMerieux Inc., Boxtel, Netherlands) which has a detection range of 1.60 to 6.7 
log10 copies/ml. Viral load testing was performed at the SANAS-accredited, Division of 
Medical Virology, Faculty of Health Sciences, Stellenbosch University. 
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2.5.3 Measurements of the percentage of CD8+ T-cells expressing CD38: This 
measurement was performed using flow cytometry. Briefly, 50µl of whole blood was stained 
with a titrated monoclonal antibody cocktail containing; CD8 Per-CP; CD38 APC; CD3 FITC 
(BD Biosciences, San Jose, CA). Data acquisition was perfomed using a BD FACSCalibur 
instrument and analysis was done using the BD Cell Quest Pro (Version 2) software. 
2.5.4 TF measurements: Monocyte tissue factor expression measurements where 
performed using flow cytometry. Briefly 50µl of citrated whole blood was stained with 5µl of 
an antibody cocktail containing; CD14 PC5 (Beckman Coulter, USA) and CD142 PE (BD 
Biosciences, San Jose, CA). Data acqusition was perfomed using a Beckman Coulter FC500 
cytometer and analysis was done Kaluza V 1.2 software (Beckman Coulter, USA). 
2.5.5 D-dimer measurements: The measurement of D-dimer levels was performed on 
citrated blood. Blood samples were collected using 4.5ml tubes containing 3.2% sodium 
citrate. Measurements were performed using the HemosIL TM Dimertest® Kit 
(Instrumentation Lab) and the ACL TOP platform at the SANAS-accredited NHLS 
Haematology coagulation laboratory at Tygerberg Hospital. 
2.6 Measurements of PMAs and PNAs  
2.6.1 Prior to in vitro monocyte and neutrophil activation 
The measurement of PMAs and PNAs was performed on whole blood. Briefly, 50µl of blood 
was stained with 5µl of titrated antibody cocktail. The cocktail consisted of titrated volume of 
monoclonal antibodies; CD16-PE, CD14-PC5, CD69-PC7 and CD42b FITC. Red blood cell 
lysis was performed using 500 µl of FACS lyse. 5µl of Transfix was added at the time of red 
blood cell lysis to limit the artefactual formation of platelet leukocyte aggregates which could 
be the result of red blood cell lysis. As a final step before acquisition, samples were stained 
with 7AAD (a viability marker) and incubated for 15 minutes. Samples were then analysed 
immediately. Fluorescence minus one (FMO) was used to distinguish positive from negative 
events and unstained whole blood was used as a control for 7AAD staining. PMAs were 
defined as CD14+ CD42b+ dual positive events while PNAs were identified as CD16+ CD42b+ 
events (shown in figure 1).The CD42b mean fluorescence intensity (MFI) and percentage 
(%) CD42b expression was used for qualitative and quantitative analysis of PMAs.  
2.6.2 Gating strategy 
Viable CD14+ monocytes were gated as shown in figure 1A and 1C. The expression of 
CD42b on monocytes was assessed (figure 1H). Monocytes expressing CD42b were 
regarded as platelet-monocyte complexes. CD69 expression was also evaluated to 
determine monocyte activation. Fluorescence minus one (FMO) control was used to 
distinguish between positive and negative CD69 and CD42b events. For the assessment of 
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platelet-neutrophil complexes CD16+ neutrophils were gated (figure 1B) and the expression 
of CD69 and CD42b on these neutrophils was assessed (figure 1E and G). Neutrophils 
expressing CD42b were regarded as platelet-neutrophil complexes. 
2.6.3 Post in vitro monocyte activation 
A volume of 20 µl of LPS (2µg/ml) was used for monocyte and neutrophil stimulation. Briefly, 
50 µl of blood was treated with 20 µl of LPS. This was followed by 16 hours overnight 
incubation at 37 °C. The blood samples were then stained as mentioned above with the 
addition of 7AAD for the assessment of cell viability (shown in figure 2A). The expression of 
CD42b on viable; monocytes (7AAD- CD14+) was measured post stimulation with LPS (figure 
2C). FMO controls were used to distinguish between positive (CD14+ CD42b+) and negative 
(CD14+ CD42b-) events (shown in figure 2E). This ensured the analysis and reporting of 
physiologically viable and functional PMAs, induced by in vitro LPS stimulation.  
 
2.7 Statistical analysis 
Statistical analysis was performed using Graph pad prism 5 for windows, version 5.00 
software .The Mann-Whitney U test was used to compare non-parametric data and these 
values were reported as median and interquartile range. For parametric data an unpaired 
student t test was performed and data was reported as mean and standard deviation. Paired 
data tests were also performed. For parametric data a paired t-test analysis performed and 
for non-parametric data Wilcoxon matched data set analysis was performed. 
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Figure 1. Gating strategy. The figure illustrates the baseline measurement of monocyte, neutrophil 
activation and platelet complexes using a control sample. Figure A represents the determination of 
viability of cells using 7AAD. The gating strategy applied to discriminate CD16b
+ 
neutrophils and 
CD14
+ 
monocytes is shown in figures B-D. The histograms E and F demonstrate the measurements of 
monocyte activation and Neutrophil activation using CD69. Histograms G and H, demonstrate the 
measurement of baseline platelet neutrophil (CD16b
+
CD42b
+
)
 
and platelet monocyte (CD14
+
CD42b
+
) 
complexes. 
 
3. Results 
The cross-sectional study consisted of a total of sixty-seven (67) participants, 32 HIV 
negative controls and 35 HIV positive ARV-naïve individuals. The characteristics of the study 
participants are tabulated in table I. The study groups demonstrated a similar mean age of 30 
years and no participants were thrombocytopenic. Differences in absolute monocyte and 
neutrophil count where observed amongst the two groups; however these were within the 
normal reference intervals (shown in table 1). The HIV group showed increased levels of 
circulating activated platelets as demonstrated by the increased median baseline levels of 
platelet %CD62P expression 5.44[2.72-11.87] vs. Control group 1.150[0.19-3.59], p<0.0001. 
The HIV group also showed increased median levels of %CD36 a marker of platelet 
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aggregation, 22.53[10.59-55.15] vs. control group 11.01[3.69-26.98], p=0.0312 (shown in 
table 1). 
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Table 1. Participant demographics and baseline characteristics 
Significant values (p<0.05), are shown in boldface 
 
 
 
 
Parameter Control HIV P- 
value 
Reference 
Interval 
No. of participants 32 35   
Age 30.00 ± 1.52 30.43 ± 1.23 0.8276  
Gender (% males) 52.4 33.3 -  
Ethnicity     
Black (%) 100 100 - - 
CD4 count (cells/µl) 743.6 ± 39.92  357.1 ± 38.77 <0.0001 500-2010 
Monocytes (x10
9
/l) 0.34[0.25-0.41] 0.28[0.19-0.33] 0.0377 0.18-0.80 
Neutrophils (x10
9
/l) 3.13[2.38-4.56] 2.51[1.73-3.42] 0.0107 2-7.50 
Platelet count (x10
9
/l) 281.5 ± 12.44 296.8 ± 17.0 0.4629 178-400 
%CD62P 1.15[0.19-3.59] 5.44[2.72-11.87] <0.0001 - 
%CD36 11.01[3.69-26.98] 22.53[10.59-55.15] 0.0312 - 
Monocyte CD69 MFI 7.49[5.463-14.74] 16.79[15.39-25.96] 0.0150 - 
Monocyte TF expression (MFI) 1.74[1.07-9.3] 4.84[4.01-8.17] 0.0240  
Neutrophil CD69 MFI 11.51 ± 8.73 34.63 ± 18.15 0.0015 - 
%Platelet monocyte aggregates 14.12[8.36-18.83] 25.26[16.16-32.28] <0.0001  
MFI Platelet-monocyte aggregates 11.34[3.67-15.99] 22.29[19.26-27.39] <0.0231 - 
%Platelet neutrophil aggregates 2.49[0.78-4.390] 1.78[0.52-4.390] 0.3604  
MFI Platelet neutrophil aggregates 23.38[17.25-32.70] 30.15[19.79-48.14] 0.6254 - 
D-dimer (mg/l) 0.2[0.2-0.2] 2.6[2.5-3.0] <0.0001 0.00-0.25 
% CD8/38 9.63[5.554-13.35] 19.45[14.02-43.32] 0.0001  
Log10 mean Viral Load(copies/ml) - 4.08 ± 0.75 -  
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3.1 Increased levels of circulating activated platelets, monocytes and PMAs in HIV 
infected individuals compared to uninfected individuals 
In order to compare the levels of platelet monocyte aggregates between the groups, the 
percentage expression of CD42b on monocytes was measured. The HIV group showed 
elevated levels of %PMAs 25.26[16.16-32.28] vs. Control group 14.12[8.36-18.83], 
p<0.0001. To further assess the relative number of platelets bound on monocytes, 
differences in the mean fluorescent intensity (MFI) were analysed. The HIV group showed 
increased levels of PMA MFI 23.07[19.26-27.39] vs. control group 11.22[3.42-16.38], 
<0.0001. This observation indicated an increased number of platelets bound to each 
monocyte. There were no significant differences in the levels of circulating PNAs between 
the two groups (shown in table 1).  
 
Figure 2. Platelet monocyte gating strategy. The figure demonstrates platelet monocyte 
measurements prior and post LPS stimulation in a control sample. Figures A and C illustrate the use 
of 7AAD as a viability dye to ensure analysis of viable monocytes. Figures B and D are gated on the 
viable cells which are 7AAD negative. Figure E demonstrates the use of an FMO control to distinguish 
between positive and negative cells. While figures F-G illustrate %PMA changes in response to LPS 
stimulation. 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
 
 
111 
 
3.2 Platelet monocyte aggregates inversely correlate with CD4 count and directly 
correlate with markers of immune activation, disease progression and platelet 
activation and aggregation 
To determine the associations between PMAs and markers of immune activation and 
coagulation, PMAs were correlated with %CD38/8 expression, (r=0.54624, p=0.0155); CD4 
count (r=-0.6964, p=0.0039) and viral load (r=0.633, P<0.009). The levels of monocyte 
activation (%CD69 expression) showed a direct correlation with PMAs (r= 0.757, p=0.030). In 
order to determine the association of %PMA levels with platelet aggregation and activation, 
the %PMA was correlated with platelet %CD36 expression (r=0.606, p= 0.017) and free 
circulating activated platelets %CD62P expression (r= 0.236, p=0.379). The %PMA showed 
no significant correlation with D-dimers (r=-0.119, p=0.638), a marker of active coagulation. 
 
3.3 Increased levels of monocyte TF expression in HIV does not correlate with the 
percentage of PMAs  
To determine the levels of pro-coagulant monocytes, tissue factor (CD142) expression on 
each cell was compared between the two groups. The HIV group showed increased TF 
expression as demonstrated by increased TF MFI 4.84[4.01-8.17] vs. 1.74[1.07-9.3], 
p=0.0240. To assess the association between monocyte TF expression and platelet 
monocyte interactions, PMA levels were correlated with monocyte TF expression. This 
analysis demonstrated that there was no relationship between PMA and TF expression on 
the monocytes (%PMAs (r=0.322, p=0.368), PMA MFI(r=-0.479, p=0.166). In addition, there 
was no correlation between TF expression and viral load (r=-0.1364, p=0.6937); CD4 count 
(r=-0.2252, p=0.4018) or; CD38/8 (r=0.09890, p=0.7479). 
 
3.4 LPS induces increased PMA levels in HIV infected individuals compared to 
uninfected controls 
To determine the effects of TLR4 ligand signalling on platelet-monocyte cross talk, the levels 
of platelet-monocyte complexes post-stimulation with LPS were measured. In the control 
group the PMA MFI was significantly increased post stimulation with LPS, median 
34.37[32.32-35.50] vs. baseline 11.22[3.42-16.38], p=0.0010. Similarly in the HIV group the 
%PMA levels were increased post LPS stimulation, median 37.24[31.14-46.90] vs. 
23.07[19.26-27.39], p=0.0157. However there were no significant differences in the %PMAs 
between the two groups post LPS stimulation, 34.37[32.32-35.50] vs. baseline 24.68[21.19-
33.86], p= 0.7094. 
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Figure 3. Platelet monocyte complexes post LPS stimulation. The graphs demonstrate the % of 
PMAs in the control group (figure A) and HIV group (figure B), post stimulation with LPS). Graph C 
illustrates the PMA MFI differences between the two groups. 
 
In the control group the PMA MFI was significantly increased post stimulation with LPS and a 
similar response was observed in the HIV group (Figure 3A and B). However, post LPS 
stimulation there were no differences between the two groups with regard to the PMA MFI. 
Notably, the control group showed a greater response to LPS (figure 3A) compared to the 
HIV group (figure 3B). This may be as a result of increased baseline levels of circulating 
PMAs in the HIV group compared to the control group (table 1). Platelets and monocytes 
may be primed in vivo and therefore demonstrate minimal in vitro stimulation and interactions 
compared to that of the control group. 
4. Discussion 
The measurement of platelet leukocyte aggregates using flow cytometry, offers a highly 
sensitive and rapid method for the qualitative (mean fluorescence intensity) and quantitative 
(%positive events) measurement of platelet leukocyte aggregates. Efforts have been made 
to standardize this technique (Harding et al., 2007; de Gaetano, 2007; Pearson et al., 2009; 
Majumder et al., 2012; Singh et al., 2012; Nagasawa et al., 2013) and measurement of 
platelet monocyte aggregates have been demonstrated to be a more sensitive and robust 
measure of platelet activation than platelet neutrophil aggregates and surface P-selectin 
(Michelson et al., 2001). The use of flow cytometry in the measurement of platelet 
aggregates however requires numerous pre-analytical and analytical methodological 
considerations in order to minimize in vivo artefacts (Singh et al., 2012, Harding et al., 2007). 
These include the type of anticoagulant used and the time between sample collection and 
immunostaining (Harding et al., 2007). In the present study the anticoagulant sodium citrate 
was used, as a previous study had reported reduced, in vivo time dependant changes in 
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platelet monocyte aggregates when blood was collected into heparinised and EDTA tubes 
(Harding et al., 2007). To further minimise in vivo induced changes in platelet aggregates, 
centrifugation and washing of samples was omitted. Although red blood cell lysis was 
performed, the addition of fixative at the time of red blood cell lysis kept the consequential 
platelet activation to a minimum, limiting platelet activation induced by ADP which is released 
upon the lysis of red blood cells. Furthermore, care was taken to ensure the viability of cells 
and in order to ensure that necrotic cells were excluded from the analysis 7AAD was utilised 
in the gating strategy (shown in figure 1a). The primary aim of this study was to determine 
the levels of platelet monocyte and platelet neutrophil interactions in HIV treatment naïve 
individuals. This was achieved by measuring the levels of platelet monocyte and platelet 
neutrophil aggregates and assessing the association between platelet aggregates; markers 
of immune activation and disease progression.  
In this study we report on increased levels of activated platelets and monocytes in HIV 
infected individuals compared to uninfected individuals. Recent studies have described the 
role platelets play in the defence against invading pathogens. In these situations platelet 
activation and aggregation is crucial for the engulfment and killing of pathogens by activated 
platelets (Flaujac et al., 2010; Metcalf et al., 2013). In our study, HIV infected individuals had 
increased levels of monocyte tissue factor expression compared to their uninfected 
counterparts. These findings are consistent with those reported by Funderburg et al., where 
the authors observed increased monocyte TF expression in HIV infected individuals on 
highly active antiretroviral therapy HAART (Funderburg et al., 2010). Activated monocytes 
are involved in the initiation of inflammation, clearance of apoptotic cells and the facilitation of 
both the innate and adaptive immune response. Based on their expression of CD16, 
monocytes are classified into three distinct subsets; classical, intermediate and nonclassical. 
Specific functions and responses to bacterial and viral products between the different 
subsets have been well described (Ziegler-Heitbrock, 2007; Cros et al., 2010) and classical 
monocytes are considered a source of infiltrating macrophages involved in atherosclerosis 
(Ingersoll et al., 2011). Activated platelets express a repertoire of receptors that enable and 
facilitate platelet leukocyte crosstalk and as a result platelet leukocyte aggregates are 
formed. Therefore, platelet leukocyte aggregates may play a key role in inflammation and 
thrombosis (Cerletti et al., 2012).  
In this study, platelet monocyte aggregates were significantly increased in HIV compared to 
the control group. These findings are consistent with recent work published by Singh et al., in 
which the authors reported that there were increased PMAs in HIV infected individuals on 
ART. The authors further observed a positive correlation between platelet CD62P expression 
and PMAs (Singh et al., 2012). However this is contrary to our findings as in our study there 
was no correlation between PMAs and CD62P. Notably, Singh et al., reported on a cohort of 
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only 8 HIV infected individuals and the differences in the size of the cohorts may explain the 
contradictory findings. 
Our observations demonstrated that PMAs in HIV infected individuals directly correlate with 
viral load, %CD38/8 and inversely correlate with CD4 count. In addition, PMAs also showed 
a positive correlation with the % of platelets expressing CD36. The role of CD36 as a 
mediator of inflammation and thrombosis has been previously described (Podrez et al., 
2007). CD36 is a scavenger receptor expressed by monocytes, macrophages capillary 
endothelial cells and platelets (Febbraio et al., 2001). Its expression on monocytes has been 
associated with the formation of foam cells which are abundantly found at sites of 
atherosclerosis (Rahaman et al., 2006). Platelet CD36 plays a crucial role in platelet 
aggregation and inflammation (Febbraio et al., 2001). Taken together with our current 
findings this may suggest that platelet CD36 expression could be a useful marker for the 
prediction of PMA formation. Interestingly, the HIV group showed increased baseline 
percentages of platelets expressing CD36. However the lack of a correlation between CD36 
expression and viral load suggests that the mechanism responsible for it‘s up-regulation is 
independent of viral load. However, platelet CD36 may be a valuable marker in the 
thrombotic risk profiling of HIV infected individuals.  
The in vivo expression of monocyte TF expression in response to TLR4 ligands has been 
well described (Funderburg et al., 2010). In our study, stimulation with LPS induced 
increased PMAs in both the HIV and control group. However, no significant differences in the 
levels of PMAs between the two groups, post stimulation, were observed. This may suggest 
that although baseline levels of PMAs are increased in HIV, LPS and TLR4 ligand 
interactions may induce PMA formation in a similar manner to uninfected individuals. In HIV, 
the persistent microbial translocation and consequential immune activation (Cassol et al., 
2010) would lead to the activation of both platelets and monocytes. This, taken together with 
our findings may suggest that the increased thrombotic risk observed in HIV infected 
individuals may be as a result of increased platelet- monocyte cross-talk and the subsequent 
increased levels of PMAs. 
In support of this theory a study, of a group of HIV infected individuals, described the 
association of bacterial translocation across the intestinal mucosa with increased levels of 
LPS (Brenchley et al., 2006). Further research by Ward et al., demonstrated that LPS 
induced platelet activation had no effect on platelet aggregation (Ward et al., 2005), however, 
contrary to this Aslam et al., reported that after  in vivo TLR4 receptor LPS-induced 
activation, decreased platelet counts were observed (Aslam et al., 2006). Our findings 
suggest that a procoagulant platelet phenotype, and monocytes which have retained their 
functional capacity, exists in HIV infected individuals. It has been suggested that platelet 
activation via TLR4 receptor signalling facilitates the clearance of activated platelets and the 
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generation of inflammatory cytokines (Smith et al., 2011). This proposal may further explain 
our current finding of increased PMAs which may be an indication of monocyte mediated 
clearance of activated platelets in HIV.  
However, due to the cross-sectional design of the study, we cannot ascertain the clinical 
value of increased PMAs in the thrombotic risk profiling of HIV infected individuals. In this 
study, age and ethnicity could be excluded as confounders, since there were no significant 
differences in the age and ethnicity of the study participants (table 1). We also suggest that 
increased PMAs are dependent on immune activation and HIV RNA replication and that 
PMAs are associated with platelet aggregation. Our findings further imply the potential 
prognostic value of PMAs in HIV infected individuals, as shown by an inverse association 
between CD4 count and PMAs in HIV infected treatment naïve individuals. To the best of our 
knowledge the present study is the first to describe a direct association between increased 
PMAs and markers of; immune activation, platelet aggregation and disease progression in 
treatment naïve HIV infected individuals. The monitoring of PMAs in HIV infected individuals 
may be crucial and a useful marker of immune activation and thrombotic risk in HIV infected 
individuals not yet prioritized for treatment. 
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Abstract 
Background 
Chronic immune activation in human immunodeficiency virus (HIV) infection induces 
activation of leucocytes and platelets, resulting in the formation of microparticles (MPs). 
Platelet microparticles (PMPs) are prothrombotic and have been described in inflammatory 
disease. Increased levels of platelet aggregation have been reported in HIV but evidence 
suggests PMP levels may be a more sensitive marker of platelet activation, compared to 
surface CD62P expression. We aimed to measure PMPs and platelet aggregates in HIV 
infected individuals, using a flow cytometry based whole blood assay. In addition, we aimed 
to investigate associations between MPs, PMPs, platelet aggregates and markers of immune 
activation with disease progression in asymptomatic treatment-naïve HIV infected 
individuals. 
Materials and methods 
Forty-Eight (48) antiretroviral therapy (ART) naïve HIV infected and 40 uninfected individuals 
were recruited at a clinic in Cape Town. Platelet microparticles (PMPs), platelet aggregates 
and platelet P-selectin CD62P were measured using flow cytometry and correlated with CD4 
count, viral load and %CD38 on CD8+ T cells.  
Results 
HIV infected individuals showed increased levels of median platelet %CD62P 2.93[1.23-
12.88] vs. control 1.15[0.19-3.59]; circulating MPs (HIV group median 1.7[0.95-2.83] vs. 
1.12[0.63-1.57] control group, p=0.0160); and levels of PMPs (median %PMPs 26.64[11.33-
36.62] vs. control 20.02[18.08-26.08], p=0.0133). In the HIV group, levels of activated 
platelets correlated with; platelet aggregates (r=0.5530, p=0.011) and activated PMPs 
(r=0.594, p=0.007). The baseline platelet aggregate % was similar between the two groups, 
however the platelet aggregates in the HIV group showed increased levels of 
activation(platelet aggregates median %CD62P 14.10[5.49-39.94] vs. 0.17[0-10.99] control 
group, p=0.0097). The HIV group of patients demonstrated increased levels of immune 
activation, (median %CD38 on CD8+ cells 24.03[15.76-43.92] vs. control 9.23[6.8-12.96], 
p<0.0001). In the HIV group levels of %CD38+ CD8+ T cells correlated with; %PMPs 
(r=0.4730, p=0.0196), %MPs (r=0.4386, p=0.025) and %PLT aggregates (r=0.321, p=0.135). 
In addition the %PMPs demonstrated no correlation with viral load (r=0.152, p=0.511) or 
CD4+ T cell count (r=0.-0.361, p=0.07).  
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Conclusions 
We describe an optimized whole blood flow cytometry based assay for the evaluation of 
circulating MPs, PMPs and levels of activated platelets and aggregates which is similar to the 
in vivo physiological environment of MPs. Furthermore we report on increased levels of 
circulating MPs and PMPs in HIV infected asymptomatic individuals together with increased 
levels of activated PMPs and platelet aggregates in HIV. 
 
1. Introduction 
 
Human imunnodeficiency virus (HIV) infection is characterized by chronic Immune activation 
and inflammation (López et al., 2012). People living with HIV (PLWH) are at an increased 
risk of developing cardiovascular disease (CVD) (Hsue et al., 2009) and are associated with 
a prothrombotic and pro-inflammatory state (Carr et al., 2008). Activated platelets play a key 
role in both inflammation and thrombosis (Nurden et al., 2011) as they release pro-
inflammatory mediators that amplify the inflammatory response (Menzes et al., 2009). 
Microparticles (MPs) are small vascular membrane-derived fragments that form upon cell 
activation or apoptosis (Freyssinet et al., 2010). They express surface antigens of the cell of 
origin which allows them to be characterized (Mostefia et al., 2008). Upon activation the 
remodeling of the platelet membrane results in the formation of sub-micrometer fragments 
described as platelet derived micro-particles (PMPs) (Zwaal et al., 1992; Holme et al., 
2004)). Circulating platelets are 2.0-4.0 by 5µm in size (George et al., 2000) and PMPs are 
defined as small vesicles with a diameter of 0.1-1µm (Robert et al., 2008).  
Increased levels of MPs in HIV are associated with uncontrolled viral replication (López et al., 
2012) and PMPs represent the majority of microparticles detected in human plasma (Burnier 
et al., 2009). Elevated levels of PMPs have been described in prothrombotic and 
inflammatory disease (Shantsila et al., 2010). Data in the context of HIV remains 
inconclusive and contradictory findings in PLWH compared to uninfected individuals have 
been reported (Corrales-Medina et al., 2010; da Silva et al., 2011). PMPs have more 
procoagulant compared to activated platelets (Morel et al., 2006; Rautou et al., 2011). This is 
because of the abundant phosphodylserine (PS) expressed on the surface of PMPs which 
acts as a potent surface for the stimulation of coagulation factors and the promotion of 
thrombin generation (Rautou et al., 2011). PS expression has been used to define MPs, 
however MPs lacking PS expression have also been described (Connor et al., 2010). MP‘s 
are involved in haemostasis and thrombosis whereas PMPs enhance thrombosis by inducing 
platelet activation and aggregation, decreasing clotting and increasing thrombus size 
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(Suades et al., 2012). In addition, PMPs modulate both innate and adaptive immunity 
(Semple et al., 2010). 
Flow cytometry allows for the rapid measurement of microparticles and numerous studies 
have reported on attempts to standardize these methods (Shah et al., 2008; Trummer et al., 
2008; Robert et al., 2009; Dey-Hazra et al., 2010). The majority of MP measurements are 
based on the preparation of platelet rich plasma (PRP) (Perez-Pujol et al., 2007) or platelet 
poor plasma (PPP) (Iversen et al., 2013) which often involves centrifugation and freezing 
steps (Yuana et al.,2011).These processes may lead to platelet activation, destruction of 
MPs and fusion of MPs (Christersson et al., 2013). The detection of MPs using flow 
cytometry is a highly sensitive technique that requires the optimization and consideration of 
all pre-analytical variables (Shah et al., 2008). Accurate and consistent instrument calibration 
is required to enable the discrimination of MPs from cellular debris (Christersson et al., 
2013). Thus, the use of calibration beads to determine the particle size detection threshold 
and the use of fluorescence as a detection parameter for MPs are essential (Robert et al., 
2009). 
 
Flow cytometry allows for the discrimination of aggregated cells from freely circulating cells 
(Wersto et al., 2001). The use of a doublet strategy designed to overcome the analysis of 
doublets in DNA studies has been applied in the measurements of platelet monocyte 
aggregates (Majumder et al., 2012). Ultrastructural changes in platelet aggregates have 
been described in HIV infected individuals (Pretorius et al., 2008) and therefore application of 
the doublet discrimination strategy in the enumeration of platelet aggregates may be a useful 
tool. The present study aimed at measuring PMPs and platelet aggregates in HIV infected 
individuals, using a flow cytometry based whole blood assay. The assay was optimised to 
ensure artefactual platelet activation is minimised by omitting any centrifugation and platelet 
isolation steps. Moreover, we aimed at evaluating associations between PMPs, platelet 
aggregates and markers of immune activation and disease progression in asymptomatic 
treatment naïve HIV infected individuals. 
 
2. Methodology 
2.1 Methodology 
Forty-six (46) HIV infected ARV-Naïve and 40 uninfected consenting individuals were 
recruited from the Emavundleni Voluntary Counselling and Testing (VCT) Clinic in 
Crossroads, Cape Town which is associated with the Institute of Infectious Diseases and 
Molecular Medicine (IIDMM) and the Desmond Tutu HIV Centre, University of Cape Town 
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(UCT). None of the participants were on aspirin on the day of testing and baseline participant 
characteristics are reported in table 1. The study protocol was reviewed by the health 
research ethics committee (HREC) at Stellenbosch University and the research ethics 
committees (REC) at University of Cape Town. Ethical review was performed according to 
the declaration of Helsinki and the study was approved by both committees and registered 
under the ethical approval number N07/09/197 and 417/2006, respectively. 
2.2 Design of the study  
Baseline levels of platelet derived micro-particles, activated platelets and platelet aggregates 
were measured among all participants. In order to assess associations between these 
measured platelet parameters and immune activation and disease progression in HIV, PMPs 
and platelet aggregates were correlated with CD4 T-cell count, viral load and % of CD8+ T-
cells expressing CD38.  
 
2.3 Sample collection 
Whole blood was collected by venipuncture into 4.5ml tubes containing 3.2% sodium citrate 
(BD Vacutainer, San Jose, CA). Samples were kept at room temperature during the 
transportation from clinic to the laboratory. The time frame between sample collection and 
analysis was limited to 1-3hrs. 
 
2.4 Markers of immune activation and disease progression  
2.4.1 CD4 T-cell counts measurements: The BD MultiTEST CD3-FITC/CD8-PE/CD45-
PerCP/CD4-APC reagent (BD Biosciences) and BD TruCOUNT tubes (BD Biosciences, San 
Jose, CA) was used for CD4T cell count measurements. Measurements were performed at 
the Division of Medical Virology, Faculty of Health Sciences, Stellenbosch University, which 
is South African national Accreditation System (SANAS) accredited. 
 
2.4.2 Viral load measurements: The NucliSensEasyQ® HIV-1 v1.2 Viral Load Test 
(BioMerieux Inc., Boxtel, Netherlands) was used for viral load measurements. All 
measurements were performed according to the manufacturer instructions at the Division of 
Medical Virology, Faculty of Health Sciences, and Stellenbosch University which is SANAS-
accredited.  
2.4.3 CD38 on CD8+ T cell measurements: BD FACSCalibur flow cytometry instrument 
was used to measure the percentage of CD8+ T-cells expressing CD38. 50µl of heparinized 
whole blood was stained using a titrated monoclonal antibody cocktail containing; CD8 
Stellenbosch University  https://scholar.sun.ac.za
 
 
124 
 
PerCP; CD38 APC; CD3 FITC (BD Biosciences, San Jose, CA). Data analysis was done 
using the BD Cell Quest Pro (Version 2) software. 
2.6 D-dimer measurements:  The HemosIL TM Dimertest® Kit (Instrumentation Lab) and 
the ACL TOP platform were used for the measurement of D-dimers. All measurements were 
performed at the NHLS Haematology coagulation laboratory at Tygerberg Hospital which is 
South African National Accreditation System (SANAS) accredited laboratory. 
2.7 Platelet flow cytometry 
2.71 Instrument settings: The Beckman Coulter FC500 flow cytometer (Beckman Coulter, 
Miami Florida) was used for data acquisition. Flow check (Beckman Coulter, Miami, USA) 
fluorescent labelled beads of known size and fluorescence intensity were used to verify 
optical path and laminar flow of the cytometer. Flow set beads (Beckman Coulter, Miami, 
USA) were used to set instrument voltages and to ensure consistent instrument detector 
settings. The Beckman Coulter Quickcomp kit (Beckman Coulter, Miami, USA) was used to 
compensate for spectral overlap. This ensured the reporting of standardized results that were 
not influenced by long-term instrumental drifts.  
 
2.7.1 Sample preparation and Staining: CD42b-FITC a platelet specific antibody was used 
to characterize the platelets (Fig 2B) and CD62P-APC expression was used to monitor 
platelet and aggregate activation levels. Briefly, 50µl of citrated whole blood was stained 
using 5µl of the antibody cocktail and incubated in the dark for 20 minutes at room 
temperature. 500µl of PBS (which did not contain Ca2+ or MgCl2) was added and samples 
were analysed immediately. 
 
 
2.7.2 Micro-particle Gating strategy: Size calibrated beads with a diameter of 0.5µm and 
1µm (Beckman Coulter, Miami, USA) were used to establish a size restricted gate in order to 
identify the microparticles, shown in figures 1A-E. The purity of the gated platelet population 
was ensured by gating on circulating free platelets (shown in figure 2A and B). In addition 
doublet discrimination strategy was applied to distinguish between free and aggregated 
platelets (shown in figure 2C). The light scatter properties of glycoprotein Ibα (CD42b) 
positive events were used to determine the percentage of platelet derived microparticles 
(PMPs) (shown in figure 2C).  
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Figure 1. Micro-particle discrimination and enumeration. The figure illustrates the use of nominal 
beads for flow cytometric discrimination of micro-particles (MPs) based on size. Figures A and B 
illustrate the exclusion of buffer and background noise from analysis. Figures C, D and E illustrate the 
use of nominal beads to determine a size reference ladder and a micro-particle gate with a particle 
size limit of >0.5 and <1.0 µm.  
2.7.3 Doublet discrimination and PMP Gating strategy. 
Doublet discrimination strategy was applied to distinguish platelet aggregates from freely 
circulating platelets (shown in figure 2B). The MP gate created using nominal latex beads 
was applied to determine the percentage of PMPs in freely circulating PLTs. Platelet micro-
particles were defined by forward scatter properties that fell within the micro-particle gate and 
by the surface expression of platelet specific glycoprotein Ib (CD42b) which is platelet 
specific  (Shown in figure 2C).  
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Figure 2. Discrimination between aggregated platelets and PMPs. The color dot plot A illustrates 
the forward scatter (FS) and side scatter (SS) properties distinguishing between platelet derived micro-
particles (PMPs), platelets (PLTs) and red blood cells (RBCs). The dot plot B illustrates the use of 
platelet specific GPIbα (CD42b) and FS to discriminate between free platelets and RBC-bound 
platelets (RBC-PLTs). Dot plot C illustrates the use of the doublet discrimination strategy to distinguish 
between free CD42b
+ 
PTLs and aggregated platelets. Nominal beads of known size (10µM) that 
fluoresce in multiple spectra were used as controls to set the limits of the free PTLs and PLT 
aggregate gate. Plot D represents the use of the MP gate created using nominal beads; to determine 
the percentage of micro-particles in freely circulating PTLs. Dot plots E-G illustrate the measurement 
of CD62P on PLTs, PMPs and PLT aggregates respectively. 
 
2.8 Statistical analysis 
Statistical analysis was performed using Graph pad prism 5 for windows, version 5.00 
software (San Diego, CA) .The Mann-Whitney U test was used to compare non-parametric 
data and these values were reported as median and interquartile range. For parametric data 
an unpaired student t test was performed and data was reported as mean and standard 
deviation. Paired data tests were also performed, for parametric data a paired t-test analysis 
was performed and for non-parametric data Wilcoxon matched data set analysis was 
performed. 
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3. Results 
The study consisted of eighty six (86) participants, 40 HIV negative controls and 46 HIV 
positive ARV-naïve individuals. Participant demographics and baseline characteristics are 
tabulated in table 1. The study groups demonstrated a similar mean age distribution, (control 
group mean age 30.3 vs. 31.55 HIV group). None of the study participants were 
thrombocytopenic and platelet counts were similar between the groups (table 1). Differences 
in D-dimer levels were observed (shown in table I); however these were within the normal 
reference intervals of 0.00-0.25 mg/ml. As expected the HIV group had lower levels of CD4+ 
T- cells (768.9 ± 21 vs. 391.5 ± 195.3 control group, p=<0.0001). The HIV group 
demonstrated increased levels of CD8+ T-cells expressing CD38 (median %CD38 on CD8+ T 
cells 24.03[15.76-43.92] vs. control 9.23[6.8-12.96], p<0.0001). In the HIV group decreased 
levels of CD4+ T cells correlated with increased levels of immune activation which was  
measured as the levels of CD38 expression on CD8+ T cells (r= -0.384, p=0.015). In addition, 
HIV-1 viral RNA levels showed an inverse correlation with CD4 + T cells (r= -0.348, p= 0.038) 
and a direct correlation with %CD38 on CD8 + T cells (r=0.471, p=0.008). The HIV group, 
also displayed increased median levels of %CD36 a marker of platelet aggregation, 
(22.53[10.59-55.15] vs. control group 11.01[3.69-26.98], p=0.0312 (shown in table 1). 
 
3.1 Increased levels of activated platelets directly correlate with activated PMPs in HIV. 
To determine the levels of platelet activation, CD62P expression on the surface of platelets 
was measured. The HIV group showed increased baseline levels of circulating activated 
platelets as demonstrated by increased median %CD62P expression (2.93[1.23-12.88] vs. 
control group 1.15 [0.19-3.59], p<0.0001). In the HIV group, increased percentages of 
platelets expressing CD62P directly correlated with PLT aggregates (r=0.5530, p=0.011) and 
the percentages of PMP‘s expressing CD62P (r=0.594, p=0.007). In addition the CD62P MFI 
directly correlated with PMPs CD62P MFI (r=0.694, p=0.002) but demonstrated no 
correlation with %PMPs (r=-0.198, p=0.389). 
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Table 1. Participant demographics and baseline characteristics 
Parameter Control HIV P- value Reference 
Interval 
No. of participants 40 46   
Age 30.3 ± 8.3 31.55 ± 6.7 -  
Gender (% males) 62.2 22.4   
Ethnicity     
Black (%) 100 100  - 
CD4 count (cells/µl) 768.9 ± 214 391.2 ± 195.3 <0.0001 500-2010 
Platelet count (x10
9
/l) 274[236-320.8] 313.5[232.5-
365.5] 
0.2620 178-400 
%CD62P 1.15[0.19-3.59] 2.93[1.23-
12.88] 
0.0058 - 
%PMPs 20.02[18.08-
26.08] 
26.64[11.33-
36.62] 
0.0133  
% Platelet aggregates 0.78[0.14-1.82] 0.7[0.33-2.31] 0.1986  
     
D-dimer (mg/l) 0.2[0.2-0.2] 0.24[0.2-0.33] 0.0020 0.00-0.25 
% CD8/38 9.23[6.8-12.96] 24.03[15.76-
43.92] 
<0.0001  
Log10 mean Viral 
Load(copies/ml) 
- 4.18 ± 0.85 -  
Significant values (p<0.05), are shown in boldface 
 
3.2 Increased percentages of platelet aggregates expressing CD62P and elevated 
CD62MFI on PMPs in HIV patients. 
In order to determine the levels of activated platelet aggregates and PMPs, the %CD62P and 
CD62P MFI levels on PMPs and PLT aggregates were measured. The HIV group revealed 
increased levels of activated PLT aggregates 14.10[5.49-39.94] vs. 0.17[0-10.99], p=0.0097 
and there were no significant differences in the %CD62P expression on PMPs as shown in 
table 2. However the MFI of CD62 expression on PMP was increased in HIV, (3.81[3.46-
4.54]) when compared to the control group (3.41[3.16-3.6], p=0.0037). No significant 
differences in the MFI of CD62P expression on PLT aggregates were observed, shown in 
table 2. 
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Table 2. Levels of CD62P expression on PMPs and PLT aggregates 
 Control Group HIV Group P-value 
%CD62P    
%PMP 0.45[0.1-0.88] 0.19[0.06-0.94] 0.5728 
%PLT 
aggregates 
0.17[0-10.99] 14.10[5.49-39.94] 0.0097 
CD62P MFI    
%PMP 3.41[3.16-3.6] 3.81[3.46-4.54] 0.0037 
%PLT 
aggregates 
6.34[5.42-7.28] 7.86[4.69-12.30] 0.5967 
Significant values (p<0.05), are shown in boldface 
3.3 Increased levels of immune activation in HIV correlates with %PMPs 
In order to determine the association between immune activation and %PMPs levels in the 
HIV group, baseline levels of %CD38+ CD8+ T cells were correlated with; %PMPs (r=0.4730, 
p=0.0196), and %PLT aggregates (r=0.321, p=0.135). In the HIV group , percentages of 
%CD38+ CD8+ T cells inversely correlated with CD4+ T cell count ( r=-0.348, p=0.015) and 
directly correlated with viral load (r=0.471, p=0.008). 
 
 
Figure3. %CD38
+
CD8
+
 T cells correlate with, %PMPs in HIV. Figure A and B illustrates the 
measurement of PMPs and figure C illustrates the direct correlation between %CD38
+
CD8
+ 
T cells and 
%PMPs (r=0.4730, p=0.0196), in the HIV group.  
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4. Discussion 
Several approaches to the enumeration of MPs have been described, with most of these 
involving the use of platelet rich (PRP) or platelet poor plasma (PPP), platelet isolation 
strategies and thawing of samples. The freezing and thawing of samples affects the 
phenotypic analysis of MPs (Gasper-Smith et al., 2008). A recent study by Christersson et 
al., demonstrated the feasibility of using a whole blood assay that mimics the in vivo state by 
omitting centrifugation and thawing of samples (Christersson et al., 2013). The present study 
aimed at measuring PMPs and platelet aggregates in HIV infected individuals, using a flow 
cytometry based whole blood assay which has been optimised to ensure artefactual platelet 
activation is kept to a minimum. Moreover we aimed at evaluating associations between 
PMPs, platelet aggregates and markers of immune activation and disease progression in 
asymptomatic treatment naïve HIV infected individuals 
We have previously reported on increased levels of activated platelets in HIV compared to 
uninfected controls (Nkambule et al., 2014) which is consistent with previously findings 
(Holme et al., 1998; Corrales-Medina et al., 2010; Mayne et al., 2012). In the HIV group, 
levels of platelet activation directly correlated with the levels of activated platelet aggregates 
which have been previously associated with thromboembolic events in HIV infected 
individuals (Shen et al., 2004). Our study found no differences in the % of platelet aggregates 
between the HIV and control group. The levels of PMPs were however significantly increased 
in the HIV infected individuals compared to their uninfected counterparts. In addition, PMP 
levels in HIV infected individuals had increased qualitative CD62P expression as measured 
by the CD62P MFI. This may suggest an increased number of adhesion molecules (CD62P) 
on the surface of PMPs in HIV and is consistent with findings reported by Mayne et al., who 
showed that PMPs in HIV infected individuals are activated and express CD62P (Mayne et 
al., 2012). These findings may further support the described prothrombotic characteristic of 
PMPs. P-selectin has been described as an adhesion molecule that can bind to leukocytes, 
resulting in increased platelet leukocyte aggregate (PLA) formation (Totani et al., 2010). 
Moreover our findings may suggest that PMPs expressing increased levels of P-selectin 
promote the adhesion and trapping of circulating platelets and leukocytes on the endothelial 
surface, which would consequently increase the thrombus size. Consistent with our finding of 
increased PMP levels in HIV, Corrales-medina et al., described a cohort of HIV infected   
participants on ART, which had increased PMP levels compared to uninfected controls. In 
addition, the authors showed no significant differences in PMPs when intragroup 
comparisons were performed amongst HIV individuals on different highly active antiretroviral 
therapy (HAART) regimes (Corrales-medina et al., 2010).  
In our study PMPs showed a direct correlation with generalized immune activation, as 
measured by the expression of CD38 on CD8+ T cells. As expected increased levels of 
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immune activation inversely correlated with the levels of CD4+ T cells and directly correlated 
with viral RNA levels. Haematopoietic cells release MPs upon cellular activation by 
lipopolysscahrides (LPS) and inflammatory cytokines. This is significant in the context of HIV 
which is characterized by increased levels of LPS and chronic immune activation (Vassalo et 
al., 2012). The association between levels of immune activation and PMPs further supports 
the link between immune activation, platelet activation and increased thrombotic risk in HIV 
infected individuals. The lack of an association between PMPs and viral RNA levels suggests 
that in HIV infected individuals MP formation may be facilitated by mechanisms involving 
immune activation rather than the direct effects of HIV. PMP levels demonstrated a trend 
towards a negative correlation with CD4 counts (r=-0.361, p=0.070). This finding is similar to 
that reported by Corrales-Medina et al., who reported on increased PMPs in HIV infected 
individuals. Interestingly, the authors also showed that in HIV, elevated PMP levels persisted, 
although levels of CD62P expression declined after ART initiation (Corrales-medina et al., 
2010). Although differences in the mean CD4+ T cell count exists between our present study 
(391 cells/µl) compared to the mean of 550 cells/µl CD4+ T cell count reported by Corrales-
Medina et al., our findings may further support the fact that PMPs are a more sensitive 
marker of residual increased platelet activity (Corrales-Medina et al., 2010) which may result 
in increased thrombotic risks in HIV infected individuals. PMP formation may be stimulated 
by sub clinical viral replication that promotes apoptosis of circulating platelets or impairs the 
clearance of apoptotic cells (Corrales-Medina et al., 2010). Notably platelets are capable of 
engulfing and internalizing HIV, a process which is facilitated by their surface receptors 
(Flaujac et al., 2010). These interactions may result in platelet activation and a subsequent 
increase in PMP formation. In contrast however, da Silva et al., reported no differences in 
PMP levels between HIV infected individuals and controls (da Silva et al., 2011).  
The early stages of HIV infection are characterized by elevated production of 
proinflammatory cytokines with a delayed or compromised adaptive immune response 
(Stacey et al., 2009; Turnbull et al., 2009; McMicheal et al., 2010). 
In this study, platelet aggregates in HIV infected individuals showed elevated quantitative 
levels of activation when compared to uninfected controls. In comparison, PMPs in HIV 
infected individuals had increased qualitative levels of activation compared to uninfected 
controls (shown in table 2). Ultrastructural changes in platelet aggregates of HIV infected 
individuals have been described. Platelet aggregates in HIV infected individuals have been 
shown to have increased areas of morphological membrane blebbing, torn membranes and 
pseudopodia when using scanning electron microscopy (Pretorius et al., 2008). These 
findings may suggest that circulating platelet aggregates in HIV infected individuals are 
activated and may contribute to the hypercoaguble state found in HIV infected patients. The 
cross sectional design of the study limits conclusive associations and thrombotic risk analysis 
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of this cohort and therefore future longitudinal studies will be required to assess and stratify 
individuals with increased risk of thrombotic events. 
 In conclusion we report on increased levels of circulating PMPs in HIV infected 
asymptomatic individuals. We also describe increased levels of activated PMPs and platelet 
aggregates in asymptomatic HIV infected individuals. 
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7.1 Conclusions 
The aim of this project was to examine the function and characteristics of platelets, in the 
context of HIV infection, in order to establish a link between platelet activity, the inflammatory 
response and the increased thrombotic events and cardiovascular disease observed in 
patients who have this disease. 
In the work presented, the levels of platelet activation were persistently elevated in HIV 
infected treatment naïve individuals. This finding is consistent with that previously reported in 
the literature (Holme et al.,1998; mayne et al., 2012). Notably the significance of the 
decreased MPV (a measure of platelet size and rate of production) in HIV, may suggest 
mechanisms involving the migration of large platelets from the circulation to extracellular 
sites of inflammation. Furthermore decreased MPV levels correlated inversely with CD4 
counts and directly with viral load. This may further support the immunological role played by 
platelets during HIV infection in which, direct interactions between platelets and HIV may 
result in the engulfment and clearance of activated platelets by leukocytes(Torre & Pugliese 
et al., 2008; Flaujac et al., 2010).  
Platelet indices have been evaluated in various inflammatory conditions however only a few 
studies have determined the clinical significance of these indices in HIV infected treatment 
naïve individuals. Our study also describes decreased levels of PDW (a measure of platelet 
activation and aggregation), which directly correlated with levels of platelet activation. To 
date this project forms the largest study evaluating platelet indices in HIV infected treatment 
naïve individuals. We further report on MPV and PDW as potential cost effective markers of 
platelet activation and immune activation. 
Platelet function in HIV is not fully understood and contradictory findings have been reported. 
The lack of reproducibility of reported findings is mainly influenced by methodological 
variations between reported data. In our study we optimized a flow cytometry based assay 
that ensured that minimal artefactual platelet activation took place and care was taken to 
retain the physiological environment of the platelets. We report on a novel platelet functional 
assay that evaluates signaling pathways involved in platelet activation using whole blood. In 
addition we report on hyper responsive platelets in HIV to low doses of strong endogenous 
agonists (AA and collagen) and high doses of the platelet agonist (ADP). We further describe 
elevated levels of activated platelets in HIV which retain their functional capacity. These 
findings are significant and  may be essential in the monitoring and thrombotic risk 
stratification of HIV infected individuals. 
Our research revealed increased numbers of circulating activated platelets in HIV infected 
individuals and is the first to describe elevated levels of activated platelets in asymptomatic 
HIV infected treatment naïve individuals. Furthermore our findings demonstrated high levels 
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of D-dimer which showed a positive correlation with platelet CD36. Platelets in HIV infected 
individuals appear to retain their  functional capacity and are able to degranulate and 
aggregate upon stimulation with ADP. Interestingly, the platelets in HIV demonstrated a 
single phase response to ADP. This may suggest that in this disease , platelets are activated 
in vivo and may respond irreversibly with submaximal concentrations of ADP. 
Baseline PMAs were significantly increased in HIV infected treatment naïve individuals. In 
addition PMA levels directly correlated with viral load and immune activation. This may 
suggest that in HIV, generalized immune activation promotes monocyte and platelet 
crosstalk. In addition, levels of platelet CD36 directly correlated with elevated PMA levels. 
Notably, CD36, a scavenger receptor, is also expressed on the surface of monocytes where 
it is involved in the formation of foam cells in atherosclerosis (Rahaman et al., 2006). We 
therefore suggest that  platelet CD36 could be utilised as a valuable marker in the monitoring 
of platelet and monocyte interactions and may therefore be of use in the thrombotic risk 
profiling of HIV infected individuals. Furthermore, in support of this theory whole blood in vitro 
stimulation with LPS resulted in increased PMA levels in both HIV infected and control 
groups.  
Further longitudinal studies are however required in order to ascertain the clinical value of 
increased PMA levels in the HIV group, Even though associations between PMA levels and 
markers of immune activation and disease progression were determined, PMAs showed a 
direct correlation with viral load and immune activation. In addition the inverse relationship 
between PMAs and CD4 count supports the potential value of PMAs as a marker of disease 
progression in HIV infected asymptomatic treatment naïve individuals. We have also 
demonstrated elevated levels of activated PMPs and platelet aggregates in this group of 
individuals which.directly correlated with generalized immune activation. This may further 
support the link between immune activation, platelet activation and increased thrombotic risk 
in HIV infected individuals. 
 
This project therefore supports previous findings of increased levels of activated platelets in 
HIV infected individuals (Holme et al.,1998; mayne et al., 2012). In addition, this work  further 
presents a novel approach, in the form of  whole blood platelet flow cytometry based assays, 
to study platelets and the underlying mechanisms of thrombotic complications in HIV infected 
individuals. Minimal work has been undertaken in this area of HIV reseach particularly in a 
cohort of asymptomatic untreated patients which have been targeted in this study. This 
approach may facilitate the earlier access to appropriate therapies and form the baseline for 
monitoring response to treatments. We propose that the above assays could be utilised as a 
‗thrombotic risk‘ panel of tests which may be of value in the assessment of specific anti-
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platelet therapies used as preventative strategies in the management of patients at risk of 
inflammatory-associated complications. 
Finally, the results of our investigations have added knowledge and evidence to the theory 
that platelets form an important link between the immune response and the increased levels 
of thrombosis in patients living with HIV. These observations could be relevant in other 
inflammatory diseases such as diabetes, multiple sclerosis and autoimmune diseases and 
furture studies should focus on the role platelets play in chronic inflammatory conditions. Our 
findings provide new knowledge in understanding platelet function in HIV. The panel of flow 
cytometry based platelet assays presented in this work, provide findings that may address 
the research gap that exists regarding platelet activation in HIV. In addition rapidly available 
platelet parameters in the form of platelet indices may be a cost effective tool in the 
monitoring of immune suppression and disease progression in HIV. Our study focused on a 
cohort consisting of asymptomatic treatment naïve HIV infected patients. This allowed the 
exclusion of treatment as a cofounding factor in our evaluation of platelet function in HIV. Our 
findings strongly suggest direct associations between the levels of platelet activation and 
markers of immune activation and disease progression in HIV. The measurement of platelet 
function using the described panel of flow cytometry based assays may be of value in 
monitoring disease progression and thrombotic risk profiling of HIV infected treatment naïve 
individuals. 
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ADDENDUM 1: 
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17th European Hematology Congress 14-17 June 2012, Amsterdam, The Netherlands  
Platelet Flow Cytometry and markers of immune activation in asympto-matic, treatment- naïve 
HIV infection. Bongani B. Nkambule1 , Richard Glashoff1 and Hayley Ipp1,2 . Divisions of Haematology 1 
and Virology 2, Department of Pathology, Stellenbosch University and NHLS, Tygerberg, South Africa 
4. Oral presentation  
Pathpoint 2012 congress, SEPT 28-30. Crystal towers hotel in Cape Town, South africa 
 
Platelet Flow Cytometry and markers of immune activation in asymptomatic, treatment- naïve HIV 
infection. Bongani Nkambule, RH Glashoff, H Ipp. Divisions of Haematology 1 and Virology 2, 
Department of Pathology, Stellenbosch University and NHLS, Tygerberg, South Africa 
Laboratory medicine congress 2013, JULY 28-31. Cape Town international convention centre in 
Cape Town, South Africa 
The value of Flow Cytometry in the measurement of platelet activation and aggregation in human 
immune-deficiency virus HIV infection. Bongani B. Nkambule, Glenda Davidson ,Hayley Ipp. 
Divisions of Haematology , Department of Pathology, Stellenbosch University, Tygerberg 1 . Department 
of Biomedical sciences, Faculty of Health and wellness sciences, Cape Peninsula University of 
Technology, Bellville, South Africa 2. 
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ADDENDUM 4: 
Participant information leaflet and consent form 
 
 
Title of the research project: Modulation of activation and apoptosis of immune cells from HIV-infected 
individuals with the neurotransmitter Vasoactive Intestinal Peptide (VIP) and other biomediators 
 
Title of sub-study: Investigating platelet function and immune activation in HIV infection and 
other chronic inflammatory conditions. 
 
Reference number: N07/09/197 
 
Principal investigator: Dr Hayley Ipp/ Dr Richard Glashoff 
 
Address: Medical virology; 8th Floor Clinical Building; Tygerberg Hospital Campus  
 
CONTACT NUMBER: 021 938 9356 
 
You are being invited to take part in a research project. Please take some time to read the information 
presented here, which will explain the details of this project. Please ask the study staff or doctor any 
questions about any part of this project that you do not fully understand.  It is very important that you are 
fully satisfied that you clearly understand what this research entails and how you could be involved. Also, 
your participation is entirely voluntary and you are free to decline to participate. If you say no, this will 
not affect you negatively in any way whatsoever. You are also free to withdraw from the study at any 
point, even if you do agree to take part. 
 
This study has been approved by the Health Research Ethics Committee (HREC) at Stellenbosch 
University and will be conducted according to the ethical guidelines and principles of the international 
Declaration of Helsinki, South African Guidelines for Good Clinical Practice and the Medical Research 
Council (MRC) Ethical Guidelines for Research. 
 
 
 
What is this research study all about? 
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 Selection of Study Volunteers This study will enroll about 70 volunteers who have been 
attending the clinics attached to the Desmond Tutu HIV Centre, have CD4 counts greater than 
200, are 21 years or older, and who have not yet received antiretroviral drugs. 
 About 40 volunteers will also be recruited from trials that are being set up for HIV- negative 
people. 
 The research on the blood will take place at Tygerberg Hospital, Department of Pathology 
 Reason for the study: The drugs (antiretrovirals) that are now available for the treatment of HIV 
have saved many people‘s lives and continue to do so on a daily basis. However, we still need to 
look for different ways to help people who are HIV positive, live for longer, before they need to 
take the antiretroviral drugs. If a person‘s CD4+ T cell count is less than 200, it is very important 
to get the antiretroviral treatment, however, for those people whose count is still greater than 
200, we will be looking for new ways in the laboratory to keep the count at this higher level, and 
hopefully this will help prevent the onset of full-blown AIDS.  
 
Study procedures 
If you decide to take part in the study, after you read, discuss and sign or mark this form, the following 
procedures will take place: 
 You will undergo a medical examination and short medical history. 
 You will be asked a number of questions about how you may have been exposed to HIV and 
when you think you may have become HIV-infected. If you have completed this questionnaire on 
a previous study with the same investigators, you will not need to complete it again. 
 You will also be asked questions about any medicines that you are taking.  
 If you are a woman, your urine will be tested to see if you are pregnant.  If you are or become 
pregnant, you will be referred to prenatal care and to programs for Prevention of Mother to Child 
Transmission (PMTCT) where you will be able to get medicines to prevent your baby from getting 
HIV. 
What will happen to your blood? Up to 10 teaspoons of blood i.e. 50ml (one or 5 small tubes) will 
be drawn from your arm. The blood will then be sent to the laboratory at Tygerberg Hospital where 
the red blood cells will be separated from the white blood cells. The cells from the immune system 
will then be tested in the laboratory, by mixing them with different medications to see which medicine 
is the best at keeping the cells alive. Some chemistry tests will be performed to determine levels of 
inflammation and small clot formation. The results of these tests are for research purposes only and 
cannot be made available to you. 
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 No genetic testing will be performed. 
 
Will you benefit from taking part in this research? 
Benefits: You may benefit by taking part in the study from receiving counseling and a medical 
examination. You or others may benefit in the future from information learned in this study. You may 
get some personal satisfaction from being part of research on HIV. If you are a woman, and you 
become pregnant, you will be referred for prenatal care and for PMTCT. 
Risks and/or Discomforts: There may be some discomfort involved in drawing blood for the tests 
which sometimes can cause pain and bruising where the needle goes into your arm. When blood is 
being drawn, you may feel dizzy or faint, but this is not common. 
 
Confidentiality 
Your participation in the study, all information collected about you as well as all results of laboratory tests 
will be private and not available to others outside of the people listed below. You will have your own 
special identity number known only to you and the clinic staff. They are required to respect your 
confidentiality. Your identity will not be disclosed in any publication or presentation of this study. Your 
blood specimens will only be identified by your study number. Any documents containing your name will 
be locked away in a secure place. 
 
Will you be paid to take part in this study and are there any costs involved? 
 
No you will not be paid to take part in the study but your transport and meal costs will be covered for 
each study visit. There will be no costs involved for you, if you do take part. 
 
 
 
Is there any thing else that you should know or do? 
 You can contact Dr Hayley Ipp……………….………..….. At tel …021 9389356…………………… 
if you have any further queries or encounter any problems. 
 You can contact the Health Research Ethics Committee at 021-938 9207 if you have any 
concerns or complaints that have not been adequately addressed by your study doctor. 
 You will receive a copy of this information and consent form for your own records. 
 
Declaration by participant 
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By signing below, I …………………………………..…………. agree to take part in a research study 
entitled (insert title of study). 
 
I declare that: 
 
 I have read or had read to me this information and consent form and it is written in a 
language with which I am fluent and comfortable. 
 I have had a chance to ask questions and all my questions have been adequately answered. 
 I understand that taking part in this study is voluntary and I have not been pressurised to 
take part. 
 I may choose to leave the study at any time and will not be penalised or prejudiced in any 
way. 
 I may be asked to leave the study before it has finished, if the study doctor or researcher 
feels it is in my best interests, or if I do not follow the study plan, as agreed to. 
 
Signed at (place).....Crossroads.................…........…………….. on (date) …………....……….. 2010 
 
 
 
 ...................................................................   .................................................................  
Signature of participant Signature of witness 
Declaration by investigator 
 
I (name) ……………………………………………..……… declare that: 
 
 I explained the information in this document to ………………………………….. 
 I encouraged him/her to ask questions and took adequate time to answer them. 
 I am satisfied that he/she adequately understands all aspects of the research, as discussed 
above 
 I did/did not use an interpreter. (If an interpreter is used then the interpreter must sign the 
declaration below. 
 
 
Signed at (place) ........Cross roads..............…........…………….. on (date) …………....……….. 2010. 
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 ...................................................................   .................................................................  
Signature of investigator Signature of witness 
 
Declaration by interpreter 
 
I (name) ……………………………………………..……… declare that: 
 I assisted the investigator (name) ………………………………………. to explain the 
information in this document to (name of participant) ……………..…………………………….. 
Using the language medium of Afrikaans/Xhosa. 
 We encouraged him/her to ask questions and took adequate time to answer them. 
 I conveyed a factually correct version of what was related to me. 
 I am satisfied that the participant fully understands the content of this informed consent 
document and has had all his/her question satisfactorily answered. 
Signed at (place) ......................…........…………….. On (date) …………....……………….. 
 
 ...................................................................   .................................................................  
Signature of interpreter Signature of witness 
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Appendix A 
Technical note:  Doublet discrimination strategy 
Introduction  
The doublet discrimination technique is applied to overcome coincident analysis of doublets 
in DNA ploidy experiments (Wersto et al., 2001). In studies where DNA staining has been 
performed , when a doublet passes through the flow cell during interrogation by the laser 
beam, it may be interpreted as a single cell with increased amount of DNA. This will result in 
incorrect histograms and percentage determinations for each cell cycle phase. It is essential 
that doublets are gated out from DNA histograms. In DNA studies doublet discrimination is 
performed using linear scale, however light scatter detected using linear scaling does not 
allow the discrimination of granulated and stimulant induced large cells (Rothe, 2009). 
The principles of this technique have been used to measure platelet monocyte complexes 
(Majumder et al., 2012). However this concept has not been used in the measurement of 
platelet aggregates. Flow cytometers can distinguish between doublets and singlets based 
on pulse processed data (Nunez, 2001). Doublets can be discriminated based on three kind 
of signals (figure 1), (1) Integral, total fluorescence (A); (2) Peak (H); (3) Time of flight (w) 
(Lopez-Sanchez et al, 2013).  
 
 
Fig 1.Three kinds of pulse signals that can be measured. 
http://www.ym.edu.tw/ymirc/flow/FC500_Cell_Cycle.pdf 
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Doublets demonstrate a lower peak pulse height compared to the integral. This allows for 
the discrimination of doublets from large single cells. The FC500 cytometer uses integral 
measurements as a major measure to discriminate doublets from single cells. An auxiliary 
parameter can be set on the FC500 which collects peak signals of a selected parameter. In 
order to apply this gating technique in the analysis of platelet aggregates, the auxiliary 
parameter was set on FL1 using log scale. A Color dot plot was used to createdto  
discriminate platelet doublets (aggregates) from single freely circulating platelets as 
described in the Beckman coulter FC500 training module. (Fig2).  
 
 
 
Figure 2 . Discrimination of singlets and doublets using flow cytometry. Doublets and large 
single cells have distinct peak and time of flight characteristics (Lopez-Sanchez et al, 2013). 
 
Methods 
Fresh blood was stained with CD31-FITC and used to set a gate for freely circulating platelets 
(Figure 1). For a positive control fresh blood was stimulated with 20mM of ADP and 
incubated for 20 min at room temperature. The sample was then stained with CD31-FITC 
and analyzed immediately using the Beckman coulter FC500. The instrument flow rate was 
kept at low to minimize coincidental events that may be interpreted as aggregates. A 
doublet discrimination protocol was set as described in the Beckman coulter training 
protocol and modified for analysis of platelet aggregates (shown figure 5). CD31 positive 
platelets were gated and the doublet discrimination strategy was then applied as outlined in 
figure 5. 
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Figure 3. Doublet discrimination peak vs. Integral (Classic method). (taken from the 
Beckman coulter FC500 training module, DN-9)) 
 
Figure 4. illustrates the doublet discrimination strategy applied on a fresh blood sample. 
Figure B demonstrates the discrimination of freely circulating platelets from aggregated 
platelets based on CD 31 integral and Peak. Figure C demonstrates the use of ADP stimulated 
platelets as a positive control. Figure (D) illustrates a back gate used to evaluate the side 
scatter and forward scatter properties of the gated platelet aggregates. 
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